

University of Louisville

## ThinkIR: The University of Louisville's Institutional Repository

---

Electronic Theses and Dissertations

---

8-2023

### The role of e-liquid constituents in e-cigarette-induced cardiac arrhythmia and autonomic imbalance.

Cory Kucera  
*University of Louisville*

Follow this and additional works at: <https://ir.library.louisville.edu/etd>



Part of the [Environmental Health Commons](#), [Environmental Public Health Commons](#), [Systems and Integrative Physiology Commons](#), and the [Toxicology Commons](#)

---

#### Recommended Citation

Kucera, Cory, "The role of e-liquid constituents in e-cigarette-induced cardiac arrhythmia and autonomic imbalance." (2023). *Electronic Theses and Dissertations*. Paper 4170.  
<https://doi.org/10.18297/etd/4170>

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [thinkir@louisville.edu](mailto:thinkir@louisville.edu).

THE ROLE OF E-LIQUID CONSTITUENTS IN E-CIGARETTE-INDUCED  
CARDIAC ARRHYTHMIA AND AUTONOMIC IMBALANCE

By

Cory James Kucera  
B.S., University of California, Irvine, 2011  
M.S., University of Louisville, 2020

A Dissertation  
Submitted to the Faculty of the  
School of Medicine of the University of Louisville  
in Partial Fulfillment of the Requirements for the Degree of

Doctor of Philosophy  
in Physiology and Biophysics

Department of Physiology  
University of Louisville  
Louisville, KY

August 2023



THE ROLE OF E-LIQUID CONSTITUENTS IN E-CIGARETTE-INDUCED  
CARDIAC ARRHYTHMIA AND AUTONOMIC IMBALANCE

By

Cory James Kucera  
B.S., University of California, Irvine, 2011  
M.S., University of Louisville, 2020

A Dissertation Approved on

July 10, 2023

By the following Dissertation Committee

---

Alex Carll, Ph.D., Committee Chair

---

Aruni Bhatnagar, Ph.D.

---

Irving Joshua, Ph.D.

---

Dale Schuschke, Ph.D.

---

Claudio Maldonado, Ph.D.

## ACKNOWLEDGEMENTS

I thank Dr. Alex Carll for his mentorship and guidance, Drs. Aruni Bhatnagar, Irving Joshua, Dale Schuschke, and Claudio Maldonado for their feedback and direction, Dr. Anand Ramalingam for his insightful contributions and technical assistance, Gregg Shirk and Dr. Shweta Srivastava for their technical assistance, Dr. Cynthia Metz for spearheading my Doctoral Dissertation Completion Award nomination, and my parents for their love and support.

## ABSTRACT

### THE ROLE OF E-LIQUID CONSTITUENTS IN E-CIGARETTE-INDUCED CARDIAC ARRHYTHMIA AND AUTONOMIC IMBALANCE

Cory James Kucera

July 10, 2023

*Introduction.* Accumulating evidence indicates that exposure to electronic cigarettes (e-cigs) promotes sympathetic dominance and electrophysiologic instability in the heart, potentially culminating in arrhythmogenesis. E-liquids contain various formulations of nicotine and flavorings, but the effects of specific e-liquid constituents and their concentrations on e-cig-induced autonomic imbalance and electrical dysfunction are unresolved. To that end, we tested the hypothesis that e-cigs modify cardiac autonomic balance and ventricular arrhythmogenesis in mice dependent on e-liquid constituent type and concentration.

*Methods.* Using a crossover design and a serial exposure regimen, ECG-telemetered male C57BL/6J mice underwent whole-body exposure to e-cig aerosols generated from e-liquids containing different cooling agents or nicotine formulations. On a given exposure day, mice were exposed to either increasing coolant concentrations (0.25%, 1%, and 2.5%) or increasing nicotine concentrations (1%, 2.5%, and 5%) for three 18 min exposure cycles (9 min puffing phase followed by 9 min washout phase) per concentration with time-matched periods for filtered air (FA) and vehicle controls. Spontaneous ventricular premature beat (VPB) incidence rates, heart rate, and heart rate variability (HRV) were

quantified and compared between exposures. Atenolol was used to test the role of  $\beta_1$ -adrenergic activation in e-cig induced changes in autonomic balance.

*Results.* Exposure to 1% menthol and racemic nicotine at 2.5% and 5% reduced heart rate and increased HRV, suggesting parasympathetic dominance. Conversely, exposure to 5% nicotine salt and WS-3 and WS-23 at 2.5% elevated heart rate and decreased HRV, indicating sympathetic dominance, and also increased VPBs. Pretreatment with atenolol abolished the heart rate elevations and HRV declines during exposure to nicotine salt, signifying  $\beta_1$ -adrenergic mediation of e-cig-induced sympathetic dominance.

*Conclusions.* Exposure to e-cig aerosols containing commercially relevant levels of synthetic cooling agents and nicotine salts may enhance the cardiac risks of vaping by promoting sympathetic dominance and ventricular arrhythmias. Importantly,  $\beta_1$ -adrenergic activation mediates nicotine salt-evoked increases in sympathetic influence. These findings may aid the design of human studies or inform tobacco regulatory initiatives that reduce the public health risks of vaping.

## TABLE OF CONTENTS

ACKNOWLEDGEMENTS .....	iii
ABSTRACT .....	iv
LIST OF TABLES .....	viii
LIST OF FIGURES .....	ix
CHAPTER I. INTRODUCTION .....	1
CARDIOVASCULAR IMPACTS OF CIGARETTE SMOKING .....	1
TRENDS IN CIGARETTE SMOKING PREVALENCE .....	1
BRIEF HISTORY OF ELECTRONIC CIGARETTES .....	2
TRENDS IN E-CIG USE PREVALENCE .....	2
FEDERAL REGULATION OF E-CIGS .....	3
E-CIG DEVICE COMPONENTS .....	3
E-CIG DEVICE TYPES .....	4
E-LIQUID CONSTITUENTS .....	5
CHEMICAL COMPOSITION OF E-CIG AEROSOLS .....	5
COOLING AGENTS .....	9
NICOTINE TYPES .....	10
PHARMACOLOGY OF NICOTINE .....	12
NICOTINE METABOLISM .....	12
AUTONOMIC NERVOUS SYSTEM .....	13
B <sub>1</sub> -ADRENOCEPTORS .....	15
HEART RATE VARIABILITY .....	17
AUTONOMIC ACTIVATION AND CARDIAC ARRHYTHMIAS .....	19
CARDIOVASCULAR TOXICITY OF E-CIGS .....	20
PROJECT SUMMARY .....	23
SPECIFIC AIMS .....	25
CHAPTER II. SYNTHETIC COOLING AGENTS EXACERBATE E-CIGARETTE- INDUCED CARDIAC ARRHYTHMIAS AND SYMPATHETIC DOMINANCE IN MICE .....	27
OVERVIEW .....	27
INTRODUCTION .....	28
MATERIALS AND METHODS .....	30
RESULTS .....	34
DISCUSSION .....	36
TABLES .....	44
FIGURES .....	47



CHAPTER III. NICOTINE FORMULATION INFLUENCES THE AUTONOMIC AND ARRHYTHMOGENIC EFFECTS OF E-CIGARETTES .....	54
OVERVIEW.....	54
INTRODUCTION .....	55
MATERIALS AND METHODS.....	57
RESULTS.....	61
DISCUSSION.....	63
TABLES.....	72
FIGURES .....	74
CHAPTER IV. CONCLUSIONS.....	82
SUMMARY .....	82
STRENGTHS .....	84
LIMITATIONS .....	85
DISCUSSION.....	87
IMPLICATIONS.....	91
REFERENCES .....	97
APPENDIX. LIST OF ABBREVIATIONS.....	119
CURRICULUM VITAE .....	122

## LIST OF TABLES

Table 2.1. Coolant e-liquid compositions (per 10 g).....	44
Table 2.2. Estimated association of changes in heart rate and SDNN with VPB incidence upon inhalation exposure to coolant-free and coolant-containing e-cig aerosols .....	45
Table 2.3. Effects of coolants on nicotine intake and metabolism .....	46
Table 3.1. Nicotine e-liquid compositions (per 10 g).....	72
Table 3.2. Effects of nicotine formulation on nicotine intake and metabolism.....	73

## LIST OF FIGURES

Figure 2.1. Experimental design and exposure regimen .....	47
Figure 2.2. Relationship between total suspended particulates (TSP) and puff normalized aerosol deposition .....	48
Figure 2.3. Baseline heart rate and HRV prior to each exposure .....	49
Figure 2.4. Influence of coolants on e-cig-induced changes in heart rate and HRV .....	50
Figure 2.5. Effects of coolants on e-cig-induced ventricular arrhythmias .....	51
Figure 2.6. Coolants modify the association between e-cig-induced ventricular arrhythmias and changes in heart rate and HRV .....	52
Figure 2.7. Impacts of coolants on nicotine intake and metabolism .....	53
Figure 3.1. Experimental design and exposure regimen .....	74
Figure 3.2. Relationship between total suspended particulates (TSP) and puff-normalized aerosol deposition .....	75
Figure 3.3. Baseline heart rate and HRV prior to each exposure .....	76
Figure 3.4. Influence of nicotine formulation on e-cig-induced changes in heart rate and HRV .....	77
Figure 3.5. Baseline heart rate and SDNN prior to each exposure.....	78
Figure 3.6. Influence of $\beta_1$ -adrenergic inhibition on e-cig-induced changes in heart rate and SDNN .....	79
Figure 3.7. Effects of nicotine formulation on e-cig-induced ventricular arrhythmias.....	80
Figure 3.8. Impacts of nicotine formulation on nicotine intake and metabolism.....	81

## CHAPTER I

### INTRODUCTION

#### **Cardiovascular Impacts of Cigarette Smoking**

Combustible cigarettes are the most commonly used form of tobacco in the U.S., and smoking is the leading preventable cause of premature death nationwide. Since 1964, roughly 480,000 annual U.S. deaths and over 20 million premature U.S. deaths have been attributed to cigarette use and exposure to secondhand smoke.<sup>1</sup> Cardiovascular disease (CVD) is the leading cause of mortality in the U.S., and smoking is responsible for one in three deaths linked to CVD.<sup>2</sup> Smoking increases the risk of heart failure,<sup>3</sup> atherosclerosis, thrombosis, coronary heart disease, stroke, aortic aneurysm, peripheral arterial disease, myocardial infarction, and sudden death.<sup>4</sup> Cigarette use is also linked to left ventricular (LV) hypertrophy, diastolic dysfunction,<sup>5</sup> aggravation of hypertension,<sup>6</sup> atrial fibrillation,<sup>7</sup> and supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients.<sup>8</sup> Additional adverse cardiovascular effects of smoking include endothelial injury and dysfunction, pathologic angiogenesis, insulin resistance, dyslipidemia,<sup>4</sup> impaired wound healing, and macular degeneration.<sup>9</sup>

#### **Trends in Cigarette Smoking Prevalence**

Smoking prevalence in the U.S. has been steadily declining among adults since 1965<sup>1</sup> and among young people since 1999.<sup>10</sup> During 2013–2020, the proportion of current adult smokers declined from 18% to 12.5%.<sup>11, 12</sup> Similarly, between 2000 and 2021, current cigarette use among middle and high school students decreased from 11% to 1% and from

28% to 1.9%, respectively.<sup>13, 14</sup>

### **Brief History of Electronic Cigarettes**

The earliest concept of an electronic cigarette (e-cig) is a patent granted in 1930 to Joseph Robinson for his electric vaporizer, which was designed to produce inhalable vapors by heating medicinal compounds.<sup>15, 16</sup> Herbert Gilbert, a scrap metal dealer from Pennsylvania, patented the first modern e-cig in 1965 as a smokeless nontobacco cigarette intended to provide a safer method of smoking.<sup>17-19</sup> In 2003, while working for Ruyan (formerly Golden Dragon Holdings) in Beijing, China, a pharmacist named Hon Lik devised the first commercially viable e-cig to function as a cigarette substitute and smoking cessation aid.<sup>15, 18, 20</sup> The first e-cig was introduced to the Chinese market the following year,<sup>21</sup> whereas e-cigs entered the European and U.S. markets in 2006 and 2007, respectively.<sup>22</sup>

### **Trends in E-cig Use Prevalence**

E-cig use prevalence in the U.S. has increased among adults since 2013 and among adolescents since 2011 but has been declining in both groups since 2019. The proportion of adults who currently vape increased from 1.9% in 2013<sup>11</sup> to 4.5% in 2019<sup>23</sup> but decreased to 3.7% in 2020.<sup>12</sup> The major pattern of e-cig use in adults is dual use (concurrent use of cigarettes and e-cigs).<sup>24</sup> Among high school students, current e-cig use rose from 1.5% in 2011<sup>25</sup> to 27.5% in 2019<sup>10</sup> but declined to 11.3% in 2021.<sup>14</sup> Similarly, the percentage of middle school students who currently vape increased from 0.6% in 2011<sup>25</sup> to 10.5% in 2019<sup>10</sup> but fell to 2.8% in 2021.<sup>14</sup> Since 2014, e-cigs have been the most commonly used tobacco product among youth in the U.S.<sup>14</sup>

## **Federal Regulation of E-cigs**

The passage of the Family Smoking Prevention and Tobacco Control Act in June 2009 authorized the U.S. Food and Drug Administration (FDA) to regulate the manufacturing, distribution, and marketing of tobacco products (excluding e-cigs) sold in the U.S. However, in May 2016, the FDA issued the Deeming Rule, which extended its regulatory authority to additional products (including e-cigs) that meet the statutory definition of a tobacco product.<sup>26</sup> Then in December 2018, a recent surge in e-cig use among middle and high school students prompted the FDA Commissioner and the U.S. Surgeon General to declare youth vaping an epidemic.<sup>10, 27</sup> In December 2019, the passage of the Tobacco 21 law raised the federal minimum age to purchase tobacco products from 18 to 21 years.<sup>28</sup> Shortly thereafter, the FDA issued a policy prioritizing enforcement against flavored, cartridge-based e-cigs (excluding tobacco and menthol) in January 2020.<sup>29</sup> In June 2022, the FDA issued marketing denial orders to former e-cig market leader JUUL Labs, Inc., forcing the company to cease the sale and distribution of all of its U.S.-marketed products.<sup>30</sup>

## **E-cig Device Components**

All e-cig devices consist of three major components: a battery, an e-liquid cartridge, and an atomizer. Most e-cigs are powered by a rechargeable lithium-ion battery connected to the atomizer. The atomizer contains an electrical heating coil that physically contacts a wick, which is typically composed of silica or cotton. The wick remains saturated by absorbing e-liquid from the cartridge and provides a steady flow of e-liquid without flooding the coil. When the user activates the device by pressing a button or simply inhaling through the mouthpiece, the coil heats and vaporizes the e-liquid, producing an inhalable

aerosol.<sup>9, 31</sup>

## **E-cig Device Types**

E-cigs have undergone several design modifications since their inception, and each successive generation has been designed to deliver greater amounts of nicotine to users.

### First-Generation

First-generation e-cigs are disposable, single-use devices and are often referred to as “cigalikes” because they resemble cigarettes.<sup>32</sup> They consist of a cartomizer, which combines the e-liquid cartridge and atomizer into a single unit<sup>33</sup> and a low-voltage battery. Some have a light-emitting diode at the end of the device to mimic the glow of a burning cigarette.<sup>9</sup> These devices are neither rechargeable nor refillable.<sup>32</sup>

### Second-Generation

Second-generation e-cigs are larger in size and are commonly known as “vape pens” due to their pen-like appearance. They are rechargeable, multiuse devices that have prefilled or refillable tanks or e-liquid cartridges, a higher-capacity battery with adjustable voltage, and a manual switch that allows users to regulate puff length and frequency.<sup>32</sup>

### Third-Generation

Third-generation e-cigs are termed “mods” because they are modifiable devices that allow users to customize several features such as temperature, voltage, heating coil resistance, and e-liquid composition.<sup>9, 33, 34</sup> They utilize a large tank system called a clearomizer with a transparent tank that allows users to monitor e-liquid levels, a refillable cartridge that can accommodate greater e-liquid volumes, and a metal casing that allows the batteries to be replaced according to user preference.<sup>33</sup> Newer models contain sub-ohm tanks with heating coils whose resistance is less than 1 ohm, allowing these devices to

operate at higher wattages and produce warmer inhaled aerosols, larger puff volumes, greater e-liquid consumption, and more intense flavor.<sup>35, 36</sup>

#### Fourth-Generation

Fourth-generation e-cigs are called “pod mods” because they are modifiable devices with a prefilled (closed system) or refillable (open system) e-liquid cartridge known as a pod that snaps into the device,<sup>34</sup> which consists of a battery and a temperature regulation system. They have a sleek, trendy, compact design that allows discreet use and pods that come in a variety of youth-friendly flavors, making them especially appealing to young people.<sup>37</sup>

#### **E-liquid Constituents**

E-liquids typically consist of propylene glycol (PG), vegetable glycerin (VG), nicotine, and flavorings. PG and VG are humectants that act as carrier solvents,<sup>9</sup> and they are classified as “generally recognized as safe” (GRAS) for ingestion, but the risks of their inhalation exposure have not been established.<sup>38</sup> Nicotine is a naturally occurring botanical insecticide present in tobacco leaves and is highly addictive.<sup>39, 40</sup> Commercial e-liquids can contain nicotine at concentrations up to 87 mg/mL.<sup>41, 42</sup> Flavorings are additives that contribute to the perceived flavor of e-cigs and can enhance the sensory appeal of these devices.<sup>43</sup> The number of distinct e-liquid flavors available online during 2016–2017 exceeded 15,500.<sup>44</sup>

#### **Chemical Composition of E-cig Aerosols**

Cigarettes transfer nicotine to the smoke by combusting tobacco, whereas e-cigs transfer nicotine to the aerosol by heating a nicotine-containing solution. Since e-cigs do not burn tobacco, they reduce or eliminate many of the combustion products of cigarette



smoke, leading to the promotion of e-cigs as reduced-harm products compared to cigarettes.<sup>45</sup> Although e-cig aerosols are compositionally less complex than cigarette smoke and contain lower toxicant levels, they are still comprised of many harmful and potentially harmful constituents,<sup>46, 47</sup> which are compounds that are known or suspected to cause direct or indirect harm to tobacco product users or non-users.<sup>48</sup>

### Nicotine

Nicotine is the principal tobacco alkaloid,<sup>39</sup> and its concentration in e-liquids strongly predicts its yield in e-cig aerosols.<sup>49</sup> Nicotine levels in e-cig emissions are also dependent on PG/VG ratio,<sup>50, 51</sup> device settings,<sup>51, 52</sup> and puff topography.<sup>52</sup> Tobacco product dependence is driven by the pharmacologic effects of nicotine.<sup>53, 54</sup>

### Carbonyls

The thermal decomposition of PG and VG yields many carbonyl compounds, potentially the most harmful of which include formaldehyde, acetaldehyde, and acrolein.<sup>55</sup> The International Agency for Research on Cancer classifies formaldehyde as a human carcinogen (Group 1)<sup>56</sup> and acetaldehyde as a possible human carcinogen (Group 2B),<sup>57</sup> while the U.S. Environmental Protection Agency considers acrolein to be a hazardous air pollutant and respiratory irritant.<sup>58</sup> All three of these compounds are associated with CVD<sup>59-63</sup> and are present in e-cig aerosols,<sup>46, 47, 49, 55, 64-98</sup> albeit at lower concentrations than cigarette smoke.<sup>46, 47, 49, 65, 74, 86, 87, 90, 91, 99, 100</sup> Carbonyl levels in e-cig emissions are dependent on PG/VG ratio,<sup>65, 76, 92, 94, 96, 97</sup> device settings,<sup>35, 49, 65, 72, 81, 87, 89, 93-97</sup> coil resistance,<sup>79</sup> puff topography,<sup>82, 96, 97</sup> and flavorings.<sup>88, 96</sup>

### Flavorings

The presence of flavoring compounds in e-liquids can affect the inhalation toxicity

of e-cig aerosols. For example, the thermal decomposition of flavoring compounds drives toxic aldehyde (e.g., formaldehyde, acetaldehyde, acrolein, glyoxal, propionaldehyde, and benzaldehyde) formation in e-cig emissions.<sup>88</sup> However, transfer of intact flavor chemicals from e-liquid to aerosol can be achieved with high efficiency.<sup>101</sup> Additionally, flavorants that are associated with pulmonary injury, such as diacetyl, acetoin, and 2,3-pentanedione, have been identified in many fruit-, candy-, and cocktail-flavored e-cigs.<sup>26, 102</sup> Furthermore, cinnamaldehyde, the primary flavoring compound in cinnamon-flavored e-cigs, is both cytotoxic and genotoxic and disrupts normal cellular processes at low concentrations.<sup>103</sup> Moreover, the highest concentrations of benzaldehyde, an aromatic aldehyde with a fruity flavor linked to ocular and respiratory irritation, were detected in cherry-flavored e-cigs.<sup>26,</sup>

104

### Reactive Oxygen Species

Reactive oxygen species (ROS), such as hydroxyl radical, hydrogen peroxide, and superoxide anion, consist of radical and non-radical oxygen species generated by the partial reduction of oxygen. ROS can cause oxidative stress, resulting in cellular damage and the initiation of pathogenic intracellular signaling pathways.<sup>105</sup> ROS have been identified in e-cig aerosols,<sup>79, 106-116</sup> albeit at 10- to-100-fold lower levels than in cigarette smoke.<sup>106, 114</sup> Free radical production is dependent on PG/VG ratio,<sup>112, 114</sup> nicotine content,<sup>109, 114, 115</sup> flavors,<sup>79, 110, 111, 114-116</sup> device settings,<sup>79, 110, 112-114</sup> puffing topography,<sup>110, 114</sup> and e-cig brand.<sup>110</sup>

### Particulate Matter

Particulate matter (PM) consists of solid particles and liquid droplets<sup>117</sup> and is present not only in ambient air pollution and cigarette smoke but also e-cig aerosols.<sup>9, 31,</sup>

<sup>117</sup> E-cig emissions contain PM<sub>2.5</sub> (diameter < 2.5 μm) and PM<sub>0.1</sub> (diameter < 0.1 μm), both of which are capable of penetrating deep into the lungs and traversing the alveolar-endothelial interface into the circulation.<sup>118-120</sup> This can lead to oxidative stress, pulmonary and systemic inflammation, vascular dysfunction, autonomic imbalance, and Ca<sup>2+</sup> channel dysregulation.<sup>117, 121</sup> Exposure to PM<sub>2.5</sub> and PM<sub>0.1</sub> is associated with hypertension, atherosclerosis, thrombosis, cerebrovascular disease, ischemic heart disease, myocardial infarction, heart failure, cardiac arrhythmias, cardiac arrest, and overall CVD risk.<sup>117, 121-</sup>  
<sup>123</sup> PM<sub>2.5</sub> levels in e-cig aerosols vary with PG/VG ratio<sup>124</sup> and wattage.<sup>125</sup>

### Metals

The metals that comprise the atomizers and tanks of e-cig devices can leach into the e-liquid and transfer to the aerosol upon vaporization.<sup>126</sup> These metals include lead, cadmium, chromium, cobalt, arsenic, antimony, manganese, tin, nickel, copper, aluminum, iron, tungsten, and barium.<sup>65, 80, 108, 126-144</sup> The public health implications of metal exposure are substantial given that these contaminants can cause multi-organ toxicity<sup>127</sup> and may increase the risk of cancer<sup>126</sup> and CVD.<sup>128</sup>

### Tobacco-Specific Nitrosamines

Tobacco-specific nitrosamines (TSNAs) are carcinogenic compounds formed during tobacco curing via nitrosation of amines.<sup>26</sup> Various TSNAs, including N'-nitrosonornicotine, N'-nitrosoanabasine, N'-nitrosoanatabine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, have been reported in e-cig aerosols in trace amounts.<sup>26, 65, 145, 146</sup>

### Polycyclic Aromatic Hydrocarbons

Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants formed during the incomplete combustion or pyrolysis of organic matter.<sup>147</sup> PAHs such as

acenaphthylene, naphthalene, phenanthrene, 1-methylphenanthrene, fluoranthene, pyrene, benz[*a*]anthracene, and chrysene have been found in e-cig aerosols at very low levels.<sup>80, 148</sup> The most prevalent PAHs that were measured in indoor air after a 2 h vaping session included the more volatile compounds naphthalene, acenaphthene, fluorene, and phenanthrene.<sup>149</sup>

### Carbon Monoxide

Carbon monoxide (CO) is typically a product of incomplete combustion or the oxidation of organic material,<sup>150</sup> yet it has been detected in e-cig aerosols.<sup>150-152</sup> Two studies reported that CO emissions increase linearly with device power,<sup>151, 152</sup> while another demonstrated an exponential relationship between CO levels and wattage. The health risks posed by CO exposure can range from headaches to death.<sup>150</sup>

### **Cooling Agents**

Cooling agents are added to tobacco products to mitigate the aversiveness of nicotine and tobacco.<sup>153</sup> Menthol is the predominant coolant in e-cigs,<sup>154</sup> and it has been shown to lessen the irritation caused by nicotine<sup>155</sup> and tobacco smoke.<sup>156</sup> Menthol also increases tobacco product initiation, dependence, and abuse liability while reducing ability to quit, especially among young people.<sup>157</sup> Recently, synthetic cooling agents such as *N*-ethyl-*p*-menthane-3-carboxamide (Wilkinson Sword [WS]-3) and 2-isopropyl-*N*,2,3-trimethylbutyramide (WS-23) have been detected in popular devices.<sup>157-159</sup> The popularity of cooling-flavored e-cigs, especially non-menthol cooling products, has increased in recent years. Indeed, sales of cooling flavors in the U.S. rose sevenfold between January 2017 and November 2021, with sales of non-menthol cooling-flavored disposables undergoing the highest percentage increase. By November 2021, cooling flavors accounted

for the majority of U.S. e-cig sales.<sup>154</sup> WS-3 and WS-23 are designated as GRAS for ingestion<sup>160</sup> despite having known *in vitro* and oral toxicities,<sup>158, 159, 161, 162</sup> but the potential health risks posed by their inhalation exposure remain unexplored.

### **Nicotine Types**

Nicotine contains two nitrogen groups; one is located in the pyridine ring ( $pK_a = 3.10$  at  $25^\circ\text{C}$  and  $2.77$  at  $37^\circ\text{C}$ ) and the other in the pyrrolidine ring ( $pK_a = 8.01$  at  $25^\circ\text{C}$  and  $7.65$  at  $37^\circ\text{C}$ ). This makes nicotine dibasic, which means it can exist in three forms depending on pH: unprotonated, monoprotonated, or diprotonated. The diprotonated species can be neglected since  $\text{pH} \leq 4$  is required for a significant proportion ( $\geq 10\%$ ) to exist.<sup>163</sup>

#### Free-Base Nicotine

When e-cigs entered the U.S. market in 2007, they contained nicotine predominantly in its unprotonated, or free-base, form. Free-base nicotine is un-ionized and therefore readily crosses biological membranes.<sup>39</sup> Free-base nicotine is also a respiratory irritant, and e-cig users perceive products with high free-base nicotine concentrations as harsh, bitter, and less appealing.<sup>164</sup> Before 2015, most commercial e-liquids contained nicotine concentrations between 1% and 2%, with 3% as the strongest available option intended for two-pack-a-day smokers.<sup>165</sup>

#### Nicotine Salts

In June 2015, PAX Labs, Inc. introduced JUUL, a pod-based device with a 5% monoprotonated nicotine, or nicotine salt, formulation.<sup>165</sup> Nicotine salts are formed by the addition of a weak organic acid to free-base nicotine.<sup>166</sup> The types of salts that have been identified in commercial e-liquids from most to least common include lactate, benzoate,

levulinate, salicylate, malate, and tartrate.<sup>167</sup> Compared to free-base nicotine, nicotine salts produce less aversive sensory effects and increase the palatability of e-cig aerosols despite higher nicotine levels.<sup>164, 165</sup> Indeed, clinical studies have demonstrated that nicotine salts enhance e-cig product appeal and improve the sensory experience of vaping relative to free-base nicotine.<sup>164, 168</sup> Notably, nicotine form does not affect its yield in e-cig aerosols,<sup>51</sup> and human studies examining the effects of form on nicotine absorption have yielded conflicting results.<sup>169-173</sup>

### Synthetic Nicotine

Synthetic nicotine, or tobacco-free nicotine, is not derived from tobacco but instead produced using a chemical manufacturing process.<sup>174</sup> There was ambiguity regarding whether this additive was within the FDA's regulatory purview, but federal legislation took effect in April 2022 that granted the FDA authority to regulate synthetic nicotine.<sup>175</sup> Synthetic nicotine is available in *S* and *R,S* formulations,<sup>174</sup> and the preferred e-cig brand among youth (Puff Bar) contains both *R* and *S* enantiomers, indicating it likely contains synthetic nicotine.<sup>176</sup> *R*- and *S*-nicotine have different biochemical properties. For instance, both *S*-nicotine and racemic nicotine exhibit greater *in vitro* toxicity than *R*-nicotine.<sup>177, 178</sup> Moreover, *R*-nicotine is metabolized 1.4 times faster than *S*-nicotine.<sup>179</sup> Additionally, *S*-nicotine is a more potent (~10-fold) agonist of nAChRs and a less potent inhibitor of acetylcholinesterase (AChE) compared to *R*-nicotine.<sup>180, 181</sup> Some reports have demonstrated that in contrast to *S*-nicotine, *R*-nicotine failed to induce weight loss,<sup>182</sup> did not trigger norepinephrine (NE) release from adrenergic nerve terminals, and generated a relatively weak pressor effect.<sup>183</sup>

## Pharmacology of Nicotine

Nicotine is a tertiary amine that consists of a pyridine and pyrrolidine ring.<sup>53, 184</sup> Over 99% of the total nicotine content in tobacco is *S*-nicotine,<sup>39</sup> which binds stereoselectively to nicotinic acetylcholine receptors (nAChRs) in the brain, autonomic ganglia, adrenal medulla, and neuromuscular junction.<sup>184</sup> Notably, the nAChRs located at the neuromuscular junction respond poorly to nicotine. When nicotine binds, the central pore of the nAChR opens, allowing Na<sup>+</sup> and Ca<sup>2+</sup> influx and K<sup>+</sup> efflux, resulting in membrane depolarization and/or activation of intracellular Ca<sup>2+</sup>-mediated signaling pathways.<sup>185</sup>

### $\alpha_4\beta_2$ nAChRs

Stimulation of central  $\alpha_4\beta_2$  nAChRs by nicotine results in dopamine release, which activates reward centers in the brain and can lead to nicotine addiction. Sustained nicotine exposure can cause desensitization, a state of ligand-induced closure and unresponsiveness of nAChRs. This induces upregulation of central nAChRs, which may underly nicotine tolerance and dependence.<sup>53, 54</sup>

### $\alpha_3\beta_4$ nAChRs

Activation of  $\alpha_3\beta_4$  nAChRs by nicotine triggers the release of NE from peripheral postganglionic sympathetic nerve endings and both epinephrine (EPI) and NE from adrenal chromaffin cells.<sup>186-189</sup> These catecholamines are responsible for nicotine's sympathomimetic effects, including increases in heart rate, systolic blood pressure (SBP), stroke volume, cardiac output, coronary blood flow,<sup>184</sup> and myocardial contractility.<sup>185</sup>

## Nicotine Metabolism

The liver is the primary site of nicotine metabolism. In humans, approximately 70–

80% of nicotine is converted to cotinine (COT). This transformation is a two-step process carried out by cytochrome P450 2A6 (CYP2A6) and aldehyde oxidase. In humans, the half-lives of nicotine and COT are 2 h and 16 h, respectively. COT is converted to other metabolites, including *trans*-3'-hydroxycotinine (3HC), which is the principal nicotine metabolite detected in the urine of tobacco product users. The nicotine metabolite ratio (NMR, 3HC/COT) can be used as a marker of nicotine metabolism by CYP2A6. About 90% of a systemic nicotine dose is excreted in urine as total nicotine equivalents (TNE), which is the sum of nicotine and its metabolites. The six primary nicotine metabolites excreted in urine are 3HC (33-40%), COT glucuronide (12-17%), COT (10-15%), 3HC glucuronide (7-9%), nicotine *N'*-oxide (4-7%), and nicotine glucuronide (3-5%).<sup>39</sup>

### **Autonomic Nervous System**

The autonomic nervous system (ANS) controls visceral or involuntary physiologic processes such as breathing, heart rhythm, vascular tone, and digestion. It consists of the sympathetic and parasympathetic divisions, which typically have opposing effects. The sympathetic branch regulates cardiac output and blood flow to promote alertness and quick physical movement (“fight or flight” or catabolic functions), whereas the parasympathetic branch modulates basal control of cardiovascular physiology (“rest and digest” or anabolic functions). In addition to their functional impacts, the sympathetic and parasympathetic divisions can be characterized by their distinct neuronal organization, neurotransmitters, and receptors.<sup>190</sup>

#### **Sympathetic Organization**

Autonomic output originates primarily in the hypothalamus and brainstem (midbrain, pons, and medulla oblongata). Descending medullary fibers transmit



sympathetic signals to cell bodies of preganglionic sympathetic neurons in the intermediolateral cell columns of the thoracic and upper lumbar spinal cord (T1–L3). Preganglionic sympathetic axons are short, cholinergic, fast conducting (~15 m/s), thinly myelinated fibers that exit the spinal column through the ventral roots and white rami communicantes. These fibers synapse with cell bodies of postganglionic sympathetic neurons in the paravertebral or prevertebral ganglia located near the spinal cord. Postganglionic sympathetic axons are long, noradrenergic, slower conducting (~1 m/s), unmyelinated fibers that project to the gray rami communicantes and peripheral spinal nerves before terminating at their effectors.<sup>190-192</sup>

### Parasympathetic Organization

Some parasympathetic outflow originates from the sacral spinal cord (S2–S4), but most is transmitted through the vagus nerve, which provides parasympathetic output to all viscera of the thorax and abdomen. Cell bodies of vagal preganglionic neurons are found within the dorsal motor nucleus of the vagus and nucleus ambiguus in the medulla. Postganglionic parasympathetic neurons are located in terminal ganglia that often lie within the walls of their target organs. Therefore, long preganglionic and short postganglionic neurons comprise the parasympathetic branch.<sup>192</sup>

### Sympathetic and Parasympathetic Cardiac Effects

Both the sympathetic and parasympathetic divisions influence the cardiac pacemaker, conduction pathways, and myocardium but have antagonistic effects. Sympathetic postganglionic fibers densely innervate the sinoatrial node (SAN), atrioventricular node (AVN), and atrial and ventricular myocardium where  $\beta$ -adrenergic activation by NE increases heart rate (chronotropy), myocardial contractility (inotropy),

AVN conduction velocity (dromotropy), and myocardial relaxation (lusitropy). Preganglionic sympathetic neurons directly supply adrenal chromaffin cells and stimulate the release of EPI and NE into the bloodstream, also leading to cardiac  $\beta$ -adrenergic stimulation. Parasympathetic postganglionic fibers innervate the SAN and AVN as well as the atrial myocardium but are sparsely distributed in the ventricular myocardium. These fibers activate  $M_2$  muscarinic receptors by releasing acetylcholine, which counteracts the sympathetic cardiac effects of EPI and NE.<sup>190</sup>

### **$\beta_1$ -Adrenoceptors**

Adrenoceptors are transmembrane proteins that belong to the G protein-coupled receptor superfamily.<sup>193</sup> They bind to and are activated by the endogenous catecholamines EPI and NE.<sup>194</sup> There are two classes of adrenoceptors,  $\alpha$  and  $\beta$ , which can be further divided into the subtypes  $\alpha_1$ ,  $\alpha_2$ ,  $\beta_1$ ,  $\beta_2$ , and  $\beta_3$ .<sup>195</sup>  $\beta_1$ -adrenoceptors are located primarily in the heart and comprise approximately 80% of all cardiac  $\beta$ -adrenoceptors.<sup>195, 196</sup>

#### $\beta_1$ -Adrenoceptor Signaling

Upon catecholamine binding, the  $\beta_1$ -adrenoceptor undergoes a conformational change that causes its heterotrimeric G protein to dissociate into  $G\alpha_s$  and  $G\beta\gamma$  components.  $G\alpha_s$  binds to and stimulates adenylyl cyclase, which converts adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP), thereby raising intracellular cAMP levels. cAMP binds to the regulatory subunits of protein kinase A (PKA), causing the release of the catalytic PKA subunits (PKA-C). PKA-C phosphorylates specific serine and threonine residues on various proteins involved in the augmentation of chronotropy, inotropy, dromotropy, and lusitropy.<sup>195, 197, 198</sup>

### Myocardial Effects

Activation of  $\beta_1$ -adrenoceptors in myocardial cells enhances inotropy and lusitropy through the phosphorylation of L-type  $\text{Ca}^{2+}$  channels ( $\text{Ca}_v1.2$ ), ryanodine receptor 2 (RyR2), cardiac troponin I (cTnI), and phospholamban (PLN).<sup>198</sup>  $\text{Ca}_v1.2$  phosphorylation augments inotropy by increasing L-type  $\text{Ca}^{2+}$  current ( $I_{\text{CaL}}$ ), which amplifies  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release and boosts the availability of  $\text{Ca}^{2+}$  for binding to cardiac troponin C (cTnC).<sup>192, 198</sup> RyR2 phosphorylation improves inotropy by inducing sarcoplasmic reticulum (SR)  $\text{Ca}^{2+}$  release. Phosphorylation of cTnI weakens its interaction with cTnC, which promotes the dissociation of  $\text{Ca}^{2+}$  from cTnC, thereby enhancing lusitropy. Phosphorylation of PLN relieves its inhibitory effect on SR  $\text{Ca}^{2+}$ -ATPase (SERCA), resulting in increased  $\text{Ca}^{2+}$  sequestration in the SR.<sup>198</sup> This simultaneously augments lusitropy by reducing cytosolic  $\text{Ca}^{2+}$  and boosts inotropy by expanding SR  $\text{Ca}^{2+}$  stores for later release.<sup>192, 198</sup>

### Pacemaker Effects

Stimulation of  $\beta_1$ -adrenoceptors in the SAN enhances chronotropy by two mechanisms. First, cAMP binds to hyperpolarization-activated cyclic nucleotide-gated channel 4, thereby increasing pacemaker current ( $I_f$ ), which accelerates diastolic depolarization.<sup>197, 199</sup> Second, the increase in  $I_{\text{Ca}}$  also hastens diastolic depolarization and makes threshold more negative.<sup>199</sup>

### $\beta$ -blockers

$\beta$ -adrenoceptor antagonists, or  $\beta$ -blockers, are compounds that compete with catecholamines for the binding site on  $\beta$ -adrenoceptors. First-generation  $\beta$ -blockers are nonselective in that they inhibit both  $\beta_1$ - and  $\beta_2$ -adrenoceptors (e.g., propranolol). Second-generation  $\beta$ -blockers are more cardioselective because they have a higher affinity for  $\beta_1$ -

adrenoceptors (e.g., atenolol and metoprolol). Third-generation  $\beta$ -blockers display a varied selectivity for  $\beta_1$ -adrenoceptors and are capable of vasodilation through  $\alpha_1$ -adrenoceptor inhibition and  $\beta_3$ -adrenoceptor activation (e.g., carvedilol and nebivolol).<sup>200, 201</sup>

### **Heart Rate Variability**

Healthy hearts display wide fluctuations in normal sinus rhythm during steady-state conditions, thereby providing them with the flexibility to quickly adapt to an unpredictable, dynamic environment. In contrast, unhealthy hearts exhibit less pronounced oscillations in sinus rate, thus impairing their ability to rapidly cope with uncertainty in a changing milieu.<sup>202-204</sup> These chronotropic variations are collectively termed heart rate variability (HRV), defined as the change in time intervals between adjacent heartbeats.<sup>203</sup> HRV provides a sensitive, noninvasive assessment of cardiac autonomic regulation.<sup>205, 206</sup> Since both the sympathetic and parasympathetic divisions are tonically active and have reciprocal actions,<sup>207</sup> the relative balance of activity between the two branches dictates their overall impact on HRV.<sup>204</sup> Reduced HRV indicates sympathetic dominance and is positively associated with CVD and all-cause mortality.<sup>208, 209</sup> Elevated HRV suggests parasympathetic dominance and directly correlates with aerobic fitness,<sup>210</sup> behavioral flexibility, cognitive performance, and psychological resiliency.<sup>203</sup> Two primary methods are used to measure HRV.

#### Time Domain Analysis

Time domain analysis quantifies the variability in RR interval duration, or time period between successive heartbeats.<sup>204, 206</sup> The standard deviation of normal RR intervals (SDNN) is one of the most commonly cited time domain parameters of HRV.<sup>190, 203</sup> “Normal” indicates that all artifacts and ectopic beats have been removed.<sup>204</sup> Both

sympathetic and parasympathetic influences contribute to SDNN, but the main source of variation is parasympathetic activity. Low age-adjusted SDNN values predict both morbidity and mortality.<sup>203, 204, 211</sup> SDNN directly correlates with parasympathetic dominance and inversely correlates with sympathetic dominance.<sup>190</sup>

Another frequently reported time domain index of HRV is the root mean square of successive differences of normal RR intervals (RMSSD). RMSSD quantifies the variance between pairs of adjacent RR intervals.<sup>190</sup> Since the onset of parasympathetic effects (< 1 s) are more rapid than sympathetic impacts (> 5 s), any abrupt beat-to-beat change in RR interval is primarily driven by parasympathetic activity.<sup>203, 204, 211</sup> Therefore, parasympathetic output influences RMSSD to a greater degree than SDNN,<sup>204</sup> and thus RMSSD is the main time domain measure used to estimate parasympathetically mediated HRV changes.<sup>203, 204, 211</sup> Like SDNN, RMSSD positively correlates with parasympathetic dominance and inversely correlates with sympathetic dominance.<sup>190</sup>

### Frequency Domain Analysis

Frequency domain analysis separates the total variance of a sequence of heartbeats into its frequency components, usually identifying two main peaks: high frequency (HF, 0.15-0.4 Hz) and low frequency (LF, 0.04-0.15 Hz). The HF band is widely considered to be an index of cardiac parasympathetic activity, whereas LF power is often assumed to reflect sympathetic drive to the heart.<sup>212</sup> However, evidence suggests that the HF band may have a sympathetic component and therefore might not solely represent cardiac parasympathetic influence.<sup>212, 213</sup> In addition, LF power can be affected by sympathetic, parasympathetic, and baroreflex mechanisms depending on testing conditions, indicating that it is not a pure measure of cardiac sympathetic activity.<sup>203, 204, 212</sup> Therefore, caution

should be exercised when using frequency domain parameters to evaluate HRV. As such, time domain indices (e.g., SDNN and RMSSD) were used to assess HRV in the studies herein.

### **Autonomic Activation and Cardiac Arrhythmias**

The ANS plays a major role in the pathogenesis of cardiac arrhythmias, which represent the leading cause of SCD in the U.S. The mechanisms by which autonomic stimulation is either arrhythmogenic or antiarrhythmic are intricate and distinct for different arrhythmia types. For instance, simultaneous discharge of both the sympathetic and parasympathetic branches is the most common trigger of atrial fibrillation. Moreover, sympathetic activation produces changes in repolarization and reduces the fibrillation threshold, facilitating the development of ventricular fibrillation (VF). These impacts are amplified in the setting of cardiac ischemia in which the ischemic myocardium becomes a sensitive arrhythmogenic substrate due to tissue remodeling. In many long QT syndromes, sympathetic excitation substantially increases  $I_{CaL}$ , which increases the likelihood of early afterdepolarizations and initiation of reentry. This increases the risk of torsades de pointes, a type of polymorphic ventricular tachycardia (PVT) that can lead to SCD. Additionally, either elevated parasympathetic tone or sympathetic withdrawal may precipitate VF in Brugada or J-wave syndromes, whereas sympathetic activation can prevent VF in these conditions. In catecholaminergic PVT, excessive SR  $Ca^{2+}$  leak leads to cytosolic  $Ca^{2+}$  overload, which provokes delayed afterdepolarizations, triggered activity, and ventricular arrhythmias, particularly under conditions of enhanced sympathetic influence. Lastly, ventricular arrhythmias associated with arrhythmogenic right ventricular cardiomyopathy are often provoked by activities that induce sympathetic excitation.<sup>214</sup>

## Cardiovascular Toxicity of E-cigs

E-cig exposure may heighten CVD risk by inducing cardiac autonomic imbalance and electrophysiologic instability, thrombosis and hemostasis, cardiac dysfunction, and vascular impairment.

### Autonomic Imbalance and Electrophysiologic Instability

Human induced pluripotent stem cell-derived cardiomyocytes treated with vanilla custard e-cig aerosol (6 mg/mL nicotine) extracts exhibited a reduced beating rate and an increased field potential duration, likely due to rapid delayed-rectifier K<sup>+</sup> current ( $I_{Kr}$ ) inhibition. Mice exposed to this e-cig aerosol presented with sympathetic predominance at 5 and 10 wk, and e-cig-exposed mouse hearts displayed more severe action potential duration alternans as well as more sustained inducible ventricular tachycardia.<sup>215</sup> Also in mice, menthol (2.4% nicotine) or nicotine-free PG e-cig aerosols acutely provoked arrhythmias concurrent with heart rate increases and HRV declines following exposure.<sup>216</sup> Additionally, an 8 wk exposure to JUUL Virginia Tobacco (5% nicotine) in rats decreased HRV, shortened effective refractory period, prolonged calcium transient duration, increased susceptibility to inducible atrial fibrillation and ventricular tachycardia, and induced intrinsic neurocardiac remodeling indicative of sympathetic hyperinnervation and parasympathetic hypoinnervation.<sup>217</sup> In humans, acute and chronic use of nicotine-containing e-cigs resulted in sympathetic dominance,<sup>218, 219</sup> and the nicotine, not non-nicotine, component of the aerosol was implicated in the acute effects.<sup>218</sup> Acute use of nicotine-containing e-cigs also prolonged an electrocardiographic index of ventricular repolarization (T<sub>peak</sub> to T<sub>end</sub>/QT ratio) that may increase sudden death risk.<sup>220</sup>

## Thrombosis and Hemostasis

Donor platelets from healthy nonsmokers exposed to e-cig aerosol extracts displayed upregulation of adhesion markers and inflammatory surface receptors as well as increases in aggregation, activation, and surface complement protein deposition.<sup>221</sup> Moreover, e-cig-exposed (18 mg/mL or 5% nicotine) mice had shortened thrombosis occlusion and bleeding times and their platelets exhibited increased aggregation, dense and  $\alpha$  granule release,  $\alpha_{IIb}\beta_3$  integrin activation, phosphatidylserine expression, RAC-alpha serine/threonine-protein kinase and extracellular signal-regulated kinase activation, and resistance to prostacyclin inhibition.<sup>2, 222</sup> In addition, sera from healthy participants contained higher levels of soluble cluster of differentiation 40 ligand, soluble P-selectin,<sup>223, 224</sup> and platelet aggregation<sup>223</sup> after acute e-cig (0.58 mg nicotine) use relative to baseline. Furthermore, short-term e-cig (18 or 19 mg/mL nicotine) use among healthy smokers elevated levels of circulating platelet microparticles, which are biomarkers of thrombosis and hemostasis.<sup>225, 226</sup>

## Cardiac Dysfunction

In mice, e-cig exposure (24 mg/mL nicotine) lowered heart rate and raised SBP at 3 months and resulted in cardiac fibrosis at 6 months.<sup>227</sup> A 12 wk exposure (2.4% nicotine) in ApoE<sup>-/-</sup> mice resulted in declines in LV fractional shortening, LV ejection fraction, and velocity of circumferential fiber shortening. Cardiomyocytes from these e-cig-exposed mice displayed nuclear (e.g., nuclear malformation and chromatin fragmentation) and myofibrillar (e.g., myofibrillar destruction, lipid accumulation, and mitophagy) abnormalities suggestive of cardiomyopathy.<sup>228</sup> Mice exposed to both nicotine-free and nicotine-containing (6 and 24 mg/mL nicotine) e-cigs for 60 wk exhibited increases in heart



weight, LV mass, and cardiac oxidative stress, while only nicotine-containing e-cigs increased LV anterior and posterior wall thicknesses.<sup>229</sup> In addition, male mice exposed to e-cig aerosol (20.2 mg/mL nicotine) for 3 months demonstrated declines in fractional shortening, end-systolic elastance, and preload-recruitable stroke work indicative of reduced contractile capacity.<sup>230</sup> In rats, an 8 wk exposure to JUUL Virginia Tobacco (5% nicotine) led to increases in SBP, LV end-systolic volume, LV mass, and left atrial diameter, decreases in ejection fraction and microvessel density, and severe cardiac fibrosis.<sup>217</sup> In humans, acute e-cig use (11 mg/mL nicotine) raised mitral annulus diastolic velocity and diastolic strain rate while lowering isovolumetric relaxation time and myocardial performance index compared to smoking.<sup>231</sup>

#### Vascular Impairment

Cultured human or rat endothelial cells treated with e-cig aerosol extracts or sera from e-cig users exhibited increases in endothelial barrier loss, reactive oxygen species, DNA damage, cell permeability, inflammatory markers, morphological alterations, caspase-3 and -7 activity, LDL uptake, and/or hydrogen peroxide release as well as declines in cell viability, proliferation, and/or nitric oxide secretion.<sup>232-237</sup> In rats, acute exposure to aerosols from either JUUL (Virginia Tobacco, Menthol, or Mango, 5% nicotine) or a tank-style e-cig (unflavored, 12 mg/mL nicotine) reduced flow-mediated dilation (FMD) indicative of endothelial dysfunction.<sup>238, 239</sup> In mice, long-term e-cig exposure (0, 6, or 24 mg/mL nicotine) elevated SBP, diastolic blood pressure (DBP), mean arterial pressure (MAP), systemic vascular resistance, aortic wall thickness, and aortic oxidative stress.<sup>229</sup> In addition, chronic e-cig exposure (18 mg/mL or 4% nicotine) increased aortic and carotid artery stiffness in wild-type or ApoE<sup>-/-</sup> mice.<sup>240, 241</sup> Further, both short- and long-term e-cig

exposures in mice increased endothelium-dependent vasoconstriction<sup>229, 236</sup> and reduced endothelium-dependent<sup>229, 236, 240, 242</sup> and -independent<sup>229</sup> vasodilation suggestive of vascular dysfunction. In humans, acute e-cig use induced changes consistent with endothelial impairment and increased arterial stiffness, including declines in FMD, hyperemic index, peak velocity, pulse wave amplitude, and pulse transit time as well as increases in flow-mediated pulse constriction, pulse wave velocity, resistivity index, augmentation index, and augmentation index corrected for heart rhythm.<sup>224, 225, 236, 237, 243-248</sup> Furthermore, short-term e-cig use among healthy sporadic smokers raised levels of circulating endothelial progenitor cells, which are associated with elevated CVD risk, up to 4 h after exposure.<sup>249, 250</sup> Moreover, acute e-cig use increased heart rate, SBP, DBP, MAP, and pulse pressure<sup>224, 225, 243, 244, 247, 251, 252</sup> and blunted endothelial-dependent vasodilation<sup>245</sup> in human participants.

### **Project Summary**

Proper regulation of cardiovascular function depends on effective coordination of the sympathetic and parasympathetic divisions of the ANS. Evidence is mounting that e-cig exposure disrupts the balance between the two autonomic branches, potentially resulting in arrhythmogenesis.<sup>215-220</sup> Prior work in our laboratory has demonstrated that acute e-cig exposure triggers sympathetic dominance, pro-arrhythmic changes in cardiac electrophysiology, and ventricular arrhythmias. Male mice were more susceptible to e-cig-induced sympathoexcitation and arrhythmogenesis compared to female mice; thus, male mice were used in the studies herein.

Menthol has been the most common cooling agent in e-cigs for several years.<sup>154</sup> We recently showed that menthol-flavored aerosols from a commercial e-liquid provoked

ventricular arrhythmias in mice, whereas tobacco-flavored aerosols did not.<sup>216</sup> Synthetic coolants such as WS-3 and WS-23 have also been identified in popular disposables (Puff Bar), which have surged in popularity since the FDA started enforcing restrictions on flavored cartridge-based e-cigs in February 2020.<sup>157-159</sup> These additives are toxic both *in vitro* and orally<sup>158, 159, 161, 162</sup> but are nonetheless present in many commercial products due to their GRAS status.<sup>160</sup> Despite their presence in e-liquids, the impacts of cooling agents and their relative amounts on e-cig-induced cardiac dysfunction remain unevaluated.

Nicotine is a highly addictive compound that drives tobacco product dependence.<sup>53, 54</sup> The nicotine found in e-liquids can be in its free-base, salt, and/or (*R,S*) forms. Almost all (> 99%) of the nicotine in most e-liquids is in the *S* form, but the preferred e-cig brand among adolescents (Puff Bar) consists of nicotine with both *R* and *S* enantiomers.<sup>176</sup> Free-base, salt, and (*R,S*)-nicotine have different biochemical properties. For example, free-base nicotine is harsher and more bitter than nicotine salt,<sup>164</sup> but it can diffuse through epithelial tissues more readily because it is un-ionized.<sup>39</sup> *R*-nicotine, for instance, is a less potent nAChR agonist compared to *S*-nicotine,<sup>180</sup> and, in contrast to *S*-nicotine, failed to trigger NE release from adrenergic nerve terminals.<sup>183</sup> Despite possessing distinct biochemical attributes, the effects of free-base, salt, and (*R,S*)-nicotine on e-cig-evoked cardiac injury remain understudied.

Delineating the e-cig-evoked cardiotoxicity of particular e-liquid constituents at specific concentrations would furnish regulators with the information necessary to devise effective regulatory strategies that mitigate the risks of vaping. To that end, we tested the hypothesis that e-cigs modify cardiac autonomic balance and ventricular arrhythmogenesis in mice dependent on e-liquid constituent type and concentration.

## Specific Aims

### Specific Aim 1

The goal of Aim 1 was to assess the influence of specific types and concentrations of cooling agents on e-cig-induced cardiac autonomic imbalance and ventricular arrhythmias. Male C57BL/6J mice (10–12 wk old) underwent whole-body exposure to filtered air (FA), vehicle (30/70 PG/VG + 2.5% nicotine salt), and vehicle plus either menthol, WS-3, or WS-23 using a serial exposure regimen. On a given exposure day, mice were exposed to either FA, vehicle, or increasing concentrations (0.25%, 1%, and 2.5%) of individual coolants for three 18 min exposure cycles (9 min puffing phase followed by 9 min washout phase) per concentration. Electrocardiograms (ECGs) were collected using implantable telemetry, and heart rate, HRV, and ventricular premature beats (VPBs) were analyzed using post-processing software. Acute exposures were conducted in separate non-telemetered mice to evaluate the effects of coolant type and concentration on nicotine absorption and breakdown.

### Specific Aim 2

The purpose of Aim 2 was to evaluate the impact of nicotine formulation on e-cig-evoked cardiac autonomic imbalance and ventricular arrhythmias while testing the role of  $\beta_1$ -adrenergic activation in cardiac autonomic responses. Using a serial exposure regimen, male C57BL/6J mice (10–12 wk old) underwent whole-body exposure to FA, vehicle (30/70 PG/VG), and vehicle plus either racemic nicotine, free-base nicotine, or nicotine salt. On each exposure day, mice were exposed to either FA, vehicle, or increasing concentrations (1%, 2.5%, and 5%) of individual nicotine types for three 18 min exposure cycles (9 min puffing phase followed by 9 min washout phase) per concentration.

Telemetry-derived ECGs were assessed for heart rate, HRV, and VPBs using post-processing software. Short-term exposures were carried out using separate non-telemetered mice to examine the influence of nicotine formulation on nicotine intake and metabolism. Since nicotine is a known sympathomimetic that stimulates  $\beta_1$ -adrenoceptors, we investigated the contribution of  $\beta_1$ -adrenergic activation to e-cig-induced cardiac autonomic imbalance using the  $\beta_1$ -blocker atenolol.

CHAPTER II  
SYNTHETIC COOLING AGENTS EXACERBATE E-CIGARETTE-INDUCED  
CARDIAC ARRHYTHMIAS AND SYMPATHETIC DOMINANCE IN MICE

**Overview**

Recent findings indicate that inhalation of electronic cigarette (e-cig) aerosols perturbs autonomic balance and enhances susceptibility to cardiac arrhythmias, but the role of specific e-liquid constituents in these effects remains unexplored. We thus investigated how popular cooling agents (menthol, WS-3, and WS-23) affect the induction of autonomic imbalance and spontaneous ventricular arrhythmias by e-cig aerosol inhalation. ECG-telemetered C57BL/6 mice were exposed to filtered air (FA) or e-cig aerosols generated from e-liquids containing propylene glycol and vegetable glycerin plus 2.5% nicotine salt without coolant (vehicle) or with increasing coolant concentrations (0.25%, 1%, and 2.5%) for three 9 min puff sessions per concentration. Changes in spontaneous ventricular premature beats (VPBs), heart rate, and heart rate variability (HRV, i.e., standard deviation of RR [SDNN] and root mean square of successive differences [RMSSD]) were analyzed using mixed models and generalized estimating equations. Compared to FA, vehicle decreased heart rate during puff phases but depressed HRV (SDNN and/or RMSSD) during washouts, indicating shifts from parasympathetic to sympathetic dominance. Exposure to 1% menthol decreased heart rate during puffing and washouts relative to both controls. During puffing, WS-3 and WS-23 (both  $\geq 1\%$ ) increased RMSSD compared to vehicle, suggesting accentuated parasympathetic dominance. During washouts, WS-3 (0.25% and

2.5%) and WS-23 ( $\geq 1\%$ ) increased heart rate, and menthol (2.5%), WS-3 (2.5%), and WS-23 ( $\geq 1\%$ ) decreased SDNN and RMSSD beyond vehicle, signifying accentuated sympathetic dominance. Only 2.5% WS-23 increased VPBs vs. both controls, and 2.5% WS-3 increased VPBs vs. FA only. Coolants modified the associations of VPBs with heart rate and SDNN, with VPBs correlating positively with heart rate and inversely with SDNN for coolants but not vehicle. Collectively, cooling agents may enhance the cardiac risks of vaping by promoting sympathetic dominance and arrhythmias. If validated in humans, our findings indicate that regulation of coolants may reduce the risks of vaping.

### **Introduction**

Electronic cigarettes (e-cigs) deliver nicotine by thermally aerosolizing e-liquids containing propylene glycol (PG), vegetable glycerin (VG), nicotine, and flavorants.<sup>31</sup> Although e-cigs may help some users quit conventional smoking,<sup>253, 254</sup> flavors increase the appeal and palatability of e-cigs<sup>9</sup> and may thereby promote use initiation or dependency. During 2011–2019, e-cig use among middle and high school students increased by more than 15-fold.<sup>10, 255</sup> In the following year, menthol e-cig sales doubled, while from 2019–2021, sales of coolant-rich flavors other than menthol and mint increased 10-fold.<sup>154</sup>

Menthol is a cooling agent common in e-cigs, including those not labeled ‘menthol’, often at higher concentrations than other flavorants.<sup>158, 256, 257</sup> In addition to its minty taste, menthol confers a soothing, analgesic effect via activation of transient receptor potential melastatin 8 (TRPM8), a cold-sensitive cation channel in peripheral sensory neurons.<sup>258</sup> Consequently, menthol can reduce the irritancy of nicotine,<sup>155</sup> cigarette smoke,<sup>156</sup> and individual constituents of cigarette smoke,<sup>259</sup> and thereby promote tobacco

use, especially among new or young users.<sup>260</sup> Yet menthol can also cause direct cellular toxicity. *In vitro* studies have shown that mentholated e-cig aerosols alter mitochondrial bioenergetics<sup>261</sup> and promote oxidative stress and inflammation<sup>262</sup> in human bronchial epithelial cells. We recently found that menthol promotes the cardiotoxicity of inhaled e-cig aerosols in mice. Aerosols from a menthol-flavored—but not a tobacco-flavored—e-liquid acutely increased spontaneous cardiac arrhythmias.<sup>216</sup> Thus, menthol and other coolants may pose unique risks to e-cig users.

Although synthetic cooling agents lack the minty flavor of menthol and its potential for irritation at high concentrations, they stimulate a menthol-like cooling sensation by activating TRPM8 channels.<sup>160, 263, 264</sup> Such a cooling effect is an important reason for their appeal and wide use.<sup>153</sup> With bans of e-cig flavors including menthol in several major U.S. markets,<sup>154</sup> synthetic coolants are likely to grow in use as menthol substitutes, but their health effects remain unclear. Many synthetic coolants are considered “generally recognized as safe” (GRAS) for ingestion by the U.S. Food and Drug Administration (FDA) and are thus widely used in confections, chewing gum, breath fresheners, and cosmetics.<sup>160</sup> Synthetic coolants such as Wilkinson Sword (WS)-3 and WS-23 are often used at high concentrations in the leading e-cig brands (e.g., Puff Bar)<sup>157-159</sup> to give an ‘ice’-like property, which a recent survey suggests is the most popular flavor attribute among youth.<sup>265</sup> This alone is concerning because ice-flavored products are tied to greater nicotine vaping frequency, intensity, and dependence as well as increased combustible tobacco product use.<sup>265</sup> Yet, several *in vitro* studies and risk evaluations suggest that synthetic cooling agents, including WS-3 and WS-23, may pose direct health risks.<sup>157-159,</sup>

<sup>161</sup> Although *in vivo* evidence is lacking, there is data indicating that oral WS-3 and WS-



23 can induce renal and hepatic toxicity with sub-chronic treatment<sup>162</sup> and that aerosols containing WS-23 can alter pulmonary function with subacute inhalation exposures.<sup>266</sup>

Despite the surging popularity of synthetic coolants and sporadic reports of their *in vitro* and *in vivo* toxicity, the cardiac toxicity of these additives has not been studied. There is thus an urgent public health need to test these compounds for cardiovascular risks. Accordingly, the present study was designed to examine the effects of synthetic coolants on cardiac excitability. We thus used a murine model to assess the influence of varying coolant types and concentrations on e-cig-induced cardiac electrical dysfunction and autonomic imbalance. We hypothesized that cooling agents exacerbate e-cig-evoked cardiac autonomic imbalance and arrhythmogenesis in a concentration-dependent manner. The new insights generated by this work may inform the design of human studies or guide the regulation of specific cooling agents in e-liquids.

## **Materials and Methods**

### Animals

Male C57BL6/J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and cared for according to the Guide for the Care and Use of Laboratory Animals. All protocols were approved by the University of Louisville Institutional Animal Care and Use Committee. Mice were housed in a temperature-controlled vivarium under pathogen-free conditions and a 12h:12h light:dark cycle. Mice were provided a standard chow diet (Rodent Diet 5010, 4.5% fat by weight, LabDiet; St. Louis, MO, USA) and water *ad libitum*. Radiotransmitters (ETA-F10, Data Sciences International, Inc., St. Paul, MN, USA) were implanted subcutaneously with electrodes positioned in a lead II configuration. For all implantations, mice were anesthetized with 2% isoflurane and injected with one

dose of pre- and post-operative analgesia (ketoprofen, 5 mg/kg, s.c.). After implantation, mice were individually housed and allowed at least 10 d for recovery prior to exposure. For all studies, euthanasia consisted of injection with sodium pentobarbital (50 mg/kg, i.p.) followed by exsanguination via cardiac puncture.

### Exposures

Two cohorts of mice (male, C57BL/6J, 10–12 wk old, n = 4/cohort) underwent whole-body exposure (inExpose, SCIREQ, Inc., Montreal, QC, CAN) to filtered air (FA) or nicotine-containing e-cig aerosols from a third-generation tank-style device operated at settings comparable to popular pod devices (10 W, 1.5  $\Omega$ , air inlets 100% open) using a crossover design (Fig. 2.1A) and a serial exposure regimen with ascending coolant concentrations (Fig. 2.1B). Each coolant exposure involved nine 9 min puffing phases, each punctuated by a 9 min washout phase, with coolant concentrations increasing after washouts three and six. Peak WS-23 concentrations reached 2.5% (27.4 mg/mL) in this study, which is well below the maximal concentration of WS-23 (45 mg/mL) found in some Puff Bar products.<sup>158, 159</sup> E-liquid compositions and ingredient sources are provided in Table 2.1. Pre-exposure (45 min), baseline (final 15 min before the start of puffing), recovery (30 min), and washout phases consisted of administration of ambient air. Puffing phases consisted of two 4 s, 91-mL puffs/min.<sup>216</sup> Total suspended particulates and puff-normalized aerosol deposition values were comparable to prior findings (Fig. 2.2).<sup>52, 267, 268</sup> Mice were acclimated to the chamber prior to exposure and allowed  $\geq 3$  d for recovery between exposures. Individual mice were separated within the chamber by dividers during all exposures and returned to their respective home cages immediately after exposure.

### Radiotelemetry data acquisition and analysis

Physiologic parameters from individual mice were collected by RSC-1 receivers (Data Sciences International, Inc. St. Paul, MN, USA) and forwarded to a computer running Ponemah 6.51 (Data Sciences International, Inc., St. Paul, MN, USA). Electrocardiograms (ECGs) were sampled at 1 kHz and continuously monitored throughout the exposure. Using ecgAUTO 3.5 (emka Technologies, Paris, FR), signal noise and abnormal beats were removed prior to calculation of 1 min means for RR intervals and time domain heart rate variability (HRV) parameters, including standard deviation of normal RR intervals (SDNN) and root mean square of successive differences of normal RR intervals (RMSSD). Heart rate and HRV are reported as each animal's percent change from baseline on a given exposure day. Across all exposures, heart rate and HRV values were generated from RR intervals successfully analyzed within each 1 min period (mean  $\pm$  SD success of  $86.6 \pm 8.7\%$  of beats). ECG waveforms were examined for VPBs using a library of 28 beats. We classified VPBs as ectopic QRS complexes with at least three of the following four features: (i) a lengthened QRS duration, (ii) premature occurrence and a subsequent compensatory pause, with the R-VPB-R interval  $\geq$  the sum of the prior two normal RR intervals, (iii) no visible P or an overtly shortened PR, and (iv) abnormal R, S, or J wave morphology (amplitudes and/or areas). VPBs occurring within episodes of non-sustained ventricular tachycardia were quantified as individual arrhythmias.

### Nicotine intake and metabolism

In additional experiments, non-telemetered mice (male, C57BL/6J, 10 wk old, n = 5 mice/exposure) underwent exposure to various nicotine-containing e-cig aerosols with

varying coolant types and concentrations. After pre-exposure (1 h), mice were exposed in a series of three 9 min puffing phases punctuated by two 9 min washout phases and removed from the chamber immediately after the final puffing phase. Blood was collected via cardiac puncture, mixed with EDTA (Millipore Sigma, Burlington, MA, USA), and centrifuged at 5000 rpm for 8 min at 4 °C. Plasma was collected and stored at -80 °C. Plasma levels of nicotine, cotinine (COT), and *trans*-3'-hydroxycotinine (3HC) were quantified using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)<sup>269</sup> for derivation of total nicotine equivalents (TNE) and nicotine metabolite ratio (NMR, 3HC/COT).

### Statistics

All statistical analyses were performed for time series data in SAS 9.4 (Cary, NC) and for cross-sectional data in Prism 7 (GraphPad, San Diego, CA, USA), with  $P < 0.05$  considered significant. For heart rate and HRV, 1 min means were normalized as each animal's percent change from its baseline and analyzed separately by phase (due to heart rate effects opposing by phase).<sup>216</sup> Linear mixed models and repeated subjects were used to test heart rate and HRV parameters for interactions between treatments and coolant concentrations relative to FA and vehicle controls time-matched by exposure cycle and phase. Arrhythmia counts were time-normalized to incidence rates and analyzed by treatment using generalized estimating equations with negative binomial distribution while matching by exposure cycle and phase, with stratification by concentration in follow-up analyses. Arrhythmia incidence rates were analyzed for correlation with heart rate and HRV by simple linear regression and Spearman's ranked  $r$ . We further tested for interactions between coolants as a binary variable and heart rate or HRV in predicting

ventricular arrhythmias using generalized estimating equations. For any interactions with  $P < 0.10$ , analyses were stratified by coolant to test the relationship between that parameter and arrhythmias. Baseline heart rate and HRV and plasma analytes were evaluated using one-way analysis of variance (ANOVA) with Tukey's post hoc test. Plasma analytes were normalized to the FA control and tested for differences across WS-23 concentrations and vehicle or across coolants at 2.5% and vehicle. All reported differences and correlations are statistically significant ( $P < 0.05$  vs. FA or vehicle controls) unless otherwise stated.

## **Results**

### Heart rate and heart rate variability

Heart rate, SDNN, and RMSSD of exposed mice were analyzed at baseline and during puffing and washout phases according to coolant type and concentration. There were no significant differences in baseline heart rate, SDNN, or RMSSD prior to exposures (Fig. 2.3). However, heart rate declined and HRV increased throughout the duration of exposure to FA, consistent with the animals assuming a resting state in the hours after handling and placement in the exposure chamber.

Exposure to aerosols containing vehicle alone (PG/VG + 2.5% nicotine) decreased heart rate and increased RMSSD vs. FA during all puff phases and increased SDNN vs. FA during puff phases time-matched with 1% and 2.5% coolants (Fig. 2.4). Vehicle depressed HRV during all washouts relative to FA, specifically decreasing RMSSD in washouts 1-3 (time-matched with washouts for 0.25% coolant) and SDNN in washouts 4-9 (time-matched with washouts for 1% and 2.5% coolant). These impacts suggest that vehicle aerosols induce phasic autonomic imbalance, oscillating from parasympathetic dominance during puffs to sympathetic dominance during washouts.

During puffing, menthol at all concentrations tested decreased heart rate—and at 1% increased SDNN—relative to both controls (Fig. 2.4), suggesting that menthol modestly accentuates e-cig-induced parasympathetic dominance. Even during 1% washouts, menthol decreased heart rate vs. both controls and increased SDNN vs. vehicle, countering the sympathetic rebound induced by vehicle at washout.

During puff phases, neither WS-3 nor WS-23 altered the impacts of vehicle exposure at 0.25%; however, WS-3 increased both SDNN and RMSSD at 1% and 2.5% relative to vehicle, suggesting accentuated parasympathetic dominance (Fig. 2.4). Similarly, during puffing, WS-23 at 1% and 2.5% accentuated RMSSD elevations relative to vehicle, but paradoxically, both concentrations attenuated heart rate reductions. During washouts at 0.25%, WS-3 increased heart rate vs. both controls without affecting HRV. Notably, during washouts for 1% and 2.5% WS-23 and for 2.5% WS-3, SDNN and RMSSD significantly decreased while heart rate increased relative to both controls, suggesting that both synthetic coolants exacerbate e-cig-induced sympathetic dominance.

### Arrhythmias

To assess the arrhythmogenicity of coolants, VPBs were quantified over the entire monitoring period. Overall, neither vehicle nor menthol significantly altered the frequency of VPBs relative to FA, and menthol did not alter VPB rates relative to vehicle. In contrast, both WS-3 and WS-23 significantly increased VPB frequency overall relative to both controls (Fig. 2.5A). When stratifying by concentration, only 2.5% WS-23 increased VPB rates compared to both controls, while 2.5% WS-3 increased VPB frequency relative to FA alone (Fig. 2.5B). Notably, VPB rates correlated positively with changes in heart rate and inversely with changes in SDNN upon exposures to all e-cigs (Table 2.2), suggesting

sympathetic mediation of e-cig-induced tachyarrhythmias. Yet, stratifying by the presence or absence of coolants revealed that VPB frequency correlated with heart rate and SDNN only for coolant aerosols but not for vehicle (Fig. 2.6), with significant modification of the heart rate-VPB relationship by coolants (Table 2.2). Further stratification demonstrated that synthetic coolants did not modify either of these relationships when compared solely to menthol (data not shown).

#### Nicotine intake and metabolism

To determine if coolant type or concentration modifies nicotine intake or metabolism, plasma was collected from separate mice exposed to e-cig aerosols generated from various coolant-containing e-liquids with identical nicotine concentrations. Plasma levels of nicotine metabolites (nicotine, COT, and 3HC), TNE, and NMR (Fig. 2.7, Table 2.3) did not vary according to coolant type or concentration.

### **Discussion**

In this study, we found that inhalation of e-cig aerosols increased parasympathetic dominance during exposures and augmented sympathetic dominance after exposures and that both of these effects were accentuated by the synthetic coolants WS-3 and WS-23 in a concentration-dependent manner. Exposure to aerosols containing synthetic coolants uniquely induced subtle increases in spontaneous ventricular arrhythmias, which themselves correlated with pro-sympathetic changes in heart rate and HRV for coolant but not vehicle aerosols. These findings provide seminal evidence that the addition of synthetic coolants exacerbates the cardiotoxicity of e-cigs.

Although previous studies have shown that e-cig exposure can adversely affect the cardiovascular system, the role of specific constituents (e.g., flavorants) in mediating these

impacts has not been clearly delineated. In the current study, we found that exposure of mice to vehicle aerosols induced acute oscillations in SDNN, recapitulating our prior findings that e-cig exposures evoke a biphasic autonomic imbalance involving parasympathetic dominance during puff phases and sympathetic dominance post-exposure.<sup>216</sup> Importantly, relative to vehicle aerosols, e-cig aerosols containing menthol, WS-3, and WS-23 enhanced parasympathetic dominance during exposures at concentrations  $\geq 1\%$  and exacerbated sympathetic dominance after exposures at 2.5%. Several studies have shown that irritant aerosols and gases can alter short-term HRV and heart rate in rodents with immediate parasympathetic dominance—consistent with pulmonary irritant reflexes<sup>270</sup>—and a subsequent sympathetic dominance.<sup>216, 271, 272</sup> Other studies have shown sympathetic dominance after inhalation of flavored nicotine-containing e-cig aerosols, including short-term use in naïve healthy non-users,<sup>218</sup> 10 wk exposures in mice,<sup>215</sup> and 8 wk exposures in rats.<sup>217</sup> Habitual e-cig use also may increase sympathetic influence.<sup>219</sup> Our data provide new evidence that the popular synthetic cooling agents, WS-3 and WS-23, can acutely exacerbate e-cig-induced autonomic imbalance and spontaneous arrhythmias. Moreover, our data suggest that the pro-arrhythmic effects of addition of these coolants to e-liquids may occur via exacerbation of the sympathetic effects of e-cigs.

The autonomic nervous system governs cardiac function via opposing sympathetic and parasympathetic inputs. Autonomic balance is indicated by the heart's rate and its variation in successive beat intervals quantified by HRV. Both acute and chronic increases in heart rate and decreases in HRV indicate sympathetic dominance, whereas declines in heart rate and increases in HRV suggest parasympathetic dominance.<sup>190, 273</sup> Prolonged sympathetic dominance promotes and positively correlates—and parasympathetic



dominance generally dampens and inversely correlates—with adverse cardiovascular outcomes.<sup>190, 208</sup> Short-term extremes in autonomic modulation also predict cardiovascular risk and can trigger adverse cardiovascular events, including arrhythmias. Generally, sympathetic dominance promotes tachyarrhythmias (e.g., VPBs).<sup>190</sup> In our study, we found that VPB rates correlated with heart rate and SDNN upon exposure to all e-cigs regardless of coolant concentration, suggesting sympathetic mediation of e-cig-induced tachyarrhythmias. Yet, stratifying by the presence or absence of coolants revealed that this relationship was mediated by cooling agents in the aerosols, as the effect was entirely absent in mice exposed to vehicle alone. Upon coolant exposures, changes in heart rate of +10% or in SDNN of -50% roughly doubled the frequency of spontaneous VPBs (+117% or +107%, respectively), whereas no such associations were evident for vehicle exposures. Altogether, these findings indicate that coolants, particularly WS-3 and WS-23, are an arrhythmogenic constituent of e-cigs and that this pro-arrhythmic effect could be attributable, at least in part, to their promotion of sympathetic dominance. Additionally, these data support the notion that heart rate and HRV are informative risk biomarkers that may be predictive of the arrhythmogenic potential of e-cig aerosols.

We recently found that e-cig aerosols from a commercial menthol e-liquid (2.4% free-base nicotine, 70/30 PG/VG) or 100% PG alone acutely induced ventricular arrhythmias while increasing heart rate and decreasing HRV after exposure.<sup>216</sup> These ectopic beats correlated inversely with HRV only for nicotine-containing aerosols, suggesting that nicotine-containing e-cigs may induce arrhythmias via sympathetic dominance. Nonetheless, the absence of any treatment-related differences in plasma TNE suggests that the arrhythmogenic effects of WS-3 or WS-23 may not be due to greater

exposure to nicotine.

From our results it appears that the cardiotoxicity of synthetic coolants likely increases with their concentration, as VPBs only increased significantly with 2.5% WS-3 and WS-23 but not at lower concentrations. The increase in VPBs is particularly noteworthy because recurrent VPBs can cause cardiomyopathy in humans,<sup>274</sup> and even infrequent VPBs (> 0.5/h) can predict all-cause mortality.<sup>275</sup> Notably, exposure to 2.5% menthol e-cig aerosols in the current study induced sympathetic dominance during washouts but did not recapitulate the arrhythmogenic effects we reported previously with bluPlus+ menthol.<sup>216</sup> Reasons for this discrepancy are unclear but may relate to differences in device type (mod vs. cigalike), menthol concentrations ( $\leq 2.5\%$  vs. unknown), nicotine type (2.5% salt vs. 2.4% free-base), PG content (30/70 vs. 70/30 PG/VG), or other unreported ingredients of commercial e-liquids.

Beyond the subtle but consistent observations that e-cigs acutely increase spontaneous arrhythmias, evidence is mounting that e-cigs increase the inducibility of ventricular arrhythmias. Exposure to e-cig aerosols for 10 wk in mice (vanilla custard, 6 mg/mL free-base nicotine) or 8 wk in rats (JUUL Virginia Tobacco, 5% nicotine salt) decreased HRV and enhanced propensity for induction of ventricular tachycardia by experimental electrical stimuli.<sup>215, 217</sup> Nevertheless, it remains unclear if long-term e-cig exposures can consistently increase spontaneous arrhythmias, and further, if they enhance arrhythmia inducibility via autonomic imbalance, electrical and neural remodeling, or their combination. Overall, our current findings suggest that the presence, type, and concentration of cooling agents may determine the arrhythmogenic and sympathetic effects of e-cig aerosols.

Inhaled irritants activate cardiopulmonary reflexes via transient receptor potential ankyrin 1 (TRPA1) receptors located on nociceptive vagal sensory C-fibers innervating the airways.<sup>276</sup> Stimulation of these fibers increases central parasympathetic outflow to the heart, resulting in reflex bradycardia.<sup>276</sup> Although WS-3 and WS-23 do not appear to alter TRPA1 activity,<sup>277</sup> menthol's actions on TRPA1 in mice follow a sinusoidal pattern, with activation at low concentrations and inhibition at high concentrations.<sup>278</sup> Based on our data, we speculate that 0.25% menthol fell below the threshold required to activate TRPA1, whereas 1% reached a concentration range necessary for activation, and 2.5% was high enough for partial inhibition. Thus, the bradycardia and increased SDNN relative to both controls during 1% menthol puff phases may have derived from menthol's TRPA1-activating properties at low concentrations. Conversely, 2.5% menthol likely attenuated e-cig-induced bradycardia during puffs and exacerbated e-cig-induced HRV reductions thereafter via the net effects of TRPA1 inhibition by a higher menthol concentration and sympathetic stimulation by nicotine.<sup>186</sup> These findings offer new evidence that menthol alters the autonomic effects of e-cigs in a concentration-dependent, sinusoidal manner.

It is well-established that menthol suppresses irritant reflexes through the activation of TRPM8,<sup>156, 259</sup> and WS-3 and WS-23 are both TRPM8 agonists.<sup>279</sup> This, coupled with our findings of increased sympathetic dominance with menthol, WS-3, and WS-23 aerosols at 2.5%, led us to hypothesize that coolants may mitigate these irritant reflexes, potentially enhancing nicotine intake and sympathetic influence. Indeed, others have found that mice exposed to cigarette smoke mixed with menthol vapor had elevated plasma cotinine levels compared to mice exposed to cigarette smoke alone.<sup>156</sup> Moreover, human studies have shown that it is the nicotine—not the non-nicotine—component of e-cig aerosol that

increases heart rate, blood pressure, and sympathetic influence.<sup>218, 280</sup> However, plasma TNE values were not significantly affected by coolant type or concentration despite the sympathetic effects of coolant aerosols. Likewise, coolants did not significantly alter NMR, a measure of nicotine metabolism by cytochrome P450 2A5 in mice. Thus, because they did not overtly modify nicotine intake or metabolism, WS-3 and WS-23 might possess qualities that promote sympathetic dominance upon e-cig aerosol exposure. Notably, because naïve mice were used for plasma assays, it is unclear whether they may have differed in nicotine intake and metabolism from mice used for physiological assessments, which were serially exposed to nicotine-containing aerosols over several days. Nevertheless, we saw no indication that prior exposure influenced nicotine intake, as physiological responses did not noticeably differ between the cohorts that followed opposing treatment sequences.

This study has several strengths. For instance, radiotelemetry allows for real-time assessments of the immediate effects of exposure, whereas measurements are often not concurrent in human studies due to limited options for timing or locations of exposures and physiological monitoring. Additionally, since commercial e-liquid formulations can vary due to inconsistent manufacturing practices, we ensured consistent e-liquid compositions by preparing our own mixtures in-house. Lastly, nose-only exposure would have necessitated restraint and increased animal stress, which could have compromised the evaluation of sensitive cardiac parameters such as heart rate, HRV, and arrhythmias. In contrast, our whole-body exposure approach circumvented the need for restraint and minimized stress on the animals, which strengthens the integrity of our physiological measurements.

This study also has a few limitations. For example, many cardiopulmonary differences exist between mice and humans,<sup>281, 282</sup> so caution should be exercised when extrapolating these results to humans. Also, since commercial e-liquids are often complex mixtures of many ingredients, the impacts we observed may not generalize to outcomes under real-world vaping scenarios. Moreover, because we controlled for the potential influence of cumulative puff sessions only through a separate vehicle exposure, our observations of increasing effects with rising coolant levels only partly suggest a concentration-dependent relationship and do not definitively rule out a concentration-independent influence of cumulative coolant exposure. In addition, although we previously found that males were more sensitive to the immediate impacts of e-cig solvents on arrhythmias, heart rate, and HRV,<sup>216</sup> the present study does not address how coolants might affect females. Furthermore, this study only addresses the acute autonomic and arrhythmogenic effects of e-cigs and the role of cooling agents. With long-term exposures, autonomic imbalance and arrhythmias might either drive or stem from other maladies associated with chronic e-cig exposures, including vascular defects,<sup>229, 237, 240, 283, 284</sup> hypertension,<sup>229</sup> and left ventricular hypertrophy<sup>229</sup> and dysfunction.<sup>217, 229, 230</sup> Although the influence of cooling agents over such long-term impacts remains unclear, it is plausible that coolants could accelerate e-cig-induced progression of cardiovascular disease through sympathetic dominance.

Ultimately, our findings suggest that exposure to e-cig aerosols containing WS-3 and WS-23 increases cardiac risk by promoting sympathetic modulation and inducing spontaneous ventricular arrhythmias independent of nicotine intake and metabolism. Our findings merit future studies to elucidate the mechanisms by which WS-3 and WS-23

disrupt cardiac autonomic balance and characterize the long-term cardiovascular effects of chronic exposure to synthetic coolants. If validated by human studies, our data may assist regulatory authorities in crafting tobacco control initiatives that mitigate the risks of synthetic cooling agents in e-cigs.

## Tables

**Table 2.1.** Coolant e-liquid compositions (per 10 g).

Exposure	Coolant (g)	Nicotine (g)	Benzoic acid (g)	30PG/70VG (g)
FA	–	–	–	–
Vehicle	–	0.25	0.19	9.56
0.25%	0.025	0.25	0.19	9.535
1%	0.1	0.25	0.19	9.46
2.5%	0.25	0.25	0.19	9.31

*Note:* Components were mixed at 55°C until fully dissolved. PG (JT9402-3) and VG (JT2142-3) from VWR, Radnor, PA, USA. Benzoic acid (242381), L-menthol (W266590), and nicotine (8.20877) from Millipore Sigma, Burlington, MA, USA. WS-3 (P895) and WS-23 (7087AB) from AK Scientific, Union City, CA, USA. FA, filtered air; PG, propylene glycol; VG, vegetable glycerin.

**Table 2.2.** Estimated association of changes in heart rate and SDNN with VPB incidence upon inhalation exposure to coolant-free and coolant-containing e-cig aerosols.

<b>Heart Rate</b> (change in VPB incidence per 1% increase from baseline)				
	Effect Estimate	95% C.I.	<i>P</i> -value	Interaction <i>P</i> -value
Vehicle	-1.0 %	(-5.9, 4.1)	0.6937	0.0104*
Coolant Aerosols	11.7 % *	(8.5, 15.0)	< 0.0001	
<b>SDNN</b> (change in VPB incidence per 1% decrease from baseline)				
	Effect Estimate	95% C.I.	<i>P</i> -value	Interaction <i>P</i> -value
Vehicle	0.0 %	(-1.5, 1.5)	0.9839	0.2022
Coolant Aerosols	2.1 % *	(0.5, 3.7)	0.0092	

*Note:* Asterisk denotes significant association determined by generalized estimating equations and two-sided  $P < 0.05$  (n = 8 mice/exposure).




**Table 2.3.** Effects of coolants on nicotine intake and metabolism.


Exposure	NIC (ng/mL)	COT (ng/mL)	3HC (ng/mL)	TNE (ng/mL)	NMR (3HC/COT)
Vehicle	9.9 ± 3.0	62.1 ± 11.4	343.0 ± 38.3	415.0 ± 41.7	5.6 ± 1.4
0.25% WS-23	9.1 ± 3.2	38.7 ± 4.9	274.5 ± 17.6	322.3 ± 15.8	6.5 ± 1.2
1% WS-23	20.6 ± 5.9	50.7 ± 3.5	262.4 ± 35.1	333.7 ± 29.1	4.5 ± 0.9
2.5% WS-23	23.1 ± 7.5	65.6 ± 20.3	240.0 ± 24.3	328.6 ± 50.1	3.5 ± 0.6
2.5% Menthol	22.1 ± 6.7	91.5 ± 15.0	350.4 ± 22.0	464.0 ± 38.3	3.5 ± 0.5
2.5% WS-3	25.1 ± 7.8	50.3 ± 13.2	244.6 ± 29.0	320.0 ± 40.3	4.9 ± 1.1

*Note:* FA-normalized values are expressed as mean ± SEM (n = 5 mice/exposure). Significance was tested using one-way ANOVA with Tukey's post hoc test for differences across WS-23 concentrations or across coolants at 2.5%, with no differences observed between groups. NIC, nicotine; COT, cotinine; 3HC, *trans*-3'-hydroxycotinine; TNE, total nicotine equivalents (NIC + COT + 3HC); NMR, nicotine metabolite ratio (3HC/COT).


## Figures




**Figure 2.1. Experimental design and exposure regimen.** (A) A crossover design was used for two cohorts of mice ( $n = 4$  mice/cohort) that underwent reverse exposure sequences distributed across 5 separate days, with  $\geq 3$  d between exposures. (B) On a given exposure day, mice were acclimated to the chamber during pre-exposure (1 h) and then exposed to coolant aerosols or vehicle over nine 18 min exposure cycles (9 min puffing phase followed by 9 min washout phase), with a recovery period (30 min) and increasing coolant concentrations following the third and sixth exposure cycles. FA, filtered air; BL, baseline.




**Figure 2.2. Relationship between total suspended particulates (TSP) and puff normalized aerosol deposition.** Change in mass of a gravimetric filter located downstream of the Microdust Pro was normalized to the total number of puffs on a given exposure day (x-axis). Nine-min TSP means were calculated using TSP values from a Microdust Pro (Casella CEL Ltd., Bedford, UK) located downstream of the exposure chamber (y-axis). Line denotes linear correlation of all values accompanied by r-squared.




**Figure 2.3. Baseline heart rate and HRV prior to each exposure.** One-min means for (A) heart rate, (B) SDNN, and (C) RMSSD were averaged during baseline for each mouse on a given exposure day. Significance was tested using repeated measures one-way ANOVA with Tukey's post hoc test. Data are expressed as mean  $\pm$  SEM.  $n = 8$  mice/exposure, circles indicate individual values, \* $P < 0.05$ .




**Figure 2.4. Influence of coolants on e-cig-induced changes in heart rate and HRV.** Baseline-normalized percent change in (A) heart rate, (B) SDNN, and (C) RMSSD during puff and washout phases at each coolant concentration. Significant differences of vehicle from FA control (a), treatment from vehicle alone (v), or treatment from both FA and vehicle controls (star) were determined by two-sided  $P < 0.05$  in mixed models ( $n = 8$  mice/exposure). Data are expressed as mean  $\pm$  SEM.



**Figure 2.5. Effects of coolants on e-cig-induced ventricular arrhythmias.** (A) Hourly VPB rate by exposure with individual animal means in white circles and a representative VPB from a mouse exposed to e-cig aerosol containing WS-23 (inset). (B) VPB rate delineated by coolant concentration. Significant differences of treatment from either FA alone (a) or both FA and vehicle (star) were determined by two-sided  $P < 0.05$  in generalized estimating equations ( $n = 8$  mice/exposure). Data are expressed as mean  $\pm$  SEM.



**Figure 2.6. Coolants modify the association between e-cig-induced ventricular arrhythmias and changes in heart rate and HRV.** Log-linear plots, delineated by the presence (red) or absence (blue) of coolant in aerosol exposures, of estimated VPB incidence rate per observed change from baseline in (A) heart rate or (B) SDNN analyzed by phase means (puffing, washout, recovery) for each exposure cycle across all e-cig treatments via generalized estimating equations ( $n = 8$  mice/treatment). Line separations occur due to puff and washout phases (9 min) differing in duration from recovery phases (30 min).



**Figure 2.7. Impacts of coolants on nicotine intake and metabolism.** (A) The exposure regimen consisted of 1 h of pre-exposure and three 9 min puffing phases punctuated by two 9 min washouts followed by blood collection, which began approximately 15 min after the final puffing phase. FA-normalized values for (B-D) plasma nicotine and metabolites, (E) TNE, and (F) NMR are expressed as mean  $\pm$  SEM. Significance was determined using one-way ANOVA with Tukey's post-hoc test for differences across WS-23 concentrations or across coolant types at 2.5%.  $n = 5$  mice/exposure, circles indicate individual values, bars indicate significance ( $P < 0.05$ ) between non-vehicle groups,  $*P < 0.05$  vs. vehicle. NIC, nicotine; COT, cotinine; 3HC, *trans*-3'-hydroxycotinine; TNE, total nicotine equivalents (NIC + COT + 3HC); NMR, nicotine metabolite ratio (3HC/COT).



CHAPTER III  
NICOTINE FORMULATION INFLUENCES THE AUTONOMIC AND  
ARRHYTHMOGENIC EFFECTS OF E-CIGARETTES

**Overview**

Evidence is mounting that electronic cigarette (e-cig) use induces cardiac sympathetic dominance and electrical dysfunction conducive to arrhythmias and dependent upon nicotine. A variety of nicotine types and concentrations are available in e-cigs, but their relative cardiovascular effects remain unclear. Here we examine how different nicotine forms (racemic, free-base, and salt) and concentrations influence e-cig-evoked cardiac dysfunction and arrhythmogenesis and provide a mechanism for nicotine salt-induced autonomic imbalance. ECG-telemetered C57BL/6J mice were exposed to filtered air (FA) or e-cig aerosols from propylene glycol and vegetable glycerin solvents either without nicotine (vehicle) or with increasing nicotine concentrations (1%, 2.5%, and 5%) for three 9 min puff sessions per concentration. Spontaneous ventricular premature beat (VPB) incidence rates, heart rate, and heart rate variability (HRV) were compared between treatments. Subsequently, to test the role of  $\beta_1$ -adrenergic activation in e-cig-induced cardiac effects, mice were pretreated with atenolol and exposed to either FA or 2.5% nicotine salt. During puffing and washout phases,  $\geq 2.5\%$  racemic nicotine reduced heart rate and increased HRV relative to FA and vehicle controls, indicating parasympathetic dominance. Relative to both controls, 5% nicotine salt elevated heart rate and decreased HRV during washout, suggesting sympathetic dominance, and also increased VPB

frequency. Atenolol abolished e-cig-induced elevations in heart rate and declines in HRV during washout, indicating e-cig-evoked sympathetic dominance is mediated by  $\beta_1$ -adrenergic stimulation. Collectively, exposure to e-cig aerosols containing commercially relevant concentrations of nicotine salt may increase nicotine delivery and impair cardiac function by eliciting  $\beta_1$ -adrenoceptor-mediated sympathoexcitation and provoking ventricular arrhythmias. If confirmed in humans, our work suggests that minimum pH standards or limits on acid additives in e-liquids may mitigate the public health risks of vaping.

### **Introduction**

The autonomic nervous system regulates cardiac function through input from the sympathetic and parasympathetic divisions, the relative balance of which influences both the duration and variability of the heart's interbeat intervals. Thus, heart rate and heart rate variability (HRV) both reflect cardiac autonomic control; increases in heart rate with declines in HRV indicate sympathetic dominance, and heart rate reductions with HRV elevations suggest parasympathetic dominance. Sympathetic dominance predicts cardiovascular disease risk and all-cause mortality,<sup>208</sup> whereas parasympathetic dominance correlates with aerobic fitness,<sup>204</sup> psychological resiliency, and behavioral flexibility.<sup>203</sup>

Nicotine is a sympathomimetic that stimulates catecholamine release by activating nicotinic acetylcholine receptors (nAChRs) on adrenal chromaffin cells and peripheral postganglionic sympathetic nerve terminals.<sup>186</sup> These sympathetic effects alone may underlie the cardiovascular risks of tobacco products. However, nicotine also activates transient receptor potential ankyrin 1 (TRPA1) cation channels located on nociceptive vagal sensory C-fibers that innervate the airways.<sup>276, 285</sup> Upon stimulation, these fibers can

trigger cardiopulmonary irritant reflexes that enhance central parasympathetic drive to the heart, leading to reflex bradycardia.<sup>276</sup> Thus, nicotine acts on several physiological targets that can induce opposing autonomic and cardiovascular effects.

Prior to 2015, electronic cigarettes (e-cigs) contained ~1–2% free-base nicotine, a respiratory irritant that at high concentrations imparts harsh and bitter sensory attributes to these devices.<sup>164</sup> Shortly thereafter, a pod-based e-cig (JUUL) overtook the market with a 5% nicotine salt formulation, created by adding weak organic acids to free-base nicotine. Compared to free-base nicotine, nicotine salts produce less aversive sensory effects and increase the palatability of e-cig aerosols despite higher nicotine levels.<sup>165</sup> Although e-cigs have typically contained tobacco-derived nicotine, consisting primarily of the *S* enantiomer (> 99%), more recent brands (Puff Bar) have gained market dominance using e-liquids that contain “tobacco-free” synthetic nicotine with nearly equimolar quantities of the *R* and *S* enantiomers.<sup>176</sup>

*R*- and *S*-nicotine differ in their biochemical properties. For example, in Chinese hamster ovary cells, both *S*-nicotine and racemic nicotine induced greater cytotoxicity and oxidative stress relative to *R*-nicotine.<sup>178</sup> In addition, *R*-nicotine is metabolized more rapidly than *S*-nicotine.<sup>179</sup> Furthermore, compared to *R*-nicotine, *S*-nicotine is a more robust agonist of nAChRs,<sup>180</sup> which influences sympathoexcitation; however, it is also a less potent inhibitor of acetylcholinesterase (AChE).<sup>286</sup> Lastly, in comparable treatments, *S*-nicotine—but not *R*-nicotine—promoted weight loss in rats<sup>182</sup> and triggered norepinephrine (NE) release from the adrenergic nerve terminals of rabbits.<sup>183</sup>

A growing body of evidence indicates that e-cig exposure promotes sympathetic dominance and electrophysiologic instability, potentially culminating in

arrhythmogenesis.<sup>215, 217-220</sup> In particular, we detailed evidence of likely autonomic mediation of nicotine-induced changes in cardiac conduction among smokers.<sup>287</sup> More recently, we showed that acute exposure of mice to e-cig aerosols from either a menthol-flavored e-liquid (2.4% free-base nicotine, 70/30 propylene glycol [PG]/vegetable glycerin [VG]) or a 100% PG e-liquid provoked ventricular arrhythmias while elevating heart rate and reducing HRV post-exposure.<sup>216</sup> However, studies directly comparing the effects of nicotine in its racemic (50*R*/50*S*), free-base, and salt formulations on e-cig-induced changes in cardiac autonomic balance and arrhythmogenesis are lacking. Therefore, we used a murine model to evaluate the impact of different nicotine formulations on e-cig-induced alterations in cardiac autonomic activity and rhythmicity. We hypothesized that, dependent on its chemical form and concentration, nicotine differentially modifies the effects of e-cigs on cardiac autonomic modulation and arrhythmogenesis and that  $\beta_1$ -adrenoceptors mediate nicotine salt-induced autonomic imbalance. Novel insights stemming from our work may inform tobacco regulatory initiatives.

## **Materials and Methods**

### **Animals**

Male C57BL6/J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and cared for according to the Guide for the Care and Use of Laboratory Animals. All protocols were approved by the University of Louisville Institutional Animal Care and Use Committee. Mice were housed in a temperature-controlled vivarium under pathogen-free conditions and a 12h:12h light:dark cycle. Mice were provided a standard chow diet (Rodent Diet 5010, 4.5% fat by weight, LabDiet, St. Louis, MO, USA) and water *ad libitum*. Radiotransmitters (ETA-F10, Data Sciences International, Inc., St. Paul, MN,

USA) were implanted subcutaneously with electrodes positioned in a lead II configuration. For all implantations, mice were anesthetized with 2% isoflurane and injected with one dose of pre- and post-operative analgesia (ketoprofen, 5 mg/kg, s.c.). After implantation, mice were individually housed and allowed at least 10 d for recovery prior to exposure. For all studies, euthanasia consisted of injection with sodium pentobarbital (50 mg/kg, i.p.) followed by exsanguination via cardiac puncture.

### Exposures

Two cohorts of mice (male, C57BL/6J, 10–12 wk old, n = 4/cohort) underwent whole-body exposure (inExpose, SCIREQ, Inc., Montreal, QC, CAN) to nicotine-containing e-cig aerosols from a third-generation tank-style device (10 W, 1.5  $\Omega$ , air inlets 100% open) using a crossover design (Fig. 3.1A) and a serial exposure regimen with each exposure day consisting of nine puff sessions equally distributed across three ascending nicotine concentrations (Fig. 3.1B). The nicotine concentrations and wattage used in this study are comparable to those found in both reusable and disposable pod devices.<sup>98, 267</sup> E-liquid compositions and ingredient sources are provided in Table 3.1. Multiple experimental phases consisted of administration of ambient air, including pre-exposure (45 min), baseline (final 15 min before the start of puffing), recovery (30 min), and washout (9 min). Puffing phases (9 min) consisted of two 4 s puffs/min (91 mL/puff).<sup>216</sup> Total suspended particulates and puff-normalized aerosol deposition values were similar to previous findings (Fig. 3.2).<sup>52, 267, 268</sup> Mice were acclimated to the chamber before exposure and allowed  $\geq 3$  d for recovery between exposures. Individual mice were separated within the chamber by dividers during all exposures and returned to their respective home cages immediately after exposure.

To test the role of  $\beta_1$ -adrenergic activation in e-cig-induced sympathetic dominance, the two cohorts (n = 4/cohort) were exposed to filtered air (FA) and e-cig aerosol (2.5% nicotine salt) according to a modified crossover design (Fig. 3.1C) and exposure regimen (Fig. 3.1D) after a 3 wk recovery period. Both cohorts were exposed concurrently with one receiving FA while the other received e-cig aerosol in a separate chamber. Mice were provided normal drinking water for the first pair of exposures. Starting at 5 d before onset of the second pair of exposures, both cohorts were provided drinking water with 0.5 g/L atenolol (Item # A7655, Millipore Sigma, Burlington, MA, USA), which continued until the final day of exposure.

#### Radiotelemetry data acquisition and analysis

Physiologic parameters from individual mice were collected by RSC-1 receivers (Data Sciences International, Inc. St. Paul, MN, USA) and forwarded to a computer running Ponemah 6.51 (Data Sciences International, Inc., St. Paul, MN, USA). Electrocardiographic (ECG) data were sampled at 1 kHz and continuously monitored throughout the exposure. Using ecgAUTO 3.5 (emka Technologies, Paris, FR), signal noise and abnormal beats were removed prior to calculation of 1 min means for RR intervals and time domain HRV parameters, including standard deviation of normal RR intervals (SDNN) and root mean square of successive differences of normal RR intervals (RMSSD). Heart rate and HRV are reported as each animal's percent change from baseline on a given exposure day. Across all exposures, heart rate and HRV values were generated from RR intervals successfully analyzed within each 1 min period (mean  $\pm$  SD success of  $76.5 \pm 12.5\%$  of beats). ECG waveforms were examined for ventricular premature beats (VPBs) using a library of 28 beats. We classified VPBs as ectopic QRS complexes with at

least three of the following four features: (i) a lengthened QRS duration, (ii) premature occurrence and a subsequent compensatory pause, with the R-VPB-R interval  $\geq$  the sum of the prior two normal RR intervals, (iii) no visible P or an overtly shortened PR, and (iv) abnormal R, S, or J wave morphology (amplitudes and/or areas). Any VPB occurring within an episode of non-sustained ventricular tachycardia was quantified as an individual arrhythmia.

#### Nicotine intake and metabolism

In additional experiments, non-telemetered mice (male, C57BL/6J, 10 wk old, n = 5 mice/exposure) underwent exposure to various e-cig aerosols with varying nicotine types and concentrations. Immediately after the final puffing phase, mice were removed from the chamber and injected i.p. with Fatal-Plus Solution (Vortech Pharmaceuticals, Ltd., Dearborn, MI, USA). Blood was collected via cardiac puncture, mixed with EDTA (Millipore Sigma, Burlington, MA, USA), and centrifuged at 5000 rpm for 8 min at 4 °C. Plasma was collected and stored at -80 °C. Plasma levels of nicotine, cotinine (COT), and *trans*-3'-hydroxycotinine (3HC) were quantified using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)<sup>269</sup> for derivation of total nicotine equivalents (TNE) and nicotine metabolite ratio (NMR, 3HC/COT).

#### Statistics

For heart rate and HRV, 1 min means were normalized as each animal's percent change from its own baseline and analyzed separately by phase (due to heart rate effects of e-cig aerosol opposing by phase).<sup>216</sup> Baseline-normalized heart rates and HRV parameters were time-matched across exposures by experimental minute and thus also by exposure cycle and phase. Linear mixed models with repeated subjects were used to test for

interactions between treatment and nicotine concentration with comparison to FA and vehicle controls in SAS 9.4 (Cary, NC, USA). For the  $\beta_1$ -adrenoceptor inhibition study, repeated measures two-way analysis of variance (ANOVA) was used to compare baseline-normalized heart rates and HRV parameters between FA and e-cig exposures (with and without atenolol) during puffing and washout phases in Prism 7 (GraphPad, San Diego, CA, USA). Arrhythmia counts were time-normalized to incidence rates (i.e., VPBs/h). To approximate a Gaussian distribution, all zero values were transformed to 0.01 and all VPB rates were log-normalized.<sup>288</sup> Repeated measures two-way ANOVA was performed with Dunnett's post hoc test to compare treatment groups to FA and vehicle controls. In secondary analyses, VPB rates were scored on a 0-4 scale and also evaluated by repeated measures two-way ANOVA. One mouse was omitted from all arrhythmia analyses per our exclusion criteria: > 5 VPBs/h during FA at any of the three nicotine concentration periods. Baseline heart rates, baseline HRV parameters, and plasma analytes were evaluated using one-way ANOVA with Tukey's post hoc test. Plasma analytes were normalized to the FA control and tested for differences across nicotine salt concentrations and vehicle or across nicotine types at 5% and vehicle. All reported differences are statistically significant ( $P < 0.05$  vs. FA or vehicle controls) unless otherwise stated.

## **Results**

### Heart rate and heart rate variability

There were no significant differences in baseline heart rate, SDNN, or RMSSD prior to exposures (Fig. 3.3). Changes in heart rate, SDNN, and RMSSD of exposed mice were analyzed for treatment effects according to phase and nicotine concentration, with time-matched comparison to FA and nicotine-free vehicle. Compared to FA, vehicle



(PG/VG) increased SDNN during the puff phases corresponding with each of the nicotine concentration time points but elevated RMSSD only during the puff phase corresponding with the 1% nicotine time point, indicating parasympathetic dominance during puffing (Fig. 3.4).

During both puffing and washout, 2.5% and 5% racemic nicotine decreased heart rate and raised SDNN and RMSSD relative to both the FA and vehicle controls, collectively indicating a relative increase in parasympathetic influence (Fig. 3.4).

While free-base nicotine did not alter heart rate at any concentration tested, it elevated SDNN at 2.5% and 5% during puffing vs. both controls. Free-base nicotine also raised RMSSD at 1% during washout and at 5% during puffing and washout compared to both controls (Fig. 3.4). Altogether, these effects suggest parasympathetic dominance.

During puffing, 2.5% nicotine salt increased heart rate relative to vehicle. Compared to both controls, 2.5% nicotine salt elevated RMSSD during puffing and heart rate during washout, consistent with phasic autonomic imbalance involving first parasympathetic and then sympathetic dominance. Similarly, 5% nicotine salt raised RMSSD during puffing; however, heart rate was also concurrently elevated. During washout, 5% nicotine salt increased heart rate and decreased SDNN and RMSSD vs. both controls, providing clear evidence of sympathetic dominance (Fig. 3.4).

To investigate the mechanism by which nicotine salt induces sympathetic dominance, mice were administered atenolol in drinking water prior to exposure to 2.5% nicotine salt aerosols. Atenolol lowered heart rate at baseline on FA days (-13.6%) but not e-cig exposure days and did not affect baseline SDNN (Fig. 3.5). During puffing, exposure to nicotine salt aerosols did not alter heart rate (Fig. 3.6A) or SDNN (Fig. 3.6B)

significantly, although atenolol significantly modified the impacts of nicotine salt aerosols on heart rate (Fig. 3.6A; interaction  $P = 0.0211$ ). However, atenolol abolished e-cig-induced elevations in heart rate (Fig. 3.6C) and decrements in SDNN (Fig. 3.6D) during washout, indicating  $\beta_1$ -adrenergic stimulation mediates e-cig-evoked sympathetic dominance. RMSSD did not differ between FA- and e-cig-exposed mice treated with normal drinking water during the puffing or washout phases (data not shown).

### Arrhythmias

To assess the arrhythmogenicity of nicotine-containing aerosols, VPBs were quantified over the entire monitoring period. Both VPB rates (Fig. 3.7A) and scores (Fig. 3.7B) were significantly higher during the 5% nicotine salt exposures compared to FA and vehicle. However, subsequent exposures solely to 2.5% nicotine salt aerosols with normal or atenolol-treated drinking water revealed no significant impacts on VPB rates (data not shown).

### Nicotine intake and metabolism

Compared to vehicle, e-cig aerosols from 2.5% nicotine salt increased plasma 3HC and TNE, whereas those from 5% nicotine salt raised nicotine, COT, 3HC, and TNE. Likewise, 5% racemic nicotine elevated nicotine, 3HC, TNE, and NMR relative to vehicle. Increasing nicotine salt concentrations (1%, 2.5%, and 5%) led to dose-dependent increases in plasma nicotine, COT, 3HC, and TNE. Across nicotine types at 5%, salt raised plasma COT vs. both racemic and free-base, while salt and racemic elevated 3HC and TNE vs. free-base only (Fig. 3.9, Table 3.2).

## **Discussion**

In this study, we demonstrated that exposure to e-cig aerosols containing

commercially relevant levels of nicotine salt induced  $\beta_1$ -adrenoceptor-mediated sympathetic dominance and provoked subtle increases in spontaneous ventricular arrhythmias. We also found that exposure to both moderate and high concentrations of racemic nicotine elicited a parasympathetic dominance that uniquely persisted into the washout phase. Additionally, inhalation of nicotine salt led to dose-dependent increases in nicotine intake, while inhalation of both nicotine salt and racemic nicotine resulted in greater nicotine absorption than free-base nicotine. Collectively, our findings provide novel evidence of and mechanistic insight into the e-cig-induced cardiotoxicity of nicotine salt at levels similar to those of popular e-cig products.

It has become increasingly clear that e-cig exposure can adversely affect cardiovascular function and that nicotine has sympathomimetic effects, but the role of specific nicotine types in these impacts remains unclear. In the present study, exposure of mice to aerosols containing 2.5% and 5% nicotine salt uniquely promoted sympathetic dominance during the washout phases. The autonomic and arrhythmogenic impacts of e-cig aerosols have been previously investigated. For example, in humans, both acute and chronic e-cig use were associated with increased sympathetic influence, and nicotine was directly implicated in the acute effects.<sup>218, 219</sup> Similarly, in rodents, acute and sub-chronic e-cig exposure resulted in sympathetic dominance accompanied by spontaneous ventricular arrhythmias<sup>216</sup> or increased arrhythmia susceptibility.<sup>215, 217</sup> However, none of these studies directly compared the autonomic and arrhythmogenic effects of nicotine by form or dose, and all involved e-liquids with flavors that may confound the effects of nicotine. Our findings provide new evidence that nicotine formulation modifies the adverse cardiovascular effects of e-cig aerosols, which may have important regulatory implications.

Pharmacological differences between nicotine salt and racemic nicotine may underlie their distinct autonomic effects. We observed that inhalation of nicotine in its racemic and salt forms resulted in nearly identical nicotine intakes, which would presumably induce comparable sympathetic effects. However, 5% racemic nicotine generated a parasympathetic response. This discrepancy could be due to three factors. First, compared to *S*-nicotine, *R*-nicotine is a ten-fold weaker nAChR agonist<sup>180</sup> and does not trigger NE release from adrenergic nerve terminals;<sup>183</sup> however, both nicotine enantiomers comparably activate TRPA1.<sup>289</sup> Consequently, racemic nicotine (50*R*/50*S*) should bear lower potential for sympathetic excitation but a comparable capacity for irritant-induced parasympathetic activation relative to free-base (pure *S*) nicotine. These pharmacological differences thus align with the divergent impacts of nicotine salt and racemic nicotine on heart rate and HRV. Second, relative to *S*-nicotine, *R*-nicotine is a more potent inhibitor of AChE,<sup>286</sup> an enzyme that hydrolyzes acetylcholine in the synaptic cleft and thus terminates neurotransmission. AChE inhibition would likely increase the amount and/or half-life of acetylcholine present in the synaptic cleft between postganglionic parasympathetic neurons and their sinoatrial (SA) effectors. In turn, this would enhance stimulation of muscarinic receptors on pacemaker cells of the SA node, leading to a decline in heart rate, which is also consistent with our findings for racemic nicotine. Third, only exposure to 5% racemic nicotine elevated NMR, consistent with evidence that *R*-nicotine is metabolized 1.4-fold faster than *S*-nicotine.<sup>179</sup> This would likely reduce the bioavailability of *R*-nicotine and attenuate its sympathetic effects compared to *S*-nicotine.

The disproportionate sympathetic impacts of nicotine salt may also stem from its greater palatability compared to free-base nicotine. Free-base nicotine is a respiratory

irritant that, along with other e-liquid constituents and their degradation products, stimulates airway irritant reflexes when inhaled.<sup>164, 285</sup> Accordingly, we observed a nearly three-fold increase in nicotine intake with 5% salt compared to 5% free-base. The irritant effects of free-base nicotine can be attenuated with the addition of weak organic acids to the e-liquid mixture, yielding a nicotine salt formulation.<sup>165</sup> Indeed, human studies have demonstrated that nicotine salt formulations containing benzoate and lactate are less aversive and more palatable upon inhalation than free-base nicotine, potentially resulting in greater nicotine delivery.<sup>164, 168, 173</sup> Moreover, a study in mice showed that free-base nicotine is a more potent stimulus of trigeminal nociceptive nerves—which innervate the airways and mouth—than protonated nicotine.<sup>290</sup> Interestingly, nicotine form does not affect its yield in e-cig aerosols,<sup>51</sup> and the impact of form on nicotine absorption in humans remains unclear.<sup>169-173</sup> Our observations are noteworthy because they demonstrate that nicotine salt-containing e-cig aerosols can provoke spontaneous ventricular arrhythmias in the absence of flavors or additives, which themselves might further exacerbate these effects. It remains unclear whether nicotine contributes to the arrhythmogenicity of e-cigs directly at the heart via the circulation or indirectly via altered central autonomic outflow; future studies should test these relationships for causality. Because we did not observe VPB increases in mice in the inhibition study, the role of sympathoexcitation in e-cig-induced arrhythmias remains unclear. However, given that nicotine salt aerosols disproportionately evoked sympathetic dominance and, in parallel, uniquely induced ventricular arrhythmias, it is plausible that the arrhythmogenic effects of nicotine salt were sympathetic in origin. Altogether, these results are particularly meaningful because even occasional VPBs can

predict cardiovascular mortality in humans,<sup>275</sup> and periodic VPBs can promote cardiomyopathy.<sup>274</sup>

E-cig aerosols are comprised of many different constituents that may contribute to the sympathetic effects of nicotine salt that we observed. Since nicotine is known to induce sympathomimetic effects via catecholamine release and consequent activation of  $\beta$ -adrenoceptors, we tested the role of  $\beta_1$ -adrenergic activation in e-cig induced sympathetic dominance using the  $\beta_1$ -adrenergic antagonist atenolol.  $\beta_1$ -adrenoceptors are located primarily in the sinoatrial and atrioventricular nodes as well as the ventricular myocardium, and stimulation of these receptors increases chronotropy and inotropy. Our findings demonstrate that acute exposure to nicotine salt-containing e-cig aerosols can induce a relative sympathetic dominance through  $\beta_1$ -adrenergic activation. Indeed, human studies have shown that nicotine underlies the sympathomimetic effects of e-cig aerosols<sup>218</sup> and that atenolol reduces heart rate after smoking.<sup>291, 292</sup> Yet, additional findings suggest that both parasympathetic withdrawal<sup>217</sup> and parasympathetic activation<sup>216</sup> could contribute to e-cig-induced cardiac dysfunction. Notably,  $\beta_1$ -blockade with atenolol can abolish the tachycardia and VPBs evoked upon inhalation of the TRPA1 agonist allyl isothiocyanate<sup>293</sup> and prevent increases in HRV and bradyarrhythmias upon inhalation of acrolein,<sup>272</sup> a TRPA1-stimulating constituent present in e-cig aerosols.<sup>72</sup> Although our findings do not isolate an upstream mediator, they are the first to our knowledge to indicate that e-cig exposure acutely alters heart rate and HRV through  $\beta_1$ -adrenoceptor activation, a quintessential source of cardiac pathogenesis that is not only acutely arrhythmogenic but also promotes cardiac hypertrophy and remodeling through a multitude of downstream signaling pathways.<sup>190</sup> Consequently, our observations add to mounting evidence that

nicotine-containing e-cig aerosols could promote not only acute events with short-term exposures but also chronic adverse outcomes with long-term exposures through  $\beta$ -adrenergic stimulation. Long-term exposure studies are needed to better elucidate the role of sympathetic modulation and nicotine salt in e-cig-induced cardiac disease pathogenesis.

Immediately prior to the FA exposure, atenolol lowered baseline heart rate but did not raise SDNN.  $\beta$ -blockade has produced similar results in mice<sup>294, 295</sup> despite reports showing an inverse correlation between heart rate and various time domain measures of HRV.<sup>296-298</sup> Other studies have demonstrated simultaneous heart rate reductions and HRV elevations with  $\beta$ -blockade in different mouse strains.<sup>299, 300</sup> One possible explanation for this observation is that cardiac sympathoinhibition by atenolol induced parasympathetic withdrawal to maintain a constant cardiac output.<sup>301</sup> Because SDNN is modulated by both sympathetic and parasympathetic influences, the inhibition of cardiac sympathetic activity would be expected to increase SDNN and the withdrawal of cardiac parasympathetic activity would be expected to decrease SDNN. The effects of these changes on SDNN could have canceled each other out, leaving SDNN unchanged, while the compensatory reduction in parasympathetic influence may not have been robust enough to prevent a decline in heart rate.

As expected, we observed dose-dependent increases in plasma nicotine in mice exposed to increasing concentrations (1%, 2.5%, and 5%) of nicotine salt. This verified that the nicotine to which the mice were exposed was absorbed into the systemic circulation. The plasma nicotine concentrations that we reported herein align with those observed in human studies,<sup>302-304</sup> indicating that our exposure studies were comparable to real-world vaping scenarios.

Because exposure to 2.5% and 5% racemic nicotine uniquely increased HRV while also depressing heart rate, we hypothesized that racemic nicotine would diminish nicotine delivery relative to nicotine salt secondary to irritant-induced respiratory depression. However, nicotine absorption after exposure to 5% racemic nicotine was nearly identical to that of 5% nicotine salt, suggesting that 5% racemic nicotine did not suppress respiration or pulmonary deposition despite cardiac responses suggesting otherwise. Notably, exposure to 5% racemic nicotine resulted in a qualitatively—albeit, not statistically—higher nicotine intake than 5% free-base nicotine. As nicotine enantiomers have not been found to differ in absorption, these findings suggest that *R*-nicotine may be less aversive than *S*-nicotine when inhaled. Indeed, in humans, both subjective assessments and electrical recordings of trigeminal nerve activation demonstrated that *S*-nicotine-containing vapor had lower thresholds for burning and stinging sensations than *R*-nicotine-containing vapor.<sup>305</sup>

Exposure to free-base nicotine increased HRV during puffing (SDNN: 2.5% and 5%; RMSSD: 5% only) and during washout (RMSSD: 1% and 5%), without affecting heart rate. These impacts suggest parasympathetic dominance but, by lacking a commensurate bradycardia, deviate from the TRPA1-mediated parasympathetic effects typical of inhaled irritants. Ostensibly, this response could derive from stimulation of nAChRs (which are 200-fold more nicotine-sensitive than TRPA1)<sup>306</sup> on tracheal sensory nerves as well as ensuing changes in respiratory patterns that enhance respiratory sinus arrhythmia and HRV without changing overall sinus rhythm. Further investigation is needed to disentangle the various physiological pathways responsible for this apparent parasympathetic response elicited by free-base nicotine.



The studies conducted herein are not without limitations. For instance, our findings may not extrapolate to humans since mice have distinct physiological attributes, including significantly smaller hearts, lower tidal volumes, and higher heart, respiratory, and metabolic rates.<sup>281, 282, 307</sup> In addition, the mice used to study nicotine intake and metabolism were naïve to e-cig aerosols, whereas those used for physiological endpoints underwent a serial exposure regimen with the potential for exposure sequence to influence responses; however, we mitigated the impacts of exposure sequence by using a crossover design. Further, relative to the nicotine study, exposures in the inhibition study were shortened to ensure sustained  $\beta_1$ -adrenoceptor inhibition through the entire inhalation regimen and only involved 2.5% nicotine salt, which was not arrhythmogenic; thus, these differences hinder comparisons between studies and precluded us from testing the role of  $\beta_1$ -adrenergic activation in e-cig-induced arrhythmias. Of note, male mice were used in the present study because we previously found that they are more prone than females to e-cig-induced autonomic imbalance and arrhythmias;<sup>216</sup> nonetheless, further investigation is needed to determine how exposures to various nicotine formulations affect female mice. Finally, we performed acute exposures that only crudely model the impacts of long-term use. As chronic repetition of exposures could either reduce or exacerbate the irritant and cardiac effects of subsequent exposures, our findings offer only modest insight into the long-term implications of repeated use of e-cigs.

Collectively, our findings suggest that exposure to e-cig aerosols containing commercially relevant concentrations of nicotine salt induces cardiac dysfunction by increasing sympathetic influence and spontaneous ventricular arrhythmias. Our observations further suggest these effects stem from enhanced nicotine absorption and are

mediated by  $\beta_1$ -adrenergic activation. With the rise of synthetic nicotine in tobacco products through e-cigs, there is an urgent need to elucidate the potential toxicity of inhaled aerosols containing both nicotine enantiomers. Future e-cig studies should characterize the cardiovascular effects of acute exposure to racemic nicotine salt as well as long-term exposure to different nicotine salt concentrations. Regulators should exercise caution when using our data to justify restrictions on maximum nicotine concentrations in e-cigs, as such regulations may lead to compensatory puffing behaviors that result in greater exposure to non-nicotine toxicants. More effective regulatory strategies may include setting minimum pH standards or placing limits on acid additives to minimize the proportion of protonated nicotine in e-liquids.

## Tables

**Table 3.1.** Nicotine e-liquid compositions (per 10 g).

Exposure	Nicotine (g)	30PG/70VG (g)	Benzoic acid (g)
Filtered Air	–	–	–
Vehicle	–	10	–
1% Racemic	0.1	9.9	–
1% Free-base	0.1	9.9	–
1% Salt	0.1	9.825	0.075
2.5% Racemic	0.25	9.75	–
2.5% Free-base	0.25	9.75	–
2.5% Salt	0.25	9.56	0.19
5% Racemic	0.5	9.5	–
5% Free-base	0.5	9.5	–
5% Salt	0.5	9.12	0.38

*Note:* Components were mixed at 55°C until fully dissolved. PG (JT9402-3) and VG (JT2142-3) from VWR, Radnor, PA, USA. Benzoic acid (242381) and nicotine (8.20877) from Millipore Sigma, Burlington, MA, USA. PG, propylene glycol; VG, vegetable glycerin.


**Table 3.2.** Effects of nicotine formulation on nicotine intake and metabolism.

Exposure	NIC (ng/mL)	COT (ng/mL)	3HC (ng/mL)	TNE (ng/mL)	NMR (3HC/COT)
Vehicle	1.6 ± 0.2	3.2 ± 1.0	24.4 ± 3.2	29.2 ± 3.9	3.4 ± 0.6
1% Salt	5.0 ± 1.6 <sup>5</sup>	23.6 ± 6.3 <sup>5</sup>	115.4 ± 18.3 <sup>5</sup>	144.0 ± 24.0 <sup>5</sup>	4.1 ± 0.6
2.5% Salt	9.9 ± 3.0 <sup>5</sup>	62.1 ± 11.4 <sup>5</sup>	343.0 ± 38.3 <sup>v,1,5</sup>	415.0 ± 41.7 <sup>v,1,5</sup>	5.6 ± 1.4
5% Salt	27.4 ± 3.9 <sup>v</sup>	154.8 ± 39.7 <sup>v,r,f</sup>	692.0 ± 62.2 <sup>v,f</sup>	874.2 ± 74.1 <sup>v,f</sup>	5.0 ± 1.2
5% Rac	27.8 ± 9.5 <sup>v</sup>	64.9 ± 7.9	605.8 ± 76.6 <sup>v,f</sup>	698.4 ± 76.4 <sup>v,f</sup>	8.6 ± 1.3 <sup>v</sup>
5% FB	9.6 ± 2.3	28.1 ± 7.2	163.8 ± 29.2	201.5 ± 36.0	5.2 ± 0.9


*Note:* FA-normalized values are expressed as mean ± SEM (n = 5 mice/exposure). Significance was tested using one-way ANOVA with Tukey's post hoc test for differences across nicotine salt concentrations or across nicotine types at 5%. <sup>v</sup>*P* < 0.05 vs. vehicle, <sup>r</sup>*P* < 0.05 vs. 5% racemic, <sup>f</sup>*P* < 0.05 vs. 5% free-base, <sup>1</sup>*P* < 0.05 vs. 1% salt, <sup>5</sup>*P* < 0.05 vs. 5% salt. FB, free-base; Rac, racemic; NIC, nicotine; COT, cotinine; 3HC, *trans*-3'-hydroxycotinine; TNE, total nicotine equivalents (NIC + COT + 3HC); NMR, nicotine metabolite ratio (3HC/COT).

## Figures


### Nicotine Study




### Inhibition Study




**Figure 3.1. Experimental design and exposure regimen.** (A) Overall exposure sequence of the nicotine study. A crossover design was used for two cohorts of mice ( $n = 8$ ) that underwent reverse sequences distributed across 5 separate exposure days, with  $\geq 3$  d between exposures. (B) Experimental timeline of each exposure day using a periodic puffing regimen. Mice were acclimated to the chamber during pre-exposure (45 min), monitored for baseline (15 min), and then exposed to nicotine-containing aerosols or vehicle over nine 9 min puff phases (each punctuated by 9 min washouts). Mice were allowed a recovery period (30 min) after every third washout phase, then concentrations were increased as indicated. (C) For the  $\beta_1$ -adrenoceptor inhibition study, two cohorts of mice ( $n = 8$ ) were pretreated with normal drinking water (NDW) or 0.5 g/L atenolol drinking water (ADW) and exposed to FA or 2.5% nicotine salt aerosols using a crossover design. (D) The exposure regimen for the inhibition study was an abbreviated version of the nicotine study in panel B. FA, filtered air; BL, baseline.



**Figure 3.2. Relationship between total suspended particulates (TSP) and puff-normalized aerosol deposition.** Change in mass of a gravimetric filter located downstream of the Microdust Pro was normalized to the total number of puffs on a given exposure day (x-axis). Nine-min TSP means were calculated using TSP values from a Microdust Pro (Casella CEL Ltd., Bedford, UK) located downstream of the exposure chamber (y-axis). Line denotes linear correlation of all values accompanied by r-squared.




**Figure 3.3. Baseline heart rate and HRV prior to each exposure.** One-min means for (A) heart rate, (B) SDNN, and (C) RMSSD were averaged during baseline for each mouse on a given exposure day. Significance was determined using repeated measures one-way ANOVA with Tukey's post hoc test.  $n = 8$  mice/exposure, circles indicate individual values, \* $P < 0.05$ . Data are expressed as mean  $\pm$  SEM.




**Figure 3.4. Influence of nicotine formulation on e-cig-induced changes in heart rate and HRV.** Baseline-normalized percent change in (A) heart rate, (B) SDNN, and (C) RMSSD during puff and washout phases at each nicotine concentration. Significant differences of vehicle from FA control (a), treatment from vehicle alone (v), or treatment from both FA and vehicle controls (star) were determined by two-sided  $P < 0.05$  in mixed models ( $n = 8$  mice/exposure). Data are expressed as mean  $\pm$  SEM.







**Figure 3.5. Baseline heart rate and SDNN prior to each exposure.** One-min means for (A) heart rate and (B) SDNN were averaged during baseline for each mouse on a given exposure day. Significance was determined using two-way repeated measures ANOVA with Tukey's post-hoc test.  $n = 8$  mice/exposure, circles indicate individual values,  $\star P < 0.05$ . Data are expressed as mean  $\pm$  SEM. FA, filtered air; NDW, normal drinking water; ADW, atenolol-treated drinking water.



**Figure 3.6. Influence of  $\beta_1$ -adrenergic inhibition on e-cig-induced changes in heart rate and SDNN.** Baseline-normalized values for (A) heart rate and (B) SDNN were analyzed during the puffing and washout phases. Significance was determined using two-way repeated measures ANOVA with Tukey's post-hoc test.  $n = 8$  mice/exposure, circles indicate individual values, "+" indicates mean,  $\star P < 0.05$ . Data are expressed as mean  $\pm$  SEM. FA, filtered air; NDW, normal drinking water; ADW, atenolol-treated drinking water.



**Figure 3.7. Effects of nicotine formulation on e-cig-induced ventricular arrhythmias.** (A) Hourly VPB rate by nicotine concentration and a representative VPB from a mouse exposed to e-cig aerosol containing nicotine salt (inset). To approximate a Gaussian distribution for hourly rate of VPBs, all zero values were transformed to 0.01 and all values log-normalized. (B) VPB scores by nicotine concentration. VPB scores were assigned according to the following incidence rates: 0/h = 0; > 0/h = 1; > 1/h = 2, > 2/h = 3, > 3/h = 4. Incidence (number of mice with > 0 VPBs) is indicated below each concentration according to treatment. One mouse was omitted from all arrhythmia analyses per our exclusion criteria: > 5 VPBs/h during FA at any of the three nicotine concentration periods. Significance was determined using repeated measures two-way ANOVA with Dunnett's post-hoc test.  $n = 7$  mice/exposure,  $\star P < 0.05$  vs. FA and vehicle. Data are expressed as mean  $\pm$  SEM.



**Figure 3.8. Impacts of nicotine formulation on nicotine intake and metabolism.** (A) The exposure regimen consisted of 1 h of pre-exposure and three 9 min puffing phases punctuated by two 9 min washouts followed by blood collection, which began approximately 15 min after the final puffing phase. FA-normalized values for (B-D) plasma nicotine and metabolites, (E) TNE, and (F) NMR are expressed as mean  $\pm$  SEM. Significance was determined using one-way ANOVA with Tukey's post-hoc test for differences across nicotine salt concentrations or across nicotine types at 5%.  $n = 5$  mice/exposure, circles indicate individual values, bars indicate significance ( $P < 0.05$ ) between non-vehicle groups,  $\star P < 0.05$  vs. vehicle. FB, free-base; Rac, racemic; NIC, nicotine; COT, cotinine; 3HC, *trans*-3'-hydroxycotinine; TNE, total nicotine equivalents (NIC + COT + 3HC); NMR, nicotine metabolite ratio (3HC/COT).

## CHAPTER IV

### CONCLUSIONS

#### **Summary**

Given that electronic cigarettes (e-cigs) contribute to many adverse health effects and are very popular among youth, thorough investigations of the short- and long-term public health impacts of these devices are paramount. Elucidating the cardiac risks of particular e-liquid components in specific quantities would provide regulatory agencies with the data needed to craft evidence-based tobacco control policies that lessen the burden of vaping on public health. Consequently, the studies included in this work were undertaken to test the hypothesis that e-cigs modify cardiac autonomic balance and ventricular arrhythmogenesis in mice dependent on coolant or nicotine formulation.

In Chapter II, we used a murine model to examine the effects of different coolant types and quantities on e-cig-evoked cardiac autonomic imbalance and electrical dysfunction. Adult male mice were exposed to filtered air (FA) and vehicle (30/70 propylene glycol [PG]/vegetable glycerin [VG] + 2.5% nicotine salt) aerosols as well as e-cig aerosols containing vehicle plus either menthol, Wilkinson Sword (WS)-3, or WS-23 at various concentrations (0.25%, 1%, and 2.5%). Implantable telemetry was used to collect electrocardiographic (ECG) data, and heart rate, heart rate variability (HRV), and ventricular arrhythmias were analyzed using post-processing software. Exposure to aerosols containing menthol, WS-3, and WS-23 at 2.5% elevated heart rate and reduced HRV, but only the aerosols containing WS-3 and WS-23 increased spontaneous ventricular

premature beats (VPBs). These arrhythmias were positively associated with changes in heart rate and inversely associated with changes in standard deviation of normal RR intervals (SDNN), indicating sympathetic mediation of e-cig-induced ventricular arrhythmias. Short-term exposures with nicotine-naïve, non-telemetered mice revealed no impact of coolant type or WS-23 concentration on nicotine absorption or metabolism, suggesting that nicotine may not be the sole determinant of the arrhythmogenicity of synthetic coolant-containing e-cig aerosols. Our work suggests that exposure to e-cig aerosols containing WS-3 and WS-23 impairs cardiac function by increasing sympathetic influence and provoking ventricular arrhythmias. Future e-cig studies should evaluate the cardiovascular effects of long-term exposure to synthetic cooling agents and elucidate the mechanisms by which these additives induce sympathetic dominance and arrhythmogenesis.

In Chapter III, we used a murine model to evaluate the impacts of various nicotine formulations on e-cig-induced autonomic imbalance and arrhythmogenesis. Adult male mice were exposed to FA and vehicle (30/70 PG/VG) aerosols as well as e-cig aerosols containing vehicle plus either racemic nicotine, free-base nicotine, or nicotine salt at various concentrations (1%, 2.5%, and 5%). Implantable telemetry was again used to collect ECG data, and heart rate, HRV, and ventricular arrhythmias were analyzed using post-processing software. During puffing and washout phases, 2.5% and 5% racemic nicotine decreased heart rate and elevated HRV, suggesting parasympathetic dominance. Exposure to 5% nicotine salt raised heart rate and reduced HRV during washout, indicating sympathetic dominance, and also increased spontaneous ventricular arrhythmias. Pretreatment with atenolol abolished these e-cig-evoked elevations in heart rate and

decrements in SDNN, suggesting that e-cig-induced sympathetic dominance is mediated by  $\beta_1$ -adrenergic activation. Acute exposures with nicotine-naïve, non-telemetered mice demonstrated dose-dependent elevations in plasma nicotine, its metabolites (COT and 3HC), and TNE with increasing concentrations of nicotine salt (1%, 2.5%, and 5%). Nicotine delivery upon exposures to 5% racemic nicotine and 5% nicotine salt was almost identical and exceeded, albeit nonsignificantly, that of the 5% free-base nicotine exposure. Our findings indicate that inhalation of e-cig aerosols containing commercially relevant levels of nicotine salt may increase nicotine delivery and increase the cardiovascular risks of vaping by inducing  $\beta_1$ -adrenoceptor-mediated sympathetic dominance and provoking ventricular arrhythmias. Future e-cig studies should assess the cardiac effects of short-term exposure to racemic nicotine salt and chronic exposure to various nicotine salt concentrations.

### **Strengths**

The studies conducted herein have several strengths. For instance, radiotelemetry allows for real-time assessments of the immediate effects of exposure, whereas measurements are often not concurrent in human studies due to limited options for timing or locations of exposures and physiological monitoring. Additionally, since commercial e-liquid formulations can vary due to inconsistent manufacturing practices, we ensured consistent e-liquid compositions by preparing our own mixtures in-house. Moreover, the 45 min administration of air immediately prior to each exposure (pre-exposure) provided a stable baseline (final 15 min before the start of puffing) that was used to normalize heart rate and HRV measurements collected during the exposures. Furthermore, nose-only exposures would have necessitated restraint and increased animal stress, which could have

compromised the evaluation of sensitive cardiac parameters such as heart rate, HRV, and arrhythmias. In contrast, our whole-body exposure approach circumvented the need for restraint and minimized stress on the animals, which strengthens the integrity of our physiological measurements. In addition, 10–12-wk-old mice were used in these studies; this age range in mice is equivalent to a young adult human,<sup>308</sup> so our exposure studies reflect e-cig use among individuals in the age group most likely to vape. Lastly, on a given exposure day, mice were allowed 30 min recovery periods between different nicotine or coolant concentrations. Nicotine's half-life in adult male C57BL/6 mice is roughly 9 min,<sup>307</sup> so these recovery periods, plus the final 9 min of the final washout immediately prior to recovery (39 min total), would have allowed nicotine to undergo approximately 4.3 half-lives before the beginning of the next exposure cycle. Thus, nearly 95% of the inhaled nicotine would have been eliminated during that time, thereby mitigating potential carryover effects of nicotine.

### **Limitations**

The experiments included in this work also have various limitations relating to study design, murine physiology, and HRV measurements.

### **Study Design**

Mice were subjected to whole-body exposure, which simulates second-hand inhalation rather than the more physiologically relevant nose-only exposure. This allows exposure via the ocular and oral routes and also subsequent oral exposure from licking fur and paws. Additionally, the serial exposure regimen may have influenced physiologic responses such that preceding exposures or concentrations may have had additive cardiotoxic effects. Alternatively, the study design allowed  $\geq 3$  d between exposures, which



may have resulted in physiologic recovery. Furthermore, studies utilizing an automated vaping machine do not predict human use patterns or systemic toxicant exposure. Moreover, a single device with a constant setting was used for all exposures; different devices or settings would likely lead to variable responses. In addition, we performed exposures during daytime, which is the inactive phase for mice; conducting exposures during the active phase (nighttime) may yield different results. Indeed, daily fluctuations in cardiac rhythm and autonomic modulation in mice may increase susceptibility to ventricular arrhythmias at the beginning of the active phase.<sup>309</sup> Also, we only examined the cardiac effects of e-cig aerosols containing cooling agents with nicotine; further studies are needed to assess the impacts of exposure to coolant-containing aerosols without nicotine. Lastly, only acute exposures were performed, so our findings cannot be extrapolated to chronic exposures.

### Murine Physiology

ECG data from mice may not be suitable for predicting human risk because mice have small hearts, high heart rates, and short action potential durations. Additionally, mice are obligate nasal breathers, so the aerosol concentration that reaches their alveoli may be lower than in humans due to deposition in the nasal cavity. Moreover, the mass of aerosol inhaled was not directly measured, so any differences in respiratory rates between animals would have likely resulted in varying levels of airway deposition, toxicant absorption, and systemic exposure. Also, irritant receptors (transient receptor potential ankyrin 1 [TRPA1] or transient receptor potential melastatin 8 [TRPM8]) may undergo modification or downregulation with subsequent exposures, thereby altering the sensitivity of the mice to e-cig aerosols. Furthermore, despite undergoing acclimation prior to study commencement,

the mice may still have experienced a disproportionately large amount of stress at the beginning of the exposure sequence or at the outset of a particular exposure day, and that stress may have lessened over time as they became more familiar with the environment. Since 10–12-wk-old mice were used in these studies, it is unclear how responses might differ in aged mice, although evidence shows that age-related reductions in cardiac vagal modulation may confer enhanced vulnerability to spontaneous and inducible arrhythmias.<sup>295</sup> Finally, these studies were conducted using male mice since our prior work showed that they are more susceptible to e-cig-induced autonomic imbalance and arrhythmias.<sup>216</sup> It is possible that estrogen confers protection against e-cig-evoked cardiac dysfunction, and as such, estrogen receptor antagonists can be used in future studies to investigate this putative mechanism.

#### HRV measurements

HRV is an indirect measure of cardiac autonomic activity and therefore does not provide direct measurements of either sympathetic or parasympathetic drive to the heart. Thus, HRV is a qualitative indicator of cardiac autonomic regulation and cannot be used to quantify the firing rate of cardiac nerves. Moreover, there are still conflicting views regarding the exact relationship between shifts in cardiac autonomic activity and a particular ANS branch.<sup>310</sup> Furthermore, unlike frequency domain parameters, time domain indices do not provide both frequency and amplitude measurements of specific rhythms in the HRV recording and therefore cannot adequately quantify autonomic dynamics or fluctuations in HRV.<sup>203</sup>

### **Discussion**

Wild-type C57BL/6J mice were used in these studies, which simulates the effects

of e-cig use in healthy populations. However, it is unclear how aerosols containing different coolant and nicotine formulations might affect at-risk groups. Studies utilizing susceptible murine models would clarify how e-cig use impacts autonomic balance and arrhythmogenesis in vulnerable populations. For example, elevated sympathetic activity is present in both heart failure<sup>311</sup> and hypertension,<sup>312</sup> so e-cig exposure in these models could exacerbate any pre-existing sympathetic dominance and worsen cardiovascular outcomes. Moreover, a model of myocardial infarction might increase susceptibility to e-cig-induced arrhythmias by enhancing automaticity, triggered activity, or reentry.<sup>313</sup> Furthermore, e-cig exposure in models of diabetes mellitus and cardiometabolic disease could aggravate the sympathoexcitation, electrophysiologic dysfunction, and arrhythmias that are associated with these maladies.<sup>314-317</sup>

Heart rate, HRV, and arrhythmias are ideal endpoints to evaluate the cardiovascular effects of acute e-cig exposure because sudden changes in these parameters can be captured using telemetry. However, e-cig-induced structural and functional alterations in the heart and vasculature would likely manifest only after long-term exposure. Indeed, e-cig-exposed (24 mg/mL nicotine) mice began exhibiting increases in systolic, diastolic, and mean arterial pressure at 8 wk, systemic vascular resistance at 16 wk, and left ventricular (LV) wall thickness and LV mass at 24 wk. Interestingly, no changes in heart rate, cardiac output, end diastolic volume, or end systolic volume were observed in these mice at 60 wk. Moreover, aortic segments from these mice were thicker and displayed enhancements in vasoconstriction and impairments in vasodilation at 16 wk.<sup>229</sup> However, phase-specific blood pressure changes might be discernible using our exposure regimen. If so, they could parallel heart rate changes, with relative blood pressure reductions during puffing and

elevations during washout. In addition, flow-mediated dilation (FMD) may be a valid method of assessing vascular dysfunction in an acute setting. For example, 5 min of e-cig exposure was enough to detect FMD impairments in rats.<sup>238, 239</sup>

Both the baroreflexes and cardiopulmonary reflexes could be involved in the bradycardia observed during the puffing phases. It is well established that nicotine-mediated elevations in plasma catecholamines raise arterial pressure by causing vasoconstriction. Heightened baroreceptor activity then increases central parasympathetic outflow to reduce heart rate. However, circulating nicotine is also present during the washout phases when heart rate rebounds. Therefore, it may be more likely that the bradycardia elicited during puffing involves significant contributions from the cardiopulmonary reflexes, which act as defense mechanisms against inhaled irritants. The Kratschmer reflex is triggered by stimulation of irritant receptors in the upper respiratory tract, and the Bezold-Jarisch reflex is induced by activation of ventricular mechanoreceptors. Both reflexes generate a parasympathetic response characterized by bradypnea, bradycardia, and hypotension, which limit the amount of irritant reaching the lower airways and reduce the systemic distribution of the irritant.<sup>318, 319</sup> Concurrent measurements of heart rate and either blood pressure or respiratory rate would elucidate the role of these cardiopulmonary reflexes in e-cig-induced bradycardia.

Cooling agents produce cooling sensations by stimulating TRPM8, and the physicochemical properties of these compounds may underlie their relative potencies. In HEK293 cells expressing recombinant mouse TRPM8, a fluorometric imaging assay was used to determine the EC<sub>50</sub> values (concentration of test compound required to produce half-maximal increases in [Ca<sup>2+</sup>]<sub>i</sub>) of WS-3 (3.7 ± 1.7 μM), L-menthol (4.1 ± 1.3 μM), and

WS-23 ( $44 \pm 7.3 \mu\text{M}$ ). These  $\text{EC}_{50}$  values reveal that WS-3 and menthol are more potent TRPM8 agonists than WS-23.<sup>279</sup> Additionally, human sensory evaluations showed that WS-3 and L-menthol have higher cooling intensities compared to WS-23.<sup>320</sup> This enhanced TRPM8 agonism may be conferred by a hexacyclic ring structure present in WS-3 and menthol but absent in WS-23.<sup>321</sup> However, the *in vitro* activity of cooling agents may differ from their *in vivo* activity, the matrix in which they are contained could alter their sensory effects, their temporal profiles (e.g., onset, plateau, and lastingness) may vary, and their agonism at different receptors may produce additional effects. Further studies are needed to address these topics, and analyses involving TRPM8 may provide a mechanistic basis for the autonomic and arrhythmogenic effects of synthetic coolants observed herein.

The studies included in this work showed that racemic nicotine induces parasympathetic dominance at 2.5% and 5%. It is unclear whether the addition of a salt would exacerbate or attenuate this effect and what impact it would have on racemic nicotine intake. Mechanistic investigation of this parasympathetic response can be accomplished using pharmacological inhibition of muscarinic receptors or TRPA1. It would also be worthwhile to evaluate the cardiac effects of exposure to e-cig aerosols containing either pure *R*- or *S*-nicotine and whether there are differences in absorption between these two enantiomeric nicotine forms.

Although these are the first studies to examine the role of  $\beta_1$ -adrenergic activation in e-cig-induced sympathetic dominance, the autonomic effects of pharmacological interventions and genetic manipulations targeting  $\beta$ -adrenoceptors have been investigated extensively in mice. For instance, atenolol reduced heart rate while SDNN and RMSSD remained unchanged in 4- and 19-month-old C57BL/6J mice.<sup>295</sup> Additionally, heart rate

was lower and SDNN was higher in  $\beta_1$ -deficient and  $\beta_1/\beta_2$ -deficient FVB mice but not in  $\beta_2$ -deficient FVB mice.<sup>322</sup> Furthermore, atrial overexpression of  $\beta_1$ -adrenoceptors did not modify heart rate but decreased the high (HF) and low frequency (LF) components of HRV in C57BL/6 mice. In the same study, propranolol induced bradycardia and enhanced HF and LF in control animals but had no impact on heart rate or HRV in transgenic animals.<sup>299</sup> Moreover, propranolol diminished heart rate but did not alter SDNN or RMSSD in FVB mice, whereas in C57BL6/SV129 mice, propranolol prevented the increase in heart rate observed with saline injection and reduced SDNN but did not change RMSSD. This study also showed that both isoproterenol and atropine elevated heart rate and reduced SDNN in C57BL6/SV129 mice but not FVB mice.<sup>294</sup> From these studies, it is evident that there are strain-specific differences in autonomic modulation in mice that could be modified by e-cig exposure.

### **Implications**

The U.S. Food and Drug Administration (FDA) has traditionally adhered to a safe and effective regulatory framework for pharmaceutical drugs, medical devices, and biological agents. However, the Family Smoking Prevention and Tobacco Control Act requires that the FDA regulate tobacco products (including e-cigs) according to a public health standard that includes a product's overall impact on the general population, including users and nonusers. This regulatory paradigm allows the FDA to develop product standards, which encompass construction, components, ingredients, additives, constituents, and nicotine yields.<sup>323, 324</sup> Therefore, the regulation of specific formulations of synthetic cooling agents and nicotine in e-liquids is within the FDA's regulatory scope.

Given our findings, the potential cardiovascular risks posed by e-cig aerosols

containing synthetic coolants warrant increased scrutiny from regulators. However, there is ambiguity regarding how e-cigs with synthetic cooling agents should be regulated given that these products do not clearly fit into conventional flavor categories. Synthetic coolants produce cooling sensations that are similar to those elicited by menthol but lack menthol's minty flavor, raising uncertainty as to whether synthetic cooling agents should fall under the same regulatory purview as menthol flavors, which are currently exempt from restrictions on flavored cartridge-based e-cigs. These federal restrictions and similar state-level policies generally apply to characterizing flavors, typically defined as flavors with a distinct taste or aroma, although no formal definition of the term exists in the Family Smoking Prevention and Tobacco Control Act. Given the absence of a standardized system with which to classify characterizing flavors, it is unclear whether synthetic coolants can be included in this category. Perhaps U.S. regulatory agencies should adopt the methodology employed by the European Union to identify characterizing flavors, which takes into account the olfactory, gustatory, and somatosensory effects of a given flavoring compound. Using this approach, synthetic cooling agents as well as menthol would likely be categorized as characterizing flavors.<sup>153, 154</sup> Nevertheless, the health effects of both acute and chronic exposure to e-cigs containing synthetic cooling agents merit further investigation.

Our findings should be cautiously interpreted with regard to a complete e-cig flavor ban. The implications of broad flavor restrictions are highly nuanced, as various populations can be differentially affected and unintended consequences could arise. For instance, while e-cig flavor bans might deter youth vaping, they could also reduce quit attempts among adult smokers since adults, like youth, prefer nontobacco flavors.<sup>325</sup>

Furthermore, San Francisco's ban on the sale of all flavored tobacco products (including e-cigs) in January 2019 was followed by a decline in flavored e-cig use among young adults and an increase in smoking among both high school students and young adults.<sup>326, 327</sup> In addition, U.S. federal restrictions on flavored cartridge-based e-cigs took effect in February 2020 and resulted in a transition to exempted flavored disposable products.<sup>328</sup> Also, given a hypothetical flavor ban (excluding tobacco), vape shop customers who preferred flavors indicated lower intention for continued vaping, while those who vaped for smoking cessation showed greater intention for continued use of e-cigs.<sup>329</sup> Moreover, in response to hypothetical restrictions on e-liquid flavors (excluding tobacco and menthol), young adult dual users reported intentions to quit or reduce vaping and increase cigarette use.<sup>330</sup> Flavor restrictions that increase smoking may prove harmful to public health and undermine efforts to reduce this behavior among youth after many years of progress. Other potential unanticipated outcomes of flavor-limiting policies could include attempts by e-cig users to obtain banned flavors from sources that increase risk, such as black markets or self-made e-liquids.<sup>331</sup> Clearly, the benefits and drawbacks of a comprehensive flavor ban should be heavily weighed prior to implementation, whether on a federal, state, or local level.

According to U.S. federal regulations, any product that contains tobacco-derived ingredients is considered a tobacco product.<sup>174</sup> Because it is not sourced from tobacco, synthetic nicotine was recognized as a potential means for e-cig manufacturers to circumvent tobacco control regulations, but a federal law became effective in April 2022 that gave the FDA authority to regulate synthetic nicotine.<sup>175</sup> The dominant e-cig brand among youth (Puff Bar) purportedly contains synthetic nicotine, which consists of both *R* and *S* enantiomers in a salt formulation.<sup>176</sup> Ideally, we would have tested the effects of



synthetic nicotine in Chapter III but were unable to obtain it and instead opted for racemic nicotine from a reputable vendor as a suitable alternative. In these initial exposures, we chose to investigate the e-cig-induced cardiac effects of pure racemic nicotine devoid of any additives (except for humectants). Future experiments can include racemic nicotine salt to more closely mimic a flavorless Puff Bar, which can be used as a vehicle control to test the impacts of flavors, or synthetic nicotine itself if we are able to acquire it. Given the popularity of Puff Bar, studies directly comparing the pharmacological, toxicological, and physiological impacts of synthetic and tobacco-derived nicotine are urgently needed.

Our work also suggests that regulatory limits on nicotine concentration in e-liquids may promote harm reduction. However, such regulations could increase harm rather than reduce it. E-cig users forced to switch to lower nicotine products may engage in compensation in which they modify their puffing behavior to sustain desired levels of nicotine intake.<sup>332</sup> Indeed, when faced with low-yield e-cigs, vapers engaged in compensatory puffing by adopting a more intensive puff topography characterized by higher puff numbers and longer puff durations.<sup>333</sup> E-cig users can also increase nicotine intake by transitioning to higher-wattage devices.<sup>334</sup> These behavioral changes in vaping can lead to greater e-liquid consumption and toxicant exposure,<sup>333-336</sup> thereby exacerbating injury to susceptible tissues. Therefore, attempting to control e-cig nicotine yield with regulatory limits on e-liquid nicotine concentration may have unintended health consequences for e-cig users. However, minimum pH thresholds or restrictions on acid additives, which increase the palatability and appeal of e-cigs, may prove more effective and warrant increased attention from regulatory authorities.

While our data provide support for policies restricting synthetic coolants and acid additives in e-cigs, our findings are too narrow in scope to justify a comprehensive e-cig ban, which has generated much public debate. Proponents of an e-cig ban assert that vaping promotes nicotine addiction among youth who never would have tried smoking, causes some never-smoking young people to experiment with cigarettes, and harms the developing adolescent brain.<sup>325</sup> Indeed, several cross-sectional and longitudinal studies have shown that e-cig use among adolescents and young adults may increase the risk of subsequent smoking initiation.<sup>337-345</sup> By contrast, opponents of e-cig restrictions contend that vaping fosters smoking cessation and poses far fewer health risks than does cigarette use. In fact, accumulating evidence suggests that vaping can facilitate smoking cessation, although the evidence is not definitive.<sup>325</sup> Additionally, the US National Academies of Sciences, Engineering, and Medicine and the British Royal College of Physicians have concluded that vaping is likely far less hazardous than smoking.<sup>26, 346</sup> Policies intended to reduce adolescent vaping may also diminish adult smokers' use of e-cigs for smoking cessation; thus, a delicate balance between the risks to young people and the potential benefits to adult smokers is required. Recognition that tobacco control policies accomplish very little without regulatory enforcement and retailer compliance is also needed. The overall goal of public health policies involving e-cigs should be to develop strategies and interventions that both curtail youth vaping and promote adult smoking cessation.<sup>325</sup>

Collectively, our findings reveal that specific e-liquid constituents at certain concentrations can differentially modify e-cig-induced cardiac autonomic balance and arrhythmogenesis in mice. In particular, e-cig aerosols containing commercially relevant levels of synthetic cooling agents (WS-3 and WS-23) or nicotine salt evoked sympathetic

dominance and increased ventricular arrhythmias. Further investigation is needed to determine if these e-liquid constituents pose the same cardiac risks in human populations. Future experiments should also be conducted to evaluate sex differences using a combination of male and female mice, determine the chemical composition of arrhythmogenic e-cig aerosols, examine the effects of synthetic nicotine and commercial e-liquids containing synthetic coolants *in vitro* and *in vivo*, and assess the impacts of arrhythmogenic e-cig aerosols in susceptible models (e.g., transverse aortic constriction and myocardial infarction). If corroborated by human studies, our work may inform tobacco control policies that lessen the public health risks of vaping.

## REFERENCES

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
2. Qasim H, Karim ZA, Silva-Espinoza JC, et al. Short-term e-cigarette exposure increases the risk of thrombogenesis and enhances platelet function in mice. *J Am Heart Assoc.* 2018;7(15).
3. Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. *Eur J Prev Cardiol.* 2019;26(3):279-288.
4. U.S. Department of Health and Human Services. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General.* Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
5. Nadruz W, Jr., Claggett B, Goncalves A, et al. Smoking and cardiac structure and function in the elderly: The ARIC study (Atherosclerosis Risk in Communities). *Circ Cardiovasc Imaging.* 2016;9(9):e004950.
6. Isles C, Brown JJ, Cumming AMM, et al. Excess smoking in malignant-phase hypertension. *Br Med J.* 1979;1:579-581.
7. Zhu W, Yuan P, Shen Y, et al. Association of smoking with the risk of incident atrial fibrillation: A meta-analysis of prospective studies. *Int J Cardiol.* 2016;218:259-266.
8. Goldenberg I, Moss AJ, McNitt S, et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. *J Cardiovasc Electrophysiol.* 2006;17(9):931-936.
9. Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. *Nat Rev Cardiol.* 2017;14(8):447-456.
10. Wang TW, Gentzke AS, Creamer MR, et al. Tobacco product use and associated factors among middle and high school students — United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(12):1-22.
11. Agaku IT, King BA, Husten CG, et al. Tobacco product use among adults — United States, 2012–2013. *MMWR Morb Mortal Wkly Rep.* 2014;63(29):542-547.
12. Cornelius ME, Loretan CG, Wang TW, et al. Tobacco product use among adults — United States, 2020. *MMWR Morb Mortal Wkly Rep.* 2022;71(11):397-405.

13. Arrazola RA, Dube SR, Kaufmann RB, et al. Tobacco use among middle and high school students — United States, 2000–2009. *MMWR Morb Mortal Wkly Rep.* 2010;59(33):1063-1068.
14. Gentzke AS, Wang TW, Cornelius M, et al. Tobacco product use and associated factors among middle and high school students — National Youth Tobacco Survey, United States, 2021. *MMWR Morb Mortal Wkly Rep.* 2022;71(5):1-29.
15. Consumer Advocates for Smoke-free Alternatives Association. Historical Timeline of Vaping & Electronic Cigarettes. 2022.  
<https://casaa.org/education/vaping/historical-timeline-of-electronic-cigarettes/>. Accessed 6 Dec 2022.
16. Robinson J. Electric Vaporizer. US 1775947 A. United States Patent and Trademark Office. 16 Sept 1930.  
<https://patentimages.storage.googleapis.com/cf/3d/d4/a46751164d1ee0/US1775947.pdf>. Accessed 6 Dec 2022.
17. Gilbert HA. Smokeless Non-Tobacco Cigarette. US 3200819 A, United States Patent and Trademark Office, 17 Aug 1965.  
<https://patentimages.storage.googleapis.com/a8/a4/ef/28cea2ddb9f425/US3200819.pdf>. Accessed 4 Dec 2022.
18. U.S. Department of Health and Human Services. *E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General.* Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2016.
19. Laucks P, Salzman GA. The dangers of vaping. *Mo Med.* 2020;117(2):159-164.
20. Lik H. Electronic Atomization Cigarette. US 8393331 B2, United States Patent and Trademark Office, 12 Mar 2013.  
<https://patentimages.storage.googleapis.com/97/b0/54/5675deba79e5e/US8393331.pdf>. Accessed 4 Dec 2022.
21. Caponnetto P, Campagna D, Papale G, et al. The emerging phenomenon of electronic cigarettes. *Expert Rev Respir Med.* 2012;6(1):63-74.
22. Noel JK, Rees VW, Connolly GN. Electronic cigarettes: a new 'tobacco' industry? *Tob Control.* 2011;20(1):81.
23. Cornelius ME, Wang TW, Jamal A, et al. Tobacco product use among adults — United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2020;69(46):1736-1742.
24. Bhatnagar A, Whitsel LP, Blaha MJ, et al. New and emerging tobacco products and the nicotine endgame: The role of robust regulation and comprehensive tobacco control and prevention: A presidential advisory from the American Heart Association. *Circulation.* 2019;139(19):e937-e958.
25. Arrazola RA, Dube SR, King BA. Tobacco product use among middle and high school students — United States, 2011 and 2012. *MMWR Morb Mortal Wkly Rep.* 2013;62(45):893-897.
26. National Academies of Sciences, Engineering, and Medicine. *Public Health Consequences of E-cigarettes.* Washington, DC: the National Academies Press, 2018.
27. Cullen KA, Gentzke AS, Sawdey MD, et al. E-cigarette use among youth in the United States, 2019. *JAMA.* 2019;322(21):2095-2103.

28. Dobbs PD, Chadwick G, Dunlap CM, et al. Tobacco 21 policies in the U.S.: The importance of local control with federal policy. *Am J Prev Med.* 2021;60(5):639-647.
29. United States Food and Drug Administration. FDA finalizes enforcement policy on unauthorized flavored cartridge-based e-cigarettes that appeal to children, including fruit and mint. 2 Jan 2020. <https://www.fda.gov/news-events/press-announcements/fda-finalizes-enforcement-policy-unauthorized-flavored-cartridge-based-e-cigarettes-appeal-children>. Accessed 7 Dec 2022.
30. United States Food and Drug Administration. FDA Denies Authorization to Market JUUL Products. 23 June 2022. <https://www.fda.gov/news-events/press-announcements/fda-denies-authorization-market-juul-products>. Accessed 7 Dec 2022.
31. Buchanan ND, Grimmer JA, Tanwar V, et al. Cardiovascular risk of electronic cigarettes: a review of preclinical and clinical studies. *Cardiovasc Res.* 2020;116(1):40-50.
32. Glantz SA, Bareham DW. E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications. *Annu Rev Public Health.* 2018;39:215-235.
33. Grana, R, Benowitz, N, Glantz SA. Background paper on e-cigarettes (electronic nicotine delivery systems). Center for Tobacco Control Research and Education, University of California, San Francisco, a WHO Collaborating Center on Tobacco Control. Prepared for World Health Organization Tobacco Free Initiative. December 2013.
34. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. E-cigarette, or Vaping, Products Visual Dictionary. [https://www.cdc.gov/tobacco/basic\\_information/e-cigarettes/pdfs/ecigarette-or-vaping-products-visual-dictionary-508.pdf](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/pdfs/ecigarette-or-vaping-products-visual-dictionary-508.pdf). Accessed 12 Dec 2022.
35. Talih S, Salman R, Karaoghlanian N, et al. "Juice monsters": Sub-ohm vaping and toxic volatile aldehyde emissions. *Chem Res Toxicol.* 2017;30(10):1791-1793.
36. Qasim H, Karim ZA, Rivera JO, et al. Impact of electronic cigarettes on the cardiovascular system. *J Am Heart Assoc.* 2017;6(9).
37. Huang J, Duan Z, Kwok J, et al. Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market. *Tob Control.* 2019;28(2):146-151.
38. Szafran BN, Pinkston R, Perveen Z, et al. Electronic-cigarette vehicles and flavoring affect lung function and immune responses in a murine model. *Int J Mol Sci.* 2020;21(17):6022.
39. Benowitz NL, Hukkanen J, Jacob III P. Nicotine chemistry, metabolism, kinetics and biomarkers. *Handb Exp Pharmacol.* 2009(192):29-60.
40. Gholap VV, Kosmider L, Golshahi L, et al. Nicotine forms: why and how do they matter in nicotine delivery from electronic cigarettes? *Expert Opin Drug Deliv.* 2020;17(12):1727-1736.
41. Kirschner RI, Gerona R, Jacobitz KL. Nicotine content of liquid for electronic cigarettes. *Clin Toxicol.* 2013;51(7):684.
42. Cheng T. Chemical evaluation of electronic cigarettes. *Tob Control.* 2014;23:ii11-ii17.

43. Krusemann EJZ, Boesveldt S, de Graaf K, et al. An e-liquid flavor wheel: A shared vocabulary based on systematically reviewing e-liquid flavor classifications in literature. *Nicotine Tob Res.* 2019;21(10):1310-1319.
44. Hsu G, Sun JY, Zhu SH. Evolution of electronic cigarette brands from 2013-2014 to 2016-2017: Analysis of brand websites. *J Med Internet Res.* 2018;20(3):e80.
45. Bhatnagar A. E-cigarettes and cardiovascular disease risk: Evaluation of evidence, policy implications, and recommendations. *Current Cardiovascular Risk Reports.* 2016;10(7).
46. Margham J, McAdam K, Forster M, et al. Chemical composition of aerosol from an e-cigarette: A quantitative comparison with cigarette smoke. *Chem Res Toxicol.* 2016;29(10):1662-1678.
47. Margham J, McAdam K, Cunningham A, et al. The chemical complexity of e-cigarette aerosols compared with the smoke from a tobacco burning cigarette. *Front Chem.* 2021;9:743060.
48. United States Food and Drug Administration. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List. *Fed Reg.* 2012;77(64):20034-20037.
49. El-Hellani A, Salman R, El-Hage R, et al. Nicotine and carbonyl emissions from popular electronic cigarette products: Correlation to liquid composition and design characteristics. *Nicotine Tob Res.* 2018;20(2):215-223.
50. Baassiri M, Talih S, Salman R, et al. Clouds and "throat hit": Effects of liquid composition on nicotine emissions and physical characteristics of electronic cigarette aerosols. *Aerosol Sci Technol.* 2017;51(11):1231-1239.
51. Talih S, Salman R, El-Hage R, et al. Effect of free-base and protonated nicotine on nicotine yield from electronic cigarettes with varying power and liquid vehicle. *Sci Rep.* 2020;10(1):16263.
52. Talih S, Balhas Z, Eissenberg T, et al. Effects of user puff topography, device voltage, and liquid nicotine concentration on electronic cigarette nicotine yield: measurements and model predictions. *Nicotine Tob Res.* 2015;17(2):150-157.
53. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. *Annu Rev Pharmacol Toxicol.* 2009;49:57-71.
54. Benowitz NL. Nicotine addiction. *N Engl J Med.* 2010;362(24):2295-2303.
55. Uchiyama S, Noguchi M, Sato A, et al. Determination of thermal decomposition products generated from e-cigarettes. *Chem Res Toxicol.* 2020;33(2):576-583.
56. International Agency for Research on Cancer. *Monographs on the Evaluation of Carcinogenic Risks to Humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol.* Volume 88. 2006.  
file:///Users/admin/Downloads/IARC%20Monographs%20on%20the%20Evaluation%20of%20Carcinogenic%20Risks%20to%20Humans%20Vol%2088.pdf. Accessed 15 Dec 2022.
57. International Agency for Research on Cancer. *Monographs on the Evaluation of Carcinogenic Risks to Humans: Re-evaluation of Some Organic Chemicals, Hydrazine, and Hydrogen Peroxide.* Volume 71. 1999.  
file:///Users/admin/Downloads/IARC%20Monographs%20on%20the%20Evaluation%20of%20Carcinogenic%20Risks%20to%20Humans.pdf. Accessed 15 Dec 2022.

58. U.S. Environmental Protection Agency. *Toxicological Review of Acrolein*. 2003. [https://cfpub.epa.gov/ncea/iris/iris\\_documents/documents/toxreviews/0364tr.pdf](https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0364tr.pdf). Accessed 14 Dec 2022.
59. DeJarnett N, Conklin DJ, Riggs DW, et al. Acrolein exposure is associated with increased cardiovascular disease risk. *J Am Heart Assoc*. 2014;3(4).
60. Henning RJ, Johnson GT, Coyle JP, et al. Acrolein can cause cardiovascular disease: A review. *Cardiovasc Toxicol*. 2017;17(3):227-236.
61. Zhang Y, Yang Y, He X, et al. The cellular function and molecular mechanism of formaldehyde in cardiovascular disease and heart development. *J Cell Mol Med*. 2021;25(12):5358-5371.
62. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. *Cardiovasc Res*. 2010;88(1):51-57.
63. Setshedi M, Wands JR, de la Monte SM. Acetaldehyde adducts in alcoholic liver disease. *Oxid Med Cell Longev*. 2010;3(3):178-185.
64. Uchiyama S, Ohta S, Inaba Y, et al. Determination of carbonyl compounds generated from the e-cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid chromatography. *Anal Sci*. 2013;29:1219-1222.
65. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*. 2014;23(2):133-139.
66. Kosmider L, Sobczak A, Fik M, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. *Nicotine Tob Res*. 2014;16(10):1319-1326.
67. Offermann FJ. Chemical emissions from e-cigarettes: Direct and indirect (passive) exposures. *Building and Environment*. 2015;93:101-105.
68. Jensen RP, Luo W, Pankow JF, et al. Hidden formaldehyde in e-cigarette aerosols. *N Engl J Med*. 2015;372(4):392-394.
69. Sleiman M, Logue JM, Montesinos VN, et al. Emissions from electronic cigarettes: Key parameters affecting the release of harmful chemicals. *Environ Sci Technol*. 2016;50(17):9644-9651.
70. Jo SH, Kim KH. Development of a sampling method for carbonyl compounds released due to the use of electronic cigarettes and quantitation of their conversion from liquid to aerosol. *J Chromatogr A*. 2016;1429:369-373.
71. Jensen RP, Strongin RM, Peyton DH. Solvent chemistry in the electronic cigarette reaction vessel. *Sci Rep*. 2017;7:42549.
72. Ogunwale MA, Li M, Ramakrishnam Raju MV, et al. Aldehyde detection in electronic cigarette aerosols. *ACS Omega*. 2017;2(3):1207-1214.
73. Klager S, Vallarino J, MacNaughton P, et al. Flavoring chemicals and aldehydes in e-cigarette emissions. *Environ Sci Technol*. 2017;51(18):10806-10813.
74. Farsalinos KE, Kistler KA, Pennington A, et al. Aldehyde levels in e-cigarette aerosol: Findings from a replication study and from use of a new-generation device. *Food Chem Toxicol*. 2018;111:64-70.
75. Conklin DJ, Ogunwale MA, Chen Y, et al. Electronic cigarette-generated aldehydes: The contribution of e-liquid components to their formation and the use of urinary aldehyde metabolites as biomarkers of exposure. *Aerosol Science and Technology*. 2018;52(11):1219-1232.



76. Ooi BG, Dutta D, Kazipeta K, et al. Influence of the e-cigarette emission profile by the ratio of glycerol to propylene glycol in e-liquid composition. *ACS Omega*. 2019;4(8):13338-13348.
77. Belushkin M, Tabin Djoko D, Esposito M, et al. Selected harmful and potentially harmful constituents levels in commercial e-cigarettes. *Chem Res Toxicol*. 2020;33(2):657-668.
78. Gillman IG, Pennington ASC, Humphries KE, et al. Determining the impact of flavored e-liquids on aldehyde production during vaping. *Regul Toxicol Pharmacol*. 2020;112:104588.
79. Cirillo S, Urena JF, Lambert JD, et al. Impact of electronic cigarette heating coil resistance on the production of reactive carbonyls, reactive oxygen species and induction of cytotoxicity in human lung cancer cells in vitro. *Regul Toxicol Pharmacol*. 2019;109:104500.
80. Beauval N, Antherieu S, Soyeux M, et al. Chemical evaluation of electronic cigarettes: Multicomponent analysis of liquid refills and their corresponding aerosols. *J Anal Toxicol*. 2017;41(8):670-678.
81. Havel CM, Benowitz NL, Jacob P, 3rd, et al. An electronic cigarette vaping machine for the characterization of aerosol delivery and composition. *Nicotine Tob Res*. 2017;19(10):1224-1231.
82. Sala C, Medana C, Pellegrino R, et al. Dynamic measurement of newly formed carbonyl compounds in vapors from electronic cigarettes. *Eur J Mass Spectrom (Chichester)*. 2017;23(2):64-69.
83. Herrington JS, Myers C. Electronic cigarette solutions and resultant aerosol profiles. *J Chromatogr A*. 2015;1418:192-199.
84. Uchiyama S, Inaba Y, Kunugita N. Determination of acrolein and other carbonyls in cigarette smoke using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine. *J Chromatogr A*. 2010;1217(26):4383-4388.
85. Hutzler C, Paschke M, Kruschinski S, et al. Chemical hazards present in liquids and vapors of electronic cigarettes. *Arch Toxicol*. 2014;88(7):1295-1308.
86. Blair SL, Epstein SA, Nizkorodov SA, et al. A real-time fast-flow tube study of VOC and particulate emissions from electronic, potentially reduced-harm, conventional, and reference cigarettes. *Aerosol Sci Technol*. 2015;49(9):816-827.
87. Geiss O, Bianchi I, Barrero-Moreno J. Correlation of volatile carbonyl yields emitted by e-cigarettes with the temperature of the heating coil and the perceived sensorial quality of the generated vapours. *Int J Hyg Environ Health*. 2016;219(3):268-277.
88. Khlystov A, Samburova V. Flavoring compounds dominate toxic aldehyde production during e-cigarette vaping. *Environ Sci Technol*. 2016;50(23):13080-13085.
89. Farsalinos KE, Voudris V, Spyrou A, et al. E-cigarettes emit very high formaldehyde levels only in conditions that are aversive to users: A replication study under verified realistic use conditions. *Food Chem Toxicol*. 2017;109:90-94.
90. Laugesen M. Nicotine and toxicant yield ratings of electronic cigarette brands in New Zealand. *N Z Med J*. 2015;128:77-82.
91. Farsalinos KE, Voudris V, Poulas K. E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. *Addiction*. 2015;110(8):1352-1356.

92. Geiss O, Bianchi I, Barahona F, et al. Characterisation of mainstream and passive vapours emitted by selected electronic cigarettes. *Int J Hyg Environ Health*. 2015;218(1):169-180.
93. Uchiyama S, Senoo Y, Hayashida H, et al. Determination of chemical compounds generated from second-generation e-cigarettes using a sorbent cartridge followed by a two-step elution method. *Anal Sci*. 2016;32:549-555.
94. Wang P, Chen W, Liao J, et al. A device-independent evaluation of carbonyl emissions from heated electronic cigarette solvents. *PLoS One*. 2017;12(1):e0169811.
95. Talih S, Balhas Z, Salman R, et al. "Direct dripping": A high-temperature, high-formaldehyde emission electronic cigarette use method. *Nicotine Tob Res*. 2016;18(4):453-459.
96. Son Y, Weisel C, Wackowski O, et al. The impact of device settings, use patterns, and flavorings on carbonyl emissions from electronic cigarettes. *Int J Environ Res Public Health*. 2020;17(16).
97. Li Y, Burns AE, Tran LN, et al. Impact of e-liquid composition, coil temperature, and puff topography on the aerosol chemistry of electronic cigarettes. *Chem Res Toxicol*. 2021;34(6):1640-1654.
98. Talih S, Salman R, El-Hage R, et al. Characteristics and toxicant emissions of JUUL electronic cigarettes. *Tob Control*. 2019;28(6):678-680.
99. Tayyarah R, Long GA. Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. *Regul Toxicol Pharmacol*. 2014;70(3):704-710.
100. Farsalinos KE, Gillman G. Carbonyl emissions in e-cigarette aerosol: A systematic review and methodological considerations. *Front Physiol*. 2017;8:1119.
101. Behar RZ, Luo W, McWhirter KJ, et al. Analytical and toxicological evaluation of flavor chemicals in electronic cigarette refill fluids. *Sci Rep*. 2018;8(1):8288.
102. Allen JG, Flanigan SS, LeBlanc M, et al. Flavoring chemicals in e-cigarettes: diacetyl, 2,3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes. *Environ Health Perspect*. 2016;124(6):733-739.
103. Behar RZ, Luo W, Lin SC, et al. Distribution, quantification and toxicity of cinnamaldehyde in electronic cigarette refill fluids and aerosols. *Tob Control*. 2016;25(Suppl 2):ii94-ii102.
104. Kosmider L, Sobczak A, Prokopowicz A, et al. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. *Thorax*. 2016;71(4):376-377.
105. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal*. 2012;24(5):981-990.
106. Goel R, Durand E, Trushin N, et al. Highly reactive free radicals in electronic cigarette aerosols. *Chem Res Toxicol*. 2015;28(9):1675-1677.
107. Sussan TE, Gajghate S, Thimmulappa RK, et al. Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. *PLoS One*. 2015;10(2):e0116861.

108. Lerner CA, Sundar IK, Watson RM, et al. Environmental health hazards of e-cigarettes and their components: Oxidants and copper in e-cigarette aerosols. *Environ Pollut*. 2015;198:100-107.
109. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. *PLoS One*. 2015;10(2):e0116732.
110. Zhao J, Zhang Y, Sisler JD, et al. Assessment of reactive oxygen species generated by electronic cigarettes using acellular and cellular approaches. *J Hazard Mater*. 2018;344:549-557.
111. Bitzer ZT, Goel R, Reilly SM, et al. Effect of flavoring chemicals on free radical formation in electronic cigarette aerosols. *Free Radic Biol Med*. 2018;120:72-79.
112. Bitzer ZT, Goel R, Reilly SM, et al. Effects of solvent and temperature on free radical formation in electronic cigarette aerosols. *Chem Res Toxicol*. 2018;31(1):4-12.
113. Haddad C, Salman R, El-Hellani A, et al. Reactive oxygen species emissions from supra- and sub-ohm electronic cigarettes. *J Anal Toxicol*. 2019;43(1):45-50.
114. Son Y, Mishin V, Laskin JD, et al. Hydroxyl radicals in e-cigarette vapor and e-vapor oxidative potentials under different vaping patterns. *Chem Res Toxicol*. 2019;32(6):1087-1095.
115. Yogeswaran S, Muthumalage T, Rahman I. Comparative reactive oxygen species (ROS) content among various flavored disposable vape bars, including cool (iced) flavored bars. *Toxics*. 2021;9(235).
116. Yogeswaran S, Rahman I. Differences in acellular reactive oxygen species (ROS) generation by e-cigarettes containing synthetic nicotine and tobacco-derived nicotine. *Toxics*. 2022;10(3).
117. Tanwar V, Katapadi A, Adelstein JM, et al. Cardiac pathophysiology in response to environmental stress: a current review. *Curr Opin Physiol*. 2018;1:198-205.
118. Nemmar A, Vanbilloen H, Hoylaerts MF, et al. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. *Am J Respir Crit Care Med*. 2001;164(9):1665-1668.
119. Nemmar A, Hoet PHM, Vanquickenborne B, et al. Passage of inhaled particles into the blood circulation in humans. *Circulation*. 2002;105:411-414.
120. Shimada A, Kawamura N, Okajima M, et al. Translocation pathway of the intratracheally instilled ultrafine particles from the lung into the blood circulation in the mouse. *Toxicol Pathol*. 2006;34(7):949-957.
121. Nelin TD, Joseph AM, Gorr MW, et al. Direct and indirect effects of particulate matter on the cardiovascular system. *Toxicol Lett*. 2012;208(3):293-299.
122. Pope III CA, Burnett RT, Krewski D, et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. *Circulation*. 2009;120(11):941-948.
123. Brook RD, Rajagopalan S, Pope CA, 3rd, et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. *Circulation*. 2010;121(21):2331-2378.

124. Protano C, Avino P, Manigrasso M, et al. Environmental electronic vape exposure from four different generations of electronic cigarettes: Airborne particulate matter levels. *Int J Environ Res Public Health*. 2018;15(10).
125. Spindle TR, Talih S, Hiler MM, et al. Effects of electronic cigarette liquid solvents propylene glycol and vegetable glycerin on user nicotine delivery, heart rate, subjective effects, and puff topography. *Drug Alcohol Depend*. 2018;188:193-199.
126. Fowles J, Barreau T, Wu N. Cancer and non-cancer risk concerns from metals in electronic cigarette liquids and aerosols. *Int J Environ Res Public Health*. 2020;17(6).
127. Gaur S, Agnihotri R. Health effects of trace metals in electronic cigarette aerosols—a systematic review. *Biol Trace Elem Res*. 2019;188(2):295-315.
128. Navas-Acien A, Martinez-Morata I, Hilpert M, et al. Early cardiovascular risk in e-cigarette users: The potential role of metals. *Curr Environ Health Rep*. 2020;7(4):353-361.
129. Re DB, Hilpert M, Saglimbeni B, et al. Exposure to e-cigarette aerosol over two months induces accumulation of neurotoxic metals and alteration of essential metals in mouse brain. *Environ Res*. 2021;202:111557.
130. Soulet S, Sussman RA. A critical review of recent literature on metal contents in e-cigarette aerosol. *Toxics*. 2022;10(9).
131. Halstead M, Gray N, Gonzalez-Jimenez N, et al. Analysis of toxic metals in electronic cigarette aerosols using a novel trap design. *J Anal Toxicol*. 2020;44(2):149-155.
132. Kapiamba KF, Hao W, Adom S, et al. Examining metal contents in primary and secondhand aerosols released by electronic cigarettes. *Chem Res Toxicol*. 2022;35(6):954-962.
133. Liu Q, Huang C, Chris Le X. Arsenic species in electronic cigarettes: Determination and potential health risk. *J Environ Sci (China)*. 2020;91:168-176.
134. Mikheev VB, Brinkman MC, Granville CA, et al. Real-time measurement of electronic cigarette aerosol size distribution and metals content analysis. *Nicotine Tob Res*. 2016;18(9):1895-1902.
135. Olmedo P, Goessler W, Tanda S, et al. Metal concentrations in e-cigarette liquid and aerosol samples: The contribution of metallic coils. *Environ Health Perspect*. 2018;126(2):027010.
136. Olmedo P, Rodrigo L, Grau-Perez M, et al. Metal exposure and biomarker levels among e-cigarette users in Spain. *Environ Res*. 2021;202:111667.
137. Palazzolo DL, Crow AP, Nelson JM, et al. Trace metals derived from electronic cigarette (ECIG) generated aerosol: Potential problem of ECIG devices that contain nickel. *Front Physiol*. 2016;7:663.
138. Rastian B, Wilbur C, Curtis DB. Transfer of metals to the aerosol generated by an electronic cigarette: Influence of number of puffs and power. *Int J Environ Res Public Health*. 2022;19(15).
139. Williams M, Bozhilov K, Ghai S, et al. Elements including metals in the atomizer and aerosol of disposable electronic cigarettes and electronic hookahs. *PLoS One*. 2017;12(4):e0175430.

140. Williams M, Li J, Talbot P. Effects of model, method of collection, and topography on chemical elements and metals in the aerosol of tank-style electronic cigarettes. *Sci Rep*. 2019;9(1):13969.
141. Williams M, Villarreal A, Bozhilov K, et al. Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. *PLoS One*. 2013;8(3):e57987.
142. Zhao D, Aravindakshan A, Hilpert M, et al. Metal/Metalloid levels in electronic cigarette liquids, aerosols, and human biosamples: A systematic review. *Environ Health Perspect*. 2020;128(3):036001.
143. Zhao D, Ilievski V, Slavkovich V, et al. Effects of e-liquid flavor, nicotine content, and puff duration on metal emissions from electronic cigarettes. *Environ Res*. 2022;204(Pt C):112270.
144. Zhao D, Navas-Acien A, Ilievski V, et al. Metal concentrations in electronic cigarette aerosol: Effect of open-system and closed-system devices and power settings. *Environ Res*. 2019;174:125-134.
145. Farsalinos KE, Gillman G, Poulas K, et al. Tobacco-specific nitrosamines in electronic cigarettes: Comparison between liquid and aerosol levels. *Int J Environ Res Public Health*. 2015;12(8):9046-9053.
146. Leigh NJ, Palumbo MN, Marino AM, et al. Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS. *Tob Control*. 2018;27:s37-s38.
147. Nikolaou K, Masclet P, Mouvier G. Sources and chemical-reactivity of polynuclear aromatic hydrocarbons in the atmosphere—a critical review. *Sci Total Environ*. 1984;32:103-132.
148. Rankin GD, Wingfors H, Uski O, et al. The toxic potential of a fourth-generation e-cigarette on human lung cell lines and tissue explants. *J Appl Toxicol*. 2019;39(8):1143-1154.
149. Schober W, Szendrei K, Matzen W, et al. Use of electronic cigarettes (e-cigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers. *Int J Hyg Environ Health*. 2014;217(6):628-637.
150. Casebolt R, Cook SJ, Islas A, et al. Carbon monoxide concentration in mainstream e-cigarette emissions measured with diode laser spectroscopy. *Tob Control*. 2020;29(6):652-655.
151. El-Hellani A, Al-Moussawi S, El-Hage R, et al. Carbon monoxide and small hydrocarbon emissions from sub-ohm electronic cigarettes. *Chem Res Toxicol*. 2019;32(2):312-317.
152. Son Y, Bhattarai C, Samburova V, et al. Carbonyls and carbon monoxide emissions from electronic cigarettes affected by device type and use patterns. *Int J Environ Res Public Health*. 2020;17(8).
153. Leventhal AM, Tackett AP, Whitted L, Jordt SE, Jabba SV. Ice flavours and non-menthol synthetic cooling agents in e-cigarette products: a review. *Tob Control* Epub ahead of print: [01 July 2022]. doi:10.1136/tobaccocontrol-2021-057073.
154. Ali FRM, Seaman EL, Diaz MC, Ajose J, King BA. Trends in unit sales of cooling flavoured e-cigarettes, USA, 2017–2021. *Tob Control* Epub ahead of print: [28 July 2022]. doi:10.1136/tobaccocontrol-2022-057395.

155. Fan L, Balakrishna S, Jabba SV, et al. Menthol decreases oral nicotine aversion in C57BL/6 mice through a TRPM8-dependent mechanism. *Tob Control*. 2016;25:ii50-ii54.
156. Ha MA, Smith GJ, Cichocki JA, et al. Menthol attenuates respiratory irritation and elevates blood cotinine in cigarette smoke exposed mice. *PLoS One*. 2015;10(2):e0117128.
157. Jabba SV, Erythropel HC, Torres DG, et al. Synthetic cooling agents in US-marketed e-cigarette refill liquids and popular disposable e-cigarettes: Chemical analysis and risk assessment. *Nicotine Tob Res*. 2022;24(7):1037-1046.
158. Omaiye EE, Luo W, McWhirter KJ, et al. Flavour chemicals, synthetic coolants and pulegone in popular mint-flavoured and menthol-flavoured e-cigarettes. *Tob Control*. 2022;31(E1):e3-e9.
159. Omaiye EE, Luo W, McWhirter KJ, et al. Disposable Puff Bar electronic cigarettes: Chemical composition and toxicity of e-liquids and a synthetic coolant. *Chem Res Toxicol*. 2022;35(8):1344-1358.
160. Leffingwell J, Rowsell D. Wilkinson Sword cooling compounds: From the beginning to now. *Perfumer & Flavorist*. 2014;39:34-44.
161. FAO/WHO. *Evaluation of Certain Food Additives: Sixty-Ninth Report of the Joint FAO/WHO Expert Committee on Food Additives*. Rome, 2009.
162. FAO/WHO. *Evaluation of Certain Food Additives: Sixty-Fifth Report of the Joint FAO/WHO Expert Committee on Food Additives*. Geneva, 2006.
163. Duell AK, Pankow JF, Peyton DH. Nicotine in tobacco product aerosols: 'It's deja vu all over again'. *Tob Control*. 2020;29(6):656-662.
164. Leventhal AM, Madden DR, Peraza N, et al. Effect of exposure to e-cigarettes with salt vs free-base nicotine on the appeal and sensory experience of vaping: A randomized clinical trial. *JAMA Netw Open*. 2021;4(1):e2032757.
165. Jackler RK, Ramamurthi D. Nicotine arms race: JUUL and the high-nicotine product market. *Tob Control*. 2019;28(6):623-628.
166. Bourgart E, Leclerc L, Pourchez J, et al. Toward better characterization of a free-base nicotine fraction in e-liquids and aerosols. *Chem Res Toxicol*. 2022;35(7):1234-1243.
167. Harvanko AM, Havel CM, Jacob P, et al. Characterization of nicotine salts in 23 electronic cigarette refill liquids. *Nicotine Tob Res*. 2020;22(7):1239-1243.
168. Han D-H, Wong M, Peraza N, Vogel EA, Cahn R, Mason TB, Kirkpatrick M, Tackett AP, Leventhal AM. Dose-response effects of two nicotine salt formulations on electronic cigarette appeal and sensory attributes. *Tob Control*. Epub ahead of print: [17 March 2023]. doi:10.1136/tc-2022-057553.
169. Burch SG, Gann LP, Olsen KM, et al. Effect of pH on nicotine absorption and side effects produced by aerosolized nicotine. *J Aerosol Med*. 1993;6(1):45-52.
170. Adrian CL, Olin HB, Dalhoff K, et al. In vivo human buccal permeability of nicotine. *Int J Pharm*. 2006;311(1-2):196-202.
171. Wilhelm J, Mishina E, Viray L, et al. The pH of smokeless tobacco determines nicotine buccal absorption: Results of a randomized crossover trial. *Clin Pharmacol Ther*. 2022;111(5):1066-1074.
172. Bowen A, Xing C. Nicotine Salt Formulations for Aerosol Devices and Methods Thereof. US 9215895 B2, United States Patent and Trademark Office, 22 Dec

2015.  
<https://patentimages.storage.googleapis.com/e2/9a/99/5a55ed883b0523/US9215895.pdf>. Accessed 9 Jan 2023.
173. O'Connell G, Pritchard JD, Prue C, et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers. *Intern Emerg Med*. 2019;14(6):853-861.
  174. Jordt SE. Synthetic nicotine has arrived. *Tob Control*. 2021.
  175. Stephenson J. FDA gains power to regulate synthetic nicotine in e-cigarettes. *JAMA Health Forum*. 2022;3(4):e221140.
  176. Duell AK, Kerber PJ, Luo W, et al. Determination of (R)-(+)- and (S)-(-)-nicotine chirality in Puff Bar e-liquids by <sup>1</sup>H NMR spectroscopy, polarimetry, and gas chromatography–mass spectrometry. *Chem Res Toxicol*. 2021;34(7):1718-1720.
  177. Barlow RB, Hamilton JT. The stereospecificity of nicotine. *Br J Pharmacol Chemother*. 1965;25(1):206-212.
  178. Yildiz D, Ercal N, Armstrong DW. Nicotine enantiomers and oxidative stress. *Toxicology*. 1998;130(2-3):155-165.
  179. Jones JP, Trager WF, Carlson TJ. The binding and regioselectivity of reaction of (R)- and (S)-nicotine with cytochrome P-450cam: Parallel experimental and theoretical studies. *J Am Chem Soc*. 1993;115(2):381-387.
  180. Pogocki D, Ruman T, Danilczuk M, et al. Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. *Eur J Pharmacol*. 2007;563(1-3):18-39.
  181. Yang J, Chen Y, Liu Z, et al. Differences between the binding modes of enantiomers S/R-nicotine to acetylcholinesterase. *RSC Adv*. 2019;9:1428-1440.
  182. Zhang X, Gong ZH, Nordberg A. Effects of chronic treatment with (+)- and (-)-nicotine on nicotinic acetylcholine receptors and N-methyl-D-aspartate receptors in rat brain. *Brain Res*. 1994;644(1):32-39.
  183. Ikushima S, Muramatsu I, Sakakibara Y, et al. The effects of d-nicotine and l-isomer on nicotinic receptors. *J Pharmacol Exp Ther*. 1982;222(2):463-470.
  184. Benowitz N. Pharmacologic aspects of cigarette smoking and nicotine addiction. *N Engl J Med*. 1988;319(20):1318-1330.
  185. Whitehead AK, Erwin AP, Yue X. Nicotine and vascular dysfunction. *Acta Physiol (Oxf)*. 2021;231(4):e13631.
  186. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. *Cardiovasc Drugs Ther*. 1997;10:657-665.
  187. Tachikawa E, Mizuma K, Kudo K, et al. Characterization of the functional subunit combination of nicotinic acetylcholine receptors in bovine adrenal chromaffin cells. *Neurosci Lett*. 2001;312:161-164.
  188. Yokotani K, Okada S, Nakamura K. Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from the isolated rat adrenal gland. *Eur J Pharmacol*. 2002;446(1-3):83-87.
  189. Munhoz E, De Lima TC, Souccar C, et al. Allosteric interaction of the anticholinergic drug [N-(4-phenyl)-phenacyl-l-hyoscyamine] (Phentonium) with nicotinic receptors of post-ganglionic sympathetic neurons of the rat vas deferens. *Eur J Pharmacol*. 2009;616(1-3):229-235.

190. Carll AP, Farraj AK, Roberts AM. The Role of the Autonomic Nervous System in Cardiovascular Toxicity. In: McQueen CA (ed.), 3rd ed. *Comprehensive Toxicology*. Amsterdam, NL: Elsevier, 2018:61-114.
191. Fisher JP, Young CN, Fadel PJ. Autonomic adjustments to exercise in humans. *Compr Physiol*. 2015;5(2):475-512.
192. Richerson GB. The Autonomic Nervous System. In: Boron WF, Boulpaep EL (eds.), 3rd ed. *Medical Physiology*. Philadelphia, PA: Elsevier 2017:334-352.
193. Ciccarelli M, Sorriento D, Coscioni E, et al. Adrenergic Receptors. In: Schisler JC, Lang CH, Willis MS (eds.), 1st ed. *Endocrinology of the Heart in Health and Disease: Integrated, Cellular, and Molecular Endocrinology of the Heart*. London, UK: Elsevier 2017:285-315.
194. O'Connell TD, Jensen BC, Baker AJ, et al. Cardiac alpha<sub>1</sub>-adrenergic receptors: Novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. *Pharmacol Rev*. 2014;66(1):308-333.
195. Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. *Cardiology*. 2012;122(2):104-112.
196. Madamanchi A.  $\beta$ -Adrenergic receptor signaling in cardiac function and heart failure. *McGill J Med*. 2007;10(2):99-104.
197. Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. *Pharmacol Res*. 2019;146:104274.
198. Liu Y, Chen J, Fontes SK, et al. Physiological and pathological roles of protein kinase A in the heart. *Cardiovasc Res*. 2022;118(2):386-398.
199. Lederer JW. Cardiac Electrophysiology and the Electrocardiogram. In: Boron WF, Boulpaep EL (eds.), 3rd ed. *Medical Physiology*. Philadelphia, PA: Elsevier 2017:483-506.
200. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? *Acta Cardiol*. 2010;65(5):565-570.
201. do Vale GT, Ceron CS, Gonzaga NA, et al. Three generations of beta-blockers: History, class differences and clinical applicability. *Curr Hypertens Rev*. 2019;15(1):22-31.
202. Glass L, Lerma C, Shrier A. New methods for the analysis of heartbeat behavior in risk stratification. *Front Physiol*. 2011;2:88.
203. Shaffer F, McCraty R, Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. *Front Psychol*. 2014;5:1040.
204. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. *Front Public Health*. 2017;5:258.
205. Stein PK, Bosner MS, Kleiger RE, et al. Heart rate variability: A measure of cardiac autonomic tone. *Am Heart J*. 1994;127(5):1376-1381.
206. Billman GE, Huikuri HV, Sacha J, et al. An introduction to heart rate variability: methodological considerations and clinical applications. *Front Physiol*. 2015;6:55.
207. Uijtdehaage SHJ, Thayer JF. Accentuated antagonism in the control of human heart rate. *Clin Auton Res*. 2000;10:107-110.
208. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. *Biol Psychol*. 2007;74(2):224-242.



209. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. *Int J Cardiol.* 2010;141(2):122-131.
210. De Meersman RE. Heart rate variability and aerobic fitness. *Am Heart J.* 1993;125(3):726-731.
211. McCraty R, Shaffer F. Heart rate variability: New perspectives on physiological mechanisms, assessment of self-regulatory capacity, and health risk. *Glob Adv Health Med.* 2015;4(1):46-61.
212. Billman GE. The LF/HF ratio does not accurately measure cardiac sympatho-vagal balance. *Front Physiol.* 2013;4:26.
213. Cohen MA, Taylor JA. Short-term cardiovascular oscillations in man: measuring and modelling the physiologies. *J Physiol.* 2002;542(Pt 3):669-683.
214. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. *Circ Res.* 2014;114(6):1004-1021.
215. Abouassali O, Chang M, Chidipi B, et al. In vitro and in vivo cardiac toxicity of flavored electronic nicotine delivery systems. *Am J Physiol Heart Circ Physiol.* 2021;320(1):H133-H143.
216. Carll AP, Arab C, Salatini R, et al. E-cigarettes and their lone constituents induce cardiac arrhythmia and conduction defects in mice. *Nat Commun.* 2022;13(1):6088.
217. Qiu H, Zhang H, Han DD, et al. Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. *Heart Rhythm.* 2023;20(1):76-86.
218. Moheimani RS, Bhetraratana M, Peters KM, et al. Sympathomimetic effects of acute e-cigarette use: Role of nicotine and non-nicotine constituents. *J Am Heart Assoc.* 2017;6(9):e006579.
219. Moheimani RS, Bhetraratana M, Yin F, et al. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: Implications for cardiovascular risk. *JAMA Cardiol.* 2017;2(3):278-284.
220. Ip M, Diamantakos E, Haptonstall K, et al. Tobacco and electronic cigarettes adversely impact ECG indexes of ventricular repolarization: implication for sudden death risk. *Am J Physiol Heart Circ Physiol.* 2020;318(5):H1176-H1184.
221. Hom S, Chen L, Wang T, et al. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of electronic cigarette extracts of variable nicotine concentrations. *Platelets.* 2016;27(7):694-702.
222. Ramirez JEM, Karim ZA, Alarabi AB, et al. The JUUL e-cigarette elevates the risk of thrombosis and potentiates platelet activation. *J Cardiovasc Pharmacol Ther.* 2020;25(6):578-586.
223. Nocella C, Biondi-Zoccai G, Sciarretta S, et al. Impact of tobacco versus electronic cigarette smoking on platelet function. *Am J Cardiol.* 2018;122(9):1477-1481.
224. Biondi-Zoccai G, Sciarretta S, Bullen C, et al. Acute effects of heat-not-burn, electronic vaping, and traditional tobacco combustion cigarettes: The Sapienza University of Rome-vascular assessment of proatherosclerotic effects of smoking (SUR-VAPES) 2 randomized trial. *J Am Heart Assoc.* 2019;8(6):e010455.
225. Kerr DMI, Brooksbank KJM, Taylor RG, et al. Acute effects of electronic and tobacco cigarettes on vascular and respiratory function in healthy volunteers: a cross-over study. *J Hypertens.* 2019;37(1):154-166.

226. Mobarrez F, Antoniewicz L, Hedman L, et al. Electronic cigarettes containing nicotine increase endothelial and platelet derived extracellular vesicles in healthy volunteers. *Atherosclerosis*. 2020;301:93-100.
227. Crotty Alexander LE, Drummond CA, Hepokoski M, et al. Chronic inhalation of e-cigarette vapor containing nicotine disrupts airway barrier function and induces systemic inflammation and multiorgan fibrosis in mice. *Am J Physiol Regul Integr Comp Physiol*. 2018;314(6):R834-R847.
228. Espinoza-Derout J, Hasan KM, Shao XM, et al. Chronic intermittent electronic cigarette exposure induces cardiac dysfunction and atherosclerosis in apolipoprotein-E knockout mice. *Am J Physiol Heart Circ Physiol*. 2019;317(2):H445-H459.
229. El-Mahdy MA, Mahgoup EM, Ewees MG, et al. Long-term electronic cigarette exposure induces cardiovascular dysfunction similar to tobacco cigarettes: role of nicotine and exposure duration. *Am J Physiol Heart Circ Physiol*. 2021;320(5):H2112-H2129.
230. Neczypor EW, Saldana TA, Mears MJ, et al. E-cigarette aerosol reduces left ventricular function in adolescent mice. *Circulation*. 2022;145(11):868-870.
231. Farsalinos KE, Tsiapras D, Kyrzopoulos S, et al. Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: comparison with the effects of regular cigarettes. *BMC Cardiovasc Disord*. 2014;14(78).
232. Schweitzer KS, Chen SX, Law S, et al. Endothelial disruptive proinflammatory effects of nicotine and e-cigarette vapor exposures. *Am J Physiol Lung Cell Mol Physiol*. 2015;309(2):L175-187.
233. Anderson C, Majeste A, Hanus J, et al. E-cigarette aerosol exposure induces reactive oxygen species, DNA damage, and cell death in vascular endothelial cells. *Toxicol Sci*. 2016;154(2):332-340.
234. Putzhammer R, Doppler C, Jakschitz T, et al. Vapours of US and EU market leader electronic cigarette brands and liquids are cytotoxic for human vascular endothelial cells. *PLoS One*. 2016;11(6):e0157337.
235. Lee WH, Ong SG, Zhou Y, et al. Modeling cardiovascular risks of e-cigarettes with human-induced pluripotent stem cell-derived endothelial cells. *J Am Coll Cardiol*. 2019;73(21):2722-2737.
236. Kuntic M, Oelze M, Steven S, et al. Short-term e-cigarette vapour exposure causes vascular oxidative stress and dysfunction: evidence for a close connection to brain damage and a key role of the phagocytic NADPH oxidase (NOX-2). *Eur Heart J*. 2020;41(26):2472-2483.
237. Mohammadi L, Han DD, Xu F, et al. Chronic e-cigarette use impairs endothelial function on the physiological and cellular levels. *Arterioscler Thromb Vasc Biol*. 2022;42(11):1333-1350.
238. Rao P, Liu J, Springer ML. JUUL and combusted cigarettes comparably impair endothelial function. *Tob Regul Sci*. 2020;6(1):30-37.
239. Rao P, Han DD, Tan K, et al. Comparable impairment of vascular endothelial function by a wide range of electronic nicotine delivery devices. *Nicotine Tob Res*. 2022;24(7):1055-1062.

240. Olfert IM, DeVallance E, Hoskinson H, et al. Chronic exposure to electronic cigarettes results in impaired cardiovascular function in mice. *J Appl Physiol.* 2018;124(3):573-582.
241. Szostak J, Wong ET, Titz B, et al. A 6-month systems toxicology inhalation study in ApoE(-/-) mice demonstrates reduced cardiovascular effects of e-vapor aerosols compared with cigarette smoke. *Am J Physiol Heart Circ Physiol.* 2020;318(3):H604-H631.
242. Jin L, Lynch J, Richardson A, et al. Electronic cigarette solvents, pulmonary irritation, and endothelial dysfunction: role of acetaldehyde and formaldehyde. *Am J Physiol Heart Circ Physiol.* 2021;320(4):H1510-H1525.
243. Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. *J Am Coll Cardiol.* 2016;67(23):2802-2803.
244. Franzen KF, Willig J, Talavera SC, et al. E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: A randomized, double-blinded pilot study. *Vasc Med.* 2018;23(5):419-425.
245. Chaumont M, de Becker B, Zaher W, et al. Differential effects of e-cigarette on microvascular endothelial function, arterial stiffness and oxidative stress: A randomized crossover trial. *Sci Rep.* 2018;8(1):10378.
246. Caporale A, Langham MC, Guo W, et al. Acute effects of electronic cigarette aerosol inhalation on vascular function detected at quantitative MRI. *Radiology.* 2019;293(1):97-106.
247. Antoniewicz L, Brynedal A, Hedman L, et al. Acute effects of electronic cigarette inhalation on the vasculature and the conducting airways. *Cardiovasc Toxicol.* 2019;19(5):441-450.
248. Chatterjee S, Caporale A, Tao JQ, et al. Acute e-cig inhalation impacts vascular health: a study in smoking naive subjects. *Am J Physiol Heart Circ Physiol.* 2021;320(1):H144-H158.
249. Antoniewicz L, Bosson JA, Kuhl J, et al. Electronic cigarettes increase endothelial progenitor cells in the blood of healthy volunteers. *Atherosclerosis.* 2016;255:179-185.
250. Heiss C. Electronic cigarettes increase EPCs. *Atherosclerosis.* 2016;255:119-121.
251. Yan XS, D'Ruiz C. Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. *Regul Toxicol Pharmacol.* 2015;71(1):24-34.
252. Gonzalez JE, Cooke WH. Acute effects of electronic cigarettes on arterial pressure and peripheral sympathetic activity in young nonsmokers. *Am J Physiol Heart Circ Physiol.* 2021;320(1):H248-H255.
253. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *The Lancet.* 2013;382(9905):1629-1637.
254. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. *N Engl J Med.* 2019;380(7):629-637.
255. Arrazola RA, Dube SR, King BA. Tobacco product use among middle and high school students — United States, 2011 and 2012. *MMWR Morb Mortal Wkly Rep.* 2013;62(45):893-897.

256. Omaiye EE, McWhirter KJ, Luo W, et al. High concentrations of flavor chemicals are present in electronic cigarette refill fluids. *Sci Rep.* 2019;9(1):2468.
257. Omaiye EE, McWhirter KJ, Luo W, et al. High-nicotine electronic cigarette products: Toxicity of JUUL fluids and aerosols correlates strongly with nicotine and some flavor chemical concentrations. *Chem Res Toxicol.* 2019;32(6):1058-1069.
258. Yudin Y, Rohacs T. Regulation of TRPM8 channel activity. *Mol Cell Endocrinol.* 2012;353(1-2):68-74.
259. Willis DN, Liu B, Ha MA, et al. Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants. *FASEB J.* 2011;25(12):4434-4444.
260. Yerger VB, McCandless PM. Menthol sensory qualities and smoking topography: a review of tobacco industry documents. *Tob Control.* 2011;20:ii37-ii43.
261. Lamb T, Muthumalage T, Rahman I. Pod-based menthol and tobacco flavored e-cigarettes cause mitochondrial dysfunction in lung epithelial cells. *Toxicol Lett.* 2020;333:303-311.
262. Nair V, Tran M, Behar RZ, et al. Menthol in electronic cigarettes: A contributor to respiratory disease? *Toxicol Appl Pharmacol.* 2020;407:115238.
263. Rosbrook K, Green BG. Sensory effects of menthol and nicotine in an e-cigarette. *Nicotine Tob Res.* 2016;18(7):1588-1595.
264. Leventhal AM, Mason TB, Kirkpatrick MG, et al. E-cigarette device power moderates the effects of non-tobacco flavors and nicotine on product appeal in young adults. *Addict Behav.* 2020;107:106403.
265. Leventhal A, Dai H, Barrington-Trimis J, et al. 'Ice' flavoured e-cigarette use among young adults. *Tob Control.* 2023;32(1):114-117.
266. Wu ZH, Liu YS, Li XD, et al. Acute and subacute inhalation toxicity assessment of WS-23 in Sprague-Dawley rats. *J Appl Toxicol.* 2021;41(11):1826-1838.
267. Talih S, Salman R, Soule E, et al. Electrical features, liquid composition and toxicant emissions from 'pod-mod'-like disposable electronic cigarettes. *Tob Control.* 2022;31(5):667-670.
268. Mallock N, Trieu HL, Macziol M, et al. Trendy e-cigarettes enter Europe: chemical characterization of JUUL pods and its aerosols. *Arch Toxicol.* 2020;94(6):1985-1994.
269. Li P, Beck WD, Callahan PM, et al. Quantitation of cotinine and its metabolites in rat plasma and brain tissue by hydrophilic interaction chromatography tandem mass spectrometry (HILIC-MS/MS). *J Chromatogr B Analyt Technol Biomed Life Sci.* 2012;907:117-125.
270. Hooper JS, Hadley SH, Morris KF, et al. Characterization of cardiovascular reflexes evoked by airway stimulation with allylisothiocyanate, capsaicin, and ATP in Sprague-Dawley rats. *J Appl Physiol (1985).* 2016;120(6):580-591.
271. Carll AP, Hazari MS, Perez CM, et al. Whole and particle-free diesel exhausts differentially affect cardiac electrophysiology, blood pressure, and autonomic balance in heart failure-prone rats. *Toxicol Sci.* 2012;128(2):490-499.
272. Kurhanewicz N, Ledbetter A, Farraj A, et al. TRPA1 mediates the cardiac effects of acrolein through parasympathetic dominance but also sympathetic modulation in mice. *Toxicol Appl Pharmacol.* 2018;347:104-114.

273. Rowan III WH, Campen MJ, Wichers LB, et al. Heart rate variability in rodents: uses and caveats in toxicological studies. *Cardiovasc Toxicol.* 2007;7(1):28-51.
274. Sossalla S, Vollmann D. Arrhythmia-induced cardiomyopathy. *Dtsch Arztebl Int.* 2018;115(19):335-341.
275. Lin CY, Chang SL, Lin YJ, et al. An observational study on the effect of premature ventricular complex burden on long-term outcome. *Medicine.* 2017;96(1):e5476.
276. Hooper JS, Taylor-Clark TE. Irritant inhalation evokes P wave morphological changes in spontaneously hypertensive rats via reflex modulation of the autonomic nervous system. *Front Physiol.* 2021;12:642299.
277. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. *Neuron.* 2004;41(6):849-857.
278. Karashima Y, Damann N, Prenen J, et al. Bimodal action of menthol on the transient receptor potential channel TRPA1. *J Neurosci.* 2007;27(37):9874-9884.
279. Behrendt HJ, Germann T, Gillen C, et al. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. *Br J Pharmacol.* 2004;141(4):737-745.
280. Arastoo S, Haptonstall KP, Choroomi Y, et al. Acute and chronic sympathomimetic effects of e-cigarette and tobacco cigarette smoking: role of nicotine and non-nicotine constituents. *Am J Physiol Heart Circ Physiol.* 2020;319(2):H262-H270.
281. Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. *Respir Res.* 2003;4(4).
282. Kaese S, Verheule S. Cardiac electrophysiology in mice: a matter of size. *Front Physiol.* 2012;3:345.
283. Carnevale R, Sciarretta S, Violi F, et al. Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function. *Chest.* 2016;150(3):606-612.
284. Fetterman JL, Keith RJ, Palmisano JN, et al. Alterations in vascular function associated with the use of combustible and electronic cigarettes. *J Am Heart Assoc.* 2020;9(9):e014570.
285. Talavera K, Gees M, Karashima Y, et al. Nicotine activates the chemosensory cation channel TRPA1. *Nat Neurosci.* 2009;12(10):1293-1299.
286. Yang J, Chen Y, Liu Z, et al. Differences between the binding modes of enantiomers S/R-nicotine to acetylcholinesterase. *RSC Adv.* 2019;9(3):1428-1440.
287. Irfan AB, Arab C, DeFilippis AP, et al. Smoking accelerates atrioventricular conduction in humans concordant with increased dopamine release. *Cardiovasc Toxicol.* 2021;21(2):169-178.
288. Curtis MJ, Hancox JC, Farkas A, et al. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. *Pharmacol Ther.* 2013;139(2):213-248.
289. Schreiner BS, Lehmann R, Thiel U, et al. Direct action and modulating effect of (+)- and (-)-nicotine on ion channels expressed in trigeminal sensory neurons. *Eur J Pharmacol.* 2014;728:48-58.
290. Ni F, Ogura T, Lin W. Electronic cigarette liquid constituents induce nasal and tracheal sensory irritation in mice in regionally dependent fashion. *Nicotine Tob Res.* 2020;22(Suppl 1):S35-S44.

291. Trap-Jensen J, Carlsen JE, Svendsen TL, et al. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. *Eur J Clin Invest.* 1979;9(3):181-183.
292. Fox K, Deanfield J, Krikler S, et al. The interaction of cigarette smoking and beta-adrenoceptor blockade. *Br J Clin Pharmacol.* 1984;17(Suppl 1):92S-93S.
293. Hooper JS, Stanford KR, Alencar PA, et al. Nociceptive pulmonary-cardiac reflexes are altered in the spontaneously hypertensive rat. *J Physiol.* 2019;597(13):3255-3279.
294. Shusterman V, Usiene I, Harrigal C, et al. Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. *Am J Physiol Heart Circ Physiol.* 2002;282(6):H2076-H2083.
295. Piantoni C, Carnevali L, Molla D, et al. Age-related changes in cardiac autonomic modulation and heart rate variability in mice. *Front Neurosci.* 2021;15:617698.
296. Kleiger RE, Miller JP, Bigger JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol.* 1987;59(4):256-262.
297. Van Hoogenhuyze D, Weinstein N, Martin GJ, et al. Reproducibility and relations to mean heart rate variability in normal subjects and patients with congestive heart failure secondary to coronary artery disease. *Am J Cardiol.* 1991;68(17):1668-1676.
298. Fleiss JL, Bigger JT, Rolnitzky LM. The correlation between heart period variability and mean period length. *Stat Med.* 1992;11(1):125-129.
299. Mansier P, Medigue C, Charlotte N, et al. Decreased heart rate variability in transgenic mice overexpressing atrial  $\beta_1$ -adrenoceptors. *Am J Physiol Heart Circ Physiol.* 1996;271(4):H1465-H1472.
300. Janssen BJA, Leenders PJA, Smits JFM. Short-term and long-term blood pressure and heart rate variability in the mouse. *Am J Physiol Regulatory Integrative Comp Physiol.* 2000;278(1):R215-R225.
301. Billman GE. The effect of heart rate on the heart rate variability response to autonomic interventions. *Front Physiol.* 2013;4:222.
302. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. *Psychopharmacology (Berl).* 2014;231(2):401-407.
303. St Helen G, Ross KC, Dempsey DA, et al. Nicotine delivery and vaping behavior during ad libitum e-cigarette access. *Tob Regul Sci.* 2016;2(4):363-376.
304. Voos N, Smith D, Kaiser L, et al. Effect of e-cigarette flavors on nicotine delivery and puffing topography: Results from a randomized clinical trial of daily smokers. *Psychopharmacology (Berl).* 2020;237(2):491-502.
305. Thuerlauf N, Kaegler M, Dietz R, et al. Dose-dependent stereoselective activation of the trigeminal sensory system by nicotine in man. *Psychopharmacology (Berl).* 1999;142:236-243.
306. Kichko TI, Lennerz J, Eberhardt M, et al. Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons. *J Pharmacol Exp Ther.* 2013;347(2):529-539.

307. Siu EC, Tyndale RF. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. *Mol Pharmacol*. 2007;71(3):826-834.
308. Dutta S, Sengupta P. Men and mice: Relating their ages. *Life Sci*. 2016;152:244-248.
309. Hayter EA, Wehrens SMT, Van Dongen HPA, et al. Distinct circadian mechanisms govern cardiac rhythms and susceptibility to arrhythmia. *Nat Commun*. 2021;12(1):2472.
310. Billman GE. Heart rate variability — a historical perspective. *Front Physiol*. 2011;2(86).
311. Wang W, Ma R. Cardiac sympathetic afferent reflexes in heart failure. *Heart Fail Rev*. 2000;5(1):57-71.
312. Somers VK, Anderson EA, Mark AL. Sympathetic neural mechanisms in human hypertension. *Curr Opin Nephrol Hypertens*. 1993;2(1):96-105.
313. Issa ZF, Miller JM, Zipes DP. Electrophysiological Mechanisms of Cardiac Arrhythmias. In: Issa ZF, Miller JM, Zipes DP (eds.), 3rd ed. *Clinical Arrhythmology and Electrophysiology*. Philadelphia, PA: Elsevier, 2019:51-80.
314. Koektuerk B, Aksoy M, Horlitz M, et al. Role of diabetes in heart rhythm disorders. *World J Diabetes*. 2016;7(3):45-49.
315. Grisanti LA. Diabetes and arrhythmias: Pathophysiology, mechanisms and therapeutic outcomes. *Front Physiol*. 2018;9:1669.
316. Carnagarin R, Lambert GW, Kiuchi MG, et al. Effects of sympathetic modulation in metabolic disease. *Ann N Y Acad Sci*. 2019;1454(1):80-89.
317. Andersen A, Jorgensen PG, Knop FK, et al. Hypoglycaemia and cardiac arrhythmias in diabetes. *Ther Adv Endocrinol Metab*. 2020;11:2042018820911803.
318. Aviado DM, Aviado DG. The Bezold-Jarisch reflex. A historical perspective of cardiopulmonary reflexes. *Ann N Y Acad Sci*. 2001;940:48-58.
319. Agboola KM, Kowlgi GN, Csecs I, et al. Bezold-Jarisch reflex mediated syncope in pulmonary arterial hypertension: An illustrative case series. *Pulm Circ*. 2022;12(4):e12147.
320. Johnson S, Tian M, Sheldon G, et al. Trigeminal receptor study of high-intensity cooling agents. *J Agric Food Chem*. 2018;66(10):2319-2323.
321. Sherkheli MA, Vogt-Eisele AK, Bura D, et al. Characterization of selective TRPM8 ligands and their structure activity response (SAR) relationship. *J Pharm Pharmaceut Sci*. 2010;13(2):242-253.
322. Ecker PM, Lin CC, Powers J, et al. Effect of targeted deletions of  $\beta_1$ - and  $\beta_2$ -adrenergic-receptor subtypes on heart rate variability. *Am J Physiol Heart Circ Physiol*. 2006;290(1):H192-199.
323. Husten CG, Deyton LR. Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future. *Lancet*. 2013;381(9877):1570-1580.
324. Ashley DL, Backinger CL, van Bommel DM, et al. Tobacco regulatory science: research to inform regulatory action at the Food and Drug Administration's Center for Tobacco Products. *Nicotine Tob Res*. 2014;16(8):1045-1049.
325. Balfour DJK, Benowitz NL, Colby SM, et al. Balancing consideration of the risks and benefits of e-cigarettes. *Am J Public Health*. 2021;111(9):1661-1672.

326. Yang Y, Lindblom EN, Salloum RG, et al. The impact of a comprehensive tobacco product flavor ban in San Francisco among young adults. *Addict Behav Rep.* 2020;11:100273.
327. Friedman AS. A difference-in-differences analysis of youth smoking and a ban on sales of flavored tobacco products in San Francisco, California. *JAMA Pediatr.* 2021;175(8):863-865.
328. Hammond D, Reid JL, Burkhalter R, et al. E-cigarette flavors, devices, and brands used by youths before and after partial flavor restrictions in the United States: Canada, England, and the United States, 2017-2020. *Am J Public Health.* 2022;112(7):1014-1024.
329. Huh J, Yu S, Galimov A, et al. Hypothetical flavour ban and intention to vape among vape shop customers: the role of flavour preference and e-cigarette dependence. *Tob Control.* 2023;32(1):110-113.
330. Pacek LR, Rass O, Sweitzer MM, et al. Young adult dual combusted cigarette and e-cigarette users' anticipated responses to hypothetical e-cigarette market restrictions. *Subst Use Misuse.* 2019;54(12):2033-2042.
331. Soule EK, Mayne S, Snipes W, et al. Electronic cigarette users' reactions and responses to a hypothetical ban of flavoured electronic cigarette liquids. *Tob Control.* 2022;31:s197-s205.
332. Benowitz, NL. Compensatory smoking of low-yield cigarettes. In: Shopland DR, Burns DM, Benowitz NL, Amacher RH (eds.). *Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine.* Bethesda, MD: U.S. National Institutes of Health, National Cancer Institute; 2001: 39-64.
333. Dawkins LE, Kimber CF, Doig M, et al. Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects. *Psychopharmacology (Berl).* 2016;233(15-16):2933-2941.
334. Smets J, Baeyens F, Chaumont M, et al. When less is more: Vaping low-nicotine vs. high-nicotine e-liquid is compensated by increased wattage and higher liquid consumption. *Int J Environ Res Public Health.* 2019;16(5).
335. Kosmider L, Kimber CF, Kurek J, et al. Compensatory puffing with lower nicotine concentration e-liquids increases carbonyl exposure in e-cigarette aerosols. *Nicotine Tob Res.* 2018;20(8):998-1003.
336. Talih S, Salman R, El-Hage R, et al. Might limiting liquid nicotine concentration result in more toxic electronic cigarette aerosols? *Tob Control.* 2021;30(3):348-350.
337. Dutra LM, Glantz SA. Electronic cigarettes and conventional cigarette use among U.S. adolescents: A cross-sectional study. *JAMA Pediatr.* 2014;168(7):610-617.
338. Primack BA, Soneji S, Stoolmiller M, et al. Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults. *JAMA Pediatr.* 2015;169(11):1018-1023.
339. Leventhal AM, Strong DR, Kirkpatrick MG, et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. *JAMA.* 2015;314(7):700-707.
340. Barrington-Trimis JL, Urman R, Berhane K, et al. E-cigarettes and future cigarette use. *Pediatrics.* 2016;138(1).



341. Wills TA, Knight R, Sargent JD, et al. Longitudinal study of e-cigarette use and onset of cigarette smoking among high school students in Hawaii. *Tob Control*. 2017;26(1):34-39.
342. Spindle TR, Hiler MM, Cooke ME, et al. Electronic cigarette use and uptake of cigarette smoking: A longitudinal examination of U.S. college students. *Addict Behav*. 2017;67:66-72.
343. Primack BA, Shensa A, Sidani JE, et al. Initiation of traditional cigarette smoking after electronic cigarette use among tobacco-naive US young adults. *Am J Med*. 2018;131(4):443.e441-443.e449.
344. Soneji S, Barrington-Trimis JL, Wills TA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: A systematic review and meta-analysis. *JAMA Pediatr*. 2017;171(8):788-797.
345. Odani S, Armour BS, King BA, et al. E-cigarette use and subsequent cigarette initiation and sustained use among youth, U.S., 2015-2017. *J Adolesc Health*. 2020;66(1):34-38.
346. Royal College of Physicians. RCP advice on vaping following reported cases of deaths and lung disease in the US. 25 October 2019. <https://www.rcplondon.ac.uk/projects/outputs/rcp-advice-vaping-following-reported-cases-deaths-and-lung-disease-us>. Accessed 14 February 2022.

APPENDIX  
LIST OF ABBREVIATIONS

3HC, *trans*-3'-hydroxycotinine

AChE, acetylcholinesterase

ANOVA, analysis of variance

ANS, autonomic nervous system

ATP, adenosine triphosphate

AVN, atrioventricular node

cAMP, cyclic adenosine monophosphate

Ca<sub>v</sub>1.2, L-type Ca<sup>2+</sup> channel

CO, carbon monoxide

COT, cotinine

cTnC, cardiac troponin C

cTnI, cardiac troponin I

CVD, cardiovascular disease

CYP2A6, cytochrome P450 2A6

DBP, diastolic blood pressure

ECG, electrocardiogram

e-cig, electronic cigarette

EPI, epinephrine

FA, filtered air

FDA, Food and Drug Administration

FMD, flow-mediated dilation

GRAS, generally recognized as safe

HF, high frequency

HRV, heart rate variability

$I_{Ca}$ ,  $Ca^{2+}$  current

$I_{CaL}$ , L-type  $Ca^{2+}$  current

$I_f$ , pacemaker current

$I_{Kr}$ , rapid delayed-rectifier  $K^+$  current

LF, low frequency

LV, left ventricular

MAP, mean arterial pressure

nAChR, nicotinic acetylcholine receptor

NE, norepinephrine

NMR, nicotine metabolite ratio

PAH, polycyclic aromatic hydrocarbon

PG, propylene glycol

PKA, protein kinase A

PKA-C, protein kinase A, catalytic subunits

PLN, phospholamban

PM, particulate matter

PM<sub>2.5</sub>, particulate matter with diameter < 2.5  $\mu$ m

PM<sub>0.1</sub>, particulate matter with diameter < 0.1 μm

PVT, polymorphic ventricular tachycardia

RMSSD, root mean square of successive differences of normal RR intervals

ROS, reactive oxygen species

RyR2, ryanodine receptor 2

SAN, sinoatrial node

SBP, systolic blood pressure

SCD, sudden cardiac death

SDNN, standard deviation of normal RR intervals

SERCA, sarcoendoplasmic reticulum Ca<sup>2+</sup>-ATPase

SR, sarcoplasmic reticulum

TNE, total nicotine equivalents

TRPA1, transient receptor potential ankyrin 1

TRPM8, transient receptor potential melastatin 8

TSNA, tobacco-specific nitrosamine

TSP, total suspended particulates

UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry

VF, ventricular fibrillation

VG, vegetable glycerin

VPB, ventricular premature beat

WS, Wilkinson Sword

WS-3, *N*-ethyl-*p*-menthane-3-carboxamide

WS-23, 2-isopropyl-*N*,2,3-trimethylbutyramide

## CURRICULUM VITAE

Cory Kucera

### EDUCATION

- 08/2023      Ph.D. Physiology  
University of Louisville  
Louisville, KY
- 12/2020      M.S. Physiology  
University of Louisville  
Louisville, KY
- 06/2011      B.S. Biological Sciences (*cum laude*)  
University of California, Irvine  
Irvine, CA

### ACADEMIC APPOINTMENTS

- 08/2016 – 08/2023      Ph.D. Candidate  
Department of Physiology  
University of Louisville  
Louisville, KY

### PROFESSIONAL APPOINTMENTS

- 02/2016 – 07/2016      Analytical Chemist
- 08/2011 – 07/2012      SunStar Laboratories, Inc.  
Lake Forest, CA
- 05/2015 – 02/2016      Manufacturing Associate  
Vista Biologicals Corporation  
Carlsbad, CA
- 09/2013 – 03/2015      Medical Assistant  
Advanced Dermatology  
Dana Point, CA
- 07/2012 – 04/2015      Research Associate  
Prodo Laboratories, Inc.  
Aliso Viejo, CA

## **FELLOWSHIPS**

- 09/2020 – 06/2021 American Heart Association Tobacco Regulation and Addiction Center
- 08/2016 – 06/2018 Integrated Programs in Biomedical Sciences

## **PROFESSIONAL MEMBERSHIPS**

- 11/2021 – Present Society of Toxicology
- 11/2020 – 11/2021 American Heart Association

## **AWARDS & HONORS**

- 06/2023 – 08/2023 Doctoral Dissertation Completion Award  
University of Louisville  
Louisville, KY
- 11/2021 Best Poster  
Ohio Valley Chapter of the Society of Toxicology

## **ABSTRACTS & POSTER PRESENTATIONS**

- 03/2023 Society of Toxicology  
Cooling Agents Exacerbate E-cigarette-Induced Cardiac Arrhythmias and Sympathetic Dominance in Mice  
**Kucera C, Ramalingam A, Bhatnagar A, Carll AP**
- 10/2022 NIH Tobacco Centers of Regulatory Science Grantee Meeting  
Coolants in E-cigarette Aerosols Induce Cardiac Autonomic Imbalance and Ventricular Arrhythmia in Mice  
**Kucera C, Ramalingam A, Bhatnagar A, Carll AP**
- 10/2022 Ohio Valley Chapter of the Society of Toxicology  
E-cigarette Aerosols Containing Coolants Disrupt Cardiac Autonomic Balance and Evoke Ventricular Premature Beats in Mice  
**Kucera C, Ramalingam A, Bhatnagar A, Carll AP**
- 03/2022 Society of Toxicology  
E-cigarette Aerosols Induce Arrhythmia in Mice Dependent on E-liquid and Device Characteristics  
**Kucera C, Ramalingam A, Stephens D, Hodges A, Conklin DJ, Bhatnagar A, Carll AP**
- 11/2021 Ohio Valley Chapter of the Society of Toxicology  
Flavored E-cigarette Aerosols Induce Cardiopulmonary Toxicity in Mice  
**Kucera C, Ramalingam A, Stephens D, Ghosh U, Hodges A, Bhatnagar A, Carll AP**

10/2021 NIH Tobacco Regulatory Science Meeting  
E-cigarette Aerosols Induce Ventricular Arrhythmia in Mice Dependent  
on Nicotine, Flavors, and Device Type  
**Kucera C**, Ramalingam A, Stephens D, Hodges A, Conklin DJ,  
Bhatnagar A, Carll AP

10/2021 Research!Louisville  
Cardiopulmonary Toxicity of Menthol in E-cigarettes  
**Kucera C**, Ramalingam A, Stephens D, Ghosh U, Hodges A, Bhatnagar  
A, Carll AP

### **PUBLICATIONS**

**Kucera C**, Ramalingam A, Srivastava S, Bhatnagar A, Carll AP. Nicotine Formulation  
Influences the Autonomic and Arrhythmogenic Effects of Electronic Cigarettes  
(submitted).

**Kucera C**, Ramalingam A, Srivastava S, Bhatnagar A, Carll AP. Synthetic Cooling  
Agents Exacerbate E-cigarette-Induced Cardiac Arrhythmias and Sympathetic  
Dominance in Mice (in preparation).

Ketchem CJ\*, **Kucera C**\*, Barve A, Beverly LJ. The Antiarrhythmic Drug, Amiodarone,  
Decreases AKT Activity and Sensitizes Human Acute Myeloid Leukemia Cells to  
Apoptosis by ABT-263. *Am J Med Sci*. 2018;355(5):488–496.

\*Authors contributed equally

### **VOLUNTEER SERVICE**

03/2014 Medical Volunteer  
Global Medical and Dental Brigades  
Honduras

10/2013 – 04/2014 Patient Experience Intern  
University of California, Irvine Medical Center  
Orange, CA

09/2013 – 11/2014 Hospice Volunteer  
Orange County Hospice  
Orange County, CA

08/2013 – 11/2014 Care Extender  
University of California, Los Angeles Medical Center  
Los Angeles, CA

05/2008 – 12/2008 Escort & Messenger  
Saddleback Memorial Medical Center  
Laguna Hills, CA

06/2002 – 12/2011 Nonprofit Volunteer  
Abiding Savior Lutheran Church  
Lake Forest, CA